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Abstract 
NAME: Dr Anathakrishnapuram Srinivasan Raghunath 
TITLE OF THESIS: Helicobacter pylori and the Management of Gastro-
Oesophageal Reflux Disease 
HIGHER DEGREE FOR WHICH SUBMITTED: Doctor of Philosophy (PhD) 
YEAR OF SUBMISSION: 2005 
This thesis is centred on the current controversy and possible links between 
H. pylori and GORD and whether the infection should be eradicated in those 
requiring long PPis. The thesis combines three methodologies: systematic 
reviews to ascertain current knowledge, qualitative research to ascertain the 
perceptions of GPs regarding this link, and, a cross sectional survey of 
patients on long term PPis, including an evaluation of their H. pylori status. 
The field work was done in Northern England. 
The findings were: 
1) Patients with oesophagitis or reflux were less likely to have H. pylori 
infection. 
2) The eradication of H. pylori in patients with duodenal ulcer did not 
influence the presence or absence of oesophagitis afterwards. The 
view that eradication provokes oesophagitis was not substantiated. 
3) The effect of H. pylori eradication in patients with reflux oesophagitis, 
without peptic ulcer, was uncertain. 
4) GPs held diverse views to justify variations in PPI prescribing. They 
did not consider a link between H. pylori and GORD and rarely 
prescribed eradication therapy to such patients. 
5) 1. 73% of the population was on long term PPis, rates varying six fold 
between practices. Reflux disease was associated with a third of this 
prescribing. 
111 
6) Over 66% of patients on long term PPis had had an upper Gl 
investigation. However, practices varied widely in their use of 
endoscopy (33%-82%). 
7) Virtually all patients on long term PPis still had ongoing symptoms. 
31% were positive for H. pylori and in them, reflux symptoms and 
quality of life measures were better than those who tested negative. 
Conclusions 
A potential link between H. pylori and GORD did not impinge upon 
decision making in general practice. Current knowledge does not 
substantiate the view that H. pylori eradication provokes reflux 
oesophagitis but there are insufficient data about the effect of eradication 
in patients treated solely for reflux. The widespread variations in PPI 
prescribing and investigation rates could not be correlated with 
epidemiological or practice characteristics but it was ascertained that the 
rate of long term PPI usage was three times than previously determined. 
Virtually all patients had ongoing symptoms despite PPI use and reflux 
symptoms and QoL measures were worse in those patients who tested 
negative. This research does not definitively answer the question whether 
H. pylori should be eradicated in patients on long term PPis. However, 
should this be considered necessary, the size of this task is quantified. 
Future research centred on therapy in this category of patients is required 
for a definitive answer. 
lV 
For Bela, Ash win and Sashin 
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Introduction 
GORD is a common condition, likely to exist in half of those presenting with 
all upper Gl symptoms. Around 25% of those who have a gastroscopy are 
diagnosed as having oesophagitis and around 25% are likely to have GORD 
even with normal gastroscopy findings. Reflux symptoms affect nearly a third 
of the entire adult European population at any one time and have a 
substantial impact on sufferers' personal and working lives. General 
practitioner consultation rates for dyspepsia in the UK primary care setting 
vary between 40 and 50 per 1000 patients annually. Thus an average 
general practice in UK with a list size of 6000 patients is likely to see nearly 
300 patients with complaints of dyspepsia including GORD each year; 
equivalent to 5% of all consultations. The majority of such consultations will 
be for reflux symptoms often characterised by heartburn and acid 
regurgitation. 
Most patients with reflux symptoms are managed empirically in primary care 
with around 10% referred to secondary care. Empirical therapy often involves 
acid suppression therapy, predominantly the proton pump inhibitors. 
Recently revised guidelines from the National Institute of Clinical Excellence 
in UK have emphasised the benign nature of dyspepsia and GORD and 
advise GPs to ration the use of proton pump inhibitors and endoscopy 
referrals. However, the guidelines have also advocated the use of PPis and 
the "test and treat" strategy for H. pylori in new dyspeptics. This has 
resource, workload and prescribing implications for primary care. The 
guidelines do not address the interface between H. pylori infection and the 
use of PPis. 
Since the discovery of H. pylori, there have been several studies that have 
unequivocally established its link to peptic ulcer disease. This message has 
been firmly taken up by GPs who now provide eradication treatment for ulcer 
and gastritis - related dyspepsia associated with H. pylori. However, the 
relationship between GORD and H. pylori is less certain and more 
controversial, particularly when it comes to eradication therapy in patients on 
6 
long-term PPis. Despite some guidelines advocating eradication therapy in 
this situation, experience suggests that this has not been applied in clinical 
practice by UK general practitioners. 
The aim of this thesis was to address the following major themes: 
a) To learn more about the attitudes of GPs in relation to GORD, H. 
pylori and use of long-term PPis and the interplay between them. 
b) To systematically gather detailed available information on the 
relationship between GORD and H. pylori and to establish definitive 
conclusions on the basis of current knowledge. 
c) To understand the extent of long-term PPI prescribing in primary care, 
the quality of life in these patients and their H. pylori status. This would 
quantify the size of the task should H. pylori eradication be considered 
necessary in those on long-term PPis. 
These research questions are important for primary care and also because 
they have implications for patients, decision makers and secondary care 
clinicians in directing the management of H. pylori positive patients with 
GORD. An additional aim was to identify differences in prescribing behaviour 
and decision making between GPs around GORD and H. pylori, to better 
understand reasons behind variations in practice. 
The thesis also aimed to explore assumptions regarding dyspepsia and 
GORD symptoms and quality of life in patients on long-term PPis, by 
undertaking a large cross-sectional survey of such patients in primary care 
and a study of any differences in these parameters between those who were 
H. pylori positive and those not. These results are likely to lead to a better 
understanding of the extent, variations and reasons for long-term PPI 
prescribing. 
The results will inform the debate around the appropriateness of testing and 
treating for H. pylori infection in patients who are on long-term PPis for 
GORD. 
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Chapter 1 
A Resume of the Literature 
8 
1.1 An overview ... 
"Heartburn" and its treatment have been written up in text books of medicine 
as far back as 150 years. Historically, indigestion was considered to be 
discomfort caused by an over-filled and overloaded stomach as a result of 
excessive indulgence, the non-solution or malassimilation of food and the 
imperfect removal of waste products. Imperfect mastication and the habit of 
eating too hastily were considered important causes of dyspepsia. Prior to 
the discovery of the acid-suppression drugs, antacids and alkalis were the 
mainstay of treatment1. Although they offered symptomatic benefit, they 
could not heal or cure patients with peptic ulcers. This resulted in high 
surgical rates with associated morbidity and mortality. Although Barrett's 
oesophagus had been known to the medical fraternity since 19502, its 
association with gastro-oesophageal reflux disease and adenocarcinoma of 
the oesophago-gastric junction were recognised largely in the last two 
decades3;4. The re-discovery of H. pylori by Marshall and Warren5 in 1982 
and its association with gastritis, peptic ulcer and gastric cancer excited 
health professionals and stimulated extensive new research and debate. 
The impact of these developments on primary care has been enormous; 
especially in empowering general practitioners in dyspepsia management. 
There has been an associated proliferation of guidelines aimed at GPs. High 
profile national groups such as the Cochrane Upper Pancreatic and Digestive 
Group and the Primary Care Society of Gastroenterology became 
established within the last 20 years. Following the discovery of the Proton 
Pump Inhibitor, omeprazole, in 1979 and its launch in 1987, the management 
of dyspepsia and gastro-oesophageal reflux disease was revolutionised. 
Debate and controversies around the link between H. pylori and GORD and 
use of long-term PPis continue unabated. Although such issues are 
important from a GP perspective, they are also potentially bewildering given 
the plethora of conflicting evidence available. There is also another 
significant concern for both GPs and patients - the rising trend in oesophago-
gastric junctional cancer and its possible association with the rising 
prevalence of GORD6. Whilst GPs have powerful therapies to improve the 
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quality of life in patients with GORD they also have to ensure that early upper 
gastro-intestinal cancer is expeditiously detected. There is a major question 
as to whether H. pylori should be eradicated in patients on long-term acid 
suppression therapy with PPis for GORD7• 
1.2 The use of acid neutralisation and suppression drugs in primary 
care 
1. 2. 1 Ancient therapies 
A clinical lecture on the disorders of assimilation and digestion by Sir Lauder 
Brunton delivered at St. Bartholomew's Hospital in 1899 provides fascinating 
insights into the perceptions of the day. 
Non-pharmacological measures such as vomiting were considered a 
treatment to ease indigestion and epigastric discomfort. If this did not 
completely empty the stomach, "much foul stuff' could be left behind that 
created an uneasy sense of discomfort in the epigastrium and retrosternal 
region. To stimulate emesis, lukewarm water was recommended. 
Bicarbonate of soda was advised to prevent acidic contents setting the 
person's teeth on edge! If vomiting did not take place spontaneously, this 
could be self induced - it was recommended in the late 18th and early 19th 
century that the tickling of the fauces was preferably be done with a feather! 
Abstinence from food and giving the stomach a rest was advocated following 
the above treatment in patients with indigestion, to allow the irritation of 
mucous membrane from the acidic substances to settle. Only plain food such 
as tea, toast, boiled rice or Indian corn flour was recommended. Additionally, 
bismuth, bicarbonate of soda, spirit of chloroform, and cinnamon or 
peppermint water was given to help with indigestion symptoms. 
Other medications that were described include belladonna in atropine and 
Gregory's powder (rhubarb, magnesia and ginger). Regular drinking of hot 
water, in combination with eating slowly, masticating thoroughly and 
10 
salivating were supposed to cure a great number of dyspeptic patients. The 
addition of a little alkali just before meals was suggested to stimulate 
secretion of gastric juice. Examples of this were calumba without tannin, 
gentian with tannin and perchloride of iron. 
1.2.2 Antacids and alginates 
These have been, and continue to be widely consumed by patients alongside 
advances in acid suppression therapy. Sales of these over the counter at the 
pharmacist and prescriptions issued by GPs in UK have risen over the years, 
indicating their popularity amongst patients and doctors8. They are perceived 
to be cheap, effective and harmless9 . 
Anecdotal experience suggests that patients are prescribed antacids or 
alginates for "mild" indigestion symptoms; a significant percentage of these 
will have heartburn as their primary complaint. However, there is paucity of 
research in this area. In particular, there are no trials to determine the 
effectiveness of antacids and alginates in uninvestigated patients with 
heartburn. A recent Cochrane Review10 based on two trials, indicated that in 
heartburn predominant uninvestigated dyspepsia, antacid-alginates were less 
effective for symptom relief than PPis. The review did not identify any trials 
comparing antacid-alginate with placebo in unselected patients in primary 
care. In cases of proven GORD as shown by the presence of oesophagitis, 
antacid-alginate combinations cured symptoms in 31% more patients than 
placebo, giving a NNT of 3 (95% Cl: 2 to 6)11 -13. 
1. 2. 3 H2-receptor antagonists 
Although it had been known for almost 200 years that gastric acid secretion 
was regulated, and for about 50 years that histamine was one mediator of 
such regulation 14, the pharmacological manipulation of gastric secretion was 
not achieved until 1972. Black et al15 utilized the concept of selective 
histamine receptor subtypes to discover the H2-receptor antagonist 
cimetidine. 
11 
This discovery established a novel treatment that for the first time could heal 
peptic ulcers and gastritis, provide relief from heartburn, and it launched the 
market for acid-controlling drugs. 
Nevertheless, cimetidine and its other family members (ranitidine, famotidine, 
and nizatidine) left room for improvement. They necessitated multiple dosing 
and were associated with undesirable fluctuations in gastric acid levels. They 
also failed to adequately treat gastro-oesophageal reflux disease and the 
excessive acid secretion that occurs in pathological hypersecretory 
conditions 16. Meta-analyses ascertained that H2RA were superior to placebo 
by 17% and 36% in the healing and maintenance of oesophagitis17, a NNT of 
6 and 2.7 respectively. These drugs are now available over the counter at the 
pharmacy and continue to be prescribed by GPs, albeit less so in comparison 
to PPis. Despite this, there is paucity of pragmatic primary care studies, both 
quantitative as well as qualitative, to ascertain their role in the management 
of uninvestigated dyspepsia and heartburn and studies on GPs perceptions 
and experiences in the use of these drugs. 
1.2.4 Prokinetics 
General practitioners relatively rarely prescribe prokinetic agents such as 
domperidone or metoclopromide as a primary treatment for uninvestigated 
dyspepsia, heartburn or GORD. There has been relatively little interest in 
undertaking research into their use in GORD, although a number of new 
initiatives have started recently. From a clinical perspective, they continue to 
be used sporadically as an addition to PPis in patients with severe GORD. 
1. 2. 5 Proton pump inhibitors 
In 1967 Astra Pharmaceuticals started a project aimed at developing a new 
drug inhibiting the production of acid in the stomach. Around the same time, 
Professor George Sachs (Fig 1) from the university of Alabama and his 
collaborators at Smith Kline & French began work that established an H+/ K+-
ATPase as the proton pump that moves acid across the gastric mucosa and 
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gastric parietal cells18;19. Furthermore, Sachs hypothesized that the H+/ K+-
ATPase proton pump might be a key drug target for control of gastric 
secretion of acid. 
Sachs in combination with Astra scientists Sjostrand, Brandstrom, Lindberg, 
and Fellenius began the collaboration that eventually yielded omeprazole in 
1978. Studies in humans had to be temporarily suspended following a scare 
that high doses produced carcinoid changes in rats but these were later 
resumed in 1985 following further experiments by Enar Carlsson and others 
that discounted the direct effect of omeprazole for such changes. 
Professor George Sachs 
Sweden was the first country to launch omeprazole following trials involving 
some 9,000 patients in 40 countries. In 1990, omeprazole became Astra 
pharmaceuticals' leading product, and six years later, the world's top selling 
drug. 
Proton pump inhibitors act at the final step in acid secretion by blocking H+/K+ 
ATPase irreversibly in gastric . parietal cells. Lansoprazole, similar to 
omeprazole in chemical structure, was developed in Japan, and the other 
proton pump inhibitors (pantoprazole, rabeprazaole and esemoprazole) have 
subsequently appeared. On an equivalent dose, all PPis appear to offer 
similar levels of acid suppression. However there are minor differences 
between the different PPis, which may offer clinical advantages in certain 
situations20. 
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Fifteen years on PPis are still leading players in the management of acid-
suppression disorders and as yet unchallenged with regard to their high 
efficacy, their popularity amongst doctors and patients and their relative 
safety. Their use by GPs in UK reflects these attributes although this has 
caused concern about the appropriateness and cost-effectiveness of such 
prescribing. In 2003 they cost the NHS £402 million21 . This has led to 
national guidelines22:23 aimed primarily at GPs to "educate" them in the 
appropriateness of PPI use. The uptake and implementation of these 
evidence based guidelines has not been widespread24. To many there 
appears to be a tension or a gulf between evidence-based advice and reality 
of individual patient care. This may reflect varying and different GP 
experiences that do not fit the evidence based, mainly traditional, models of 
quantitative statistics-meta-analysis and randomised trials. 
Since the introduction of PPis, there has been a burgeoning of research 
publications, mostly industry sponsored, that have in one way or the other 
demonstrated the clinical efficacy, safety, and superiority of PPis over other 
acid suppression agents particularly H2RAs (Fig 2). The overwhelming 
majority of these have been conducted by secondary care specialists on 
referred patients in the areas of GORD, H. pylori and peptic ulcer disease. 
Some have been of major importance and have had a tremendous impact on 
the medical profession as a whole: for example PPis as a part of eradication 
therapy against H. pylotf5:26 and the healing of severe oesophagitis including 
benign strictures27"30. 
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Figure 2. Meta-analysis of trials comparing PPI vs. H2RA in the healing 
of oesophagitis. Source: National Institute of Clinical Excellence, 
200417• 
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Unsurprisingly, there are few primary care initiated and/or based studies in 
this field although there has been a steady increase recently, especially in 
collaboration with secondary care. These have provided important data and 
explanations to answer pragmatic questions for general practitioners. 
1. 2. 6 Examples of some important studies are listed below. 
Alberti31 in 2002 determined the utility and acceptance of lnfai 13C-UBT in 
General Practice. It was demonstrated that the UBT can be easily performed 
in a primary care setting and that its usefulness as a standard non-invasive 
test for H. pylori was well received by GPs. The study reflected increasing 
pressure on GPs to manage patients presenting with dyspepsia without 
referral for endoscopy. 
Arents et a/. 32 in 2003 performed a randomised trial of test and treat vs. 
prompt endoscopy of dyspepsia management in primary care. They found 
that the "test and treat" strategy was as effective and safe as prompt 
endoscopy. There were more dyspepsia related visits to the GP in the test 
and treat group and more patients in the endoscopy group were prescribed 
PPis. Coming from an unselected primary care population, and done by 
primary care physicians, the results are likely to resonate with generalist 
GPs. 
Bashford et a/. 33 in 1998 ascertained the indications for PPis prescribing by 
GPs. They found that oesophagitis and peptic ulcer disease were the 
commonest recorded indications. Non-specific morbidity (unlicensed 
indications) accounted for 46% of PPI prescribing. 
Boathe and Blenkinsopp34 in 1997 explored patients' perspectives of PPI use 
in a qualitative study. The results reaffirmed the potential benefits of rapid 
and sustained symptom relief by patients and concerns if "step-down" or 
stoppage of PPis was attempted. The findings and explanations of this study 
are shared by many GPs who have the experience of difficulty in reducing 
the dosage of or stopping PPis. 
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Boutet et a/. 35 in 1999 surveyed the repeat prescribing of acid suppression 
drugs in primary care. They found wide variation in repeat prescribing rates 
from 1.61 to 11% between practices. In nearly 60%, no proven diagnosis was 
recorded. This study raised questions about the reasons for this variation and 
a need for the better understanding of factors. 
Cooper eta/. 36 in 2000 audited their practice PPI prescribing. They found that 
there was a potential cost saving of £50,000 in a practice with a list size of 
10,000 patients if "sensible approaches" to therapy were adopted. This audit 
highlighted the importance of reviewing patients after initiating PPI therapy. 
Delaney et a/. 37;38 in 2000 and 2001 ascertained the cost- effectiveness of 
initial endoscopy and usual GP care in patients over the age of 50 years and 
the cost-effectiveness of testing for H. pylori and endoscopy for positive 
patients vs. usual GP care. They found that initial endoscopy in the over 50s 
may be cost-effective but that test and endoscopy of the positive testing 
patients was not. These two studies appear to support the way most GPs 
function in the "real world": GPs instinctively have a low threshold for 
referring patients above 45 years old for endoscopy; likewise, they are 
unlikely to refer patients for endoscopy if H. pylori testing done in primary 
care shows a positive result. 
Delaney et a/. 39 in 1998 explored the health beliefs of patients (>50 years) 
consulting for dyspepsia in a qualitative study. They found that patients 
consulted because of the perceived threat of cancer and a need for 
reassurance. Delayed consultations were related to patients' perceptions of 
the cause being related to factors such as "old age" or "spicy food". Many 
patients had a fatalistic attitude to their health. This study reiterated the 
responsibility that GPs have to enable older patients to report symptoms 
early. 
Hobbs et a/. 40 in 1996 ascertained the effect of H. pylori eradication on 
dyspeptic symptoms. There was significant improvement in dyspepsia 
symptoms following H. pylori eradication in patients with known peptic ulcer 
17 
disease. This study indicated that opportunistic case finding of peptic ulcer 
disease patients followed by a test and treat strategy was cost-effective. 
Hungin et a/.41 :42 in 1999, studied factors that determine compliance with 
long-term PPI therapy in general practice and, in a different study, 
ascertained the extent, indications and the cost-implications of long-term PPI 
prescribing. The authors found that compliance was determined by 
symptoms and need for personal control. Most patients appeared to use their 
PPI on an "as required" basis. Long-term PPI prescribing rates were found to 
be 0.5% of the population of which reflux symptoms or disease constituted 
more half of long-term PPI prescribing. These two studies have been of 
major importance in learning about GPs use of "on-demand" approaches to 
PPis. 
Jasani43 in 1999, determined patients' knowledge and attitudes about GORD 
and its effects on their quality of life. It was found that GORD adversely 
affected the quality of life in nearly two thirds of sufferers. 
Jones et a/.44 in 2001 compared GPs' usage of different PPis and explored 
how the PPI prescribing of a particular brand changed following the 
introduction of cheaper competitors. It was shown that hospital prescribing 
was an important influence on the choice of PPI by GPs. The wide variation 
in PPI prescribing by GPs suggested that there was scope for improvement 
in the quality processes PPI prescribing. This study also indicated the need 
for further research to ascertain the extent of variation and reasons for PPI 
prescribing by GPs. 
Jones et a/.45 in 2003 undertook a study to characterise patients with GORD 
who consult a physician because of heartburn, with respect to their medical 
background and to ascertain the burden of disease in Germany and Sweden. 
They found that heartburn conferred a significant burden on patients with 
GORD as reflected in the reduction in health related quality of life. Since the 
majority of patients presenting in primary care with persistent heartburn have 
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GORD, this needs to be treated effectively because of its significant impact 
on quality of life. 
Martinet a/.46 in 1998 examined the use of antisecretory drugs in UK primary 
care between October 1991 and September 1996 and found that the 
prescribing of proton pump inhibitors increased sharply each year from 1991. 
This study also confirmed that GPs perceived proton pump inhibitors to be 
highly effective, and significantly more so than the H2-receptor antagonists. 
Bramble et a/. 47;48 in 2000 and 2004 ascertained the impact of prior acid-
suppression therapy on the diagnosis of gastric or oesophago-gastric cancer. 
They found that patients taking PPis at the time of initial endoscopy can have 
their cancer diagnosis delayed; patients on prior empirical acid suppression 
PPI therapy were also likely to be referred later. These can result in delayed 
diagnoses. This study has important implications for GPs and PPI 
prescribing, especially in relation to reviews and the point of referral. 
Panter et a/.48 in 2004, ascertained the effect of antisecretory drugs on time 
to diagnosis, symptoms, tumour stage and the outcome of upper 
gastrointestinal cancers. The authors concluded that prior antisecretory drug 
therapy was associated with a delayed diagnosis of upper gastrointestinal 
adenocarcinoma irrespective of presenting symptoms. From a GP 
perspective, this study highlighted need for care and caution to be exercised 
in prescribing of PPis, particularly for uninvestigated dyspepsia. 
Parente et a/.48 in 2004, evaluated the appropriateness of acid-suppressive 
therapy in a large teaching hospital in northern Italy, and the fall-out of 
hospital prescription on general practice. The authors concluded that acid-
suppressive agents were over-used in hospitalised patients. Most of the 
inappropriate hospital prescriptions were for ulcer prophylaxis in low-risk 
patients. This study has indicated the need for further research to ascertain 
-the proportion of primary care patients on lolig~term PPI 'therapy in whom 
PPis were initiated in the hospital and the reasons for this prescribing. 
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Pollock and Grime49 in 2003, undertook a qualitative study to consider 
responses of general practitioners in relation to PPI prescribing. The authors 
found that GPs were subject to conflicting pressures in their efforts to meet 
clinical need while also attempting to reduce the cost of PPI prescribing. The 
results of this study suggested that there may a risk of progressive inertia 
towards patient centred care. 
Weijnen et al.50 in 2001, in their study determined the current management of 
H. pylori-related dyspepsia by Dutch general practitioners. The authors 
concluded that H. pylori diagnosis played only a modest role in the 
management of dyspepsia in Dutch general practices. The results of this 
study were consistent with the findings amongst GPs in UK who generally 
appear not to follow guidelines. The same authors in a separate study in 
2001 sought to identify the most accurate and efficient test for diagnosing H. 
pylori infection in primary care patients. They found that both the ELISA and 
the UBT were equally effective in the primary care setting. These findings are 
important in the light of the NICE dyspepsia guidelines which recommend a 
test and treat strategy in favour of endoscopy as initial management for all 
uncomplicated dyspepsia 
1.3 Use of Proton Pump Inhibitors in Primary Care 
1.3.1 Extent of usage and indications 
PPis are widely used by GPs in UK; the majority of such prescribing for long-
term use21 . Research from northern England ascertained that 0.5% of the 
population was on long-term repeat prescriptions for PPis, mainly for GORD 
or non-specified "dyspepsia"42. The authors collected data from 21 GPs with 
46,650 patients representing a cross section of the local population. 209 
patients were identified as being on long term PPis; 87% were on 
omeprazole, 13% lansoprazole. Their average age was 60 yrs, and the chief 
indications of treatment, as defined from the records were: "reflux" 39%, 
"oesophagitis" 17%, "non specified dyspepsia" 24%, "peptic ulcer" 8%. A total 
of 1,952 prescriptions (defined as 28 day courses) were issued during the 
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year, a mean of 9 per patient (range 1-18). 16% of patients drew <6 
prescriptions; 27%, 6-9 prescriptions; only 21% sufficient for the entire year. 
The total cost of long term PPI prescribing (@ omeprazole £35.45, 
lansoprazole £33.36) was £68,700; average £3,000 per GP. The results 
indicated that large number of patients received long term prescriptions for 
PPis; most for symptom relief rather than healing of any specific lesions; that 
most took their treatment only intermittently; and the total costs were 
substantial. Prior investigations had been performed in 78% of the patients, 
probably a reflection of the local availability of open access gastroscopy. The 
authors pointed out that, it was likely that a normal endoscopy report in 
patients with persisting symptoms led to a trial of PPI therapy; in some 
patients this acid suppression therapy then became established. Also, in this 
study, there evidence of considerable co-prescribing suggesting that many 
patients were prescribed PPis for protection or to relieve drug induced 
dyspepsia. The authors raised the question, "Should there be strategies for 
rationalisation of therapy and cost containment, particularly in patients 
needing symptom relief only? 
Other studies have also ascertained that a significant number of patients in 
primary care, between 25% to 45% do not have an investigation based 
diagnosis when on long-term PPis35;51 -53. Furthermore Jones et af4 found a 
23 fold variation in prescribing of PPis based on 50 inner-city, mainly ethnic 
minority GPs, in the midlands region of the UK. 
1.3.2 What influences General Practitioners to prescribe Proton Pump 
Inhibitors? 
Neither GORD or "non specified dyspepsia" is potentially life threatening. In 
theory, cheaper alternatives can be used. Very little research exists about the 
patterns of PPI prescribing by individual GPs, variations between them, and 
the factors influencing their prescribing decisions. In general guidelines 
- appear not- to ·inflt.iehce COr cnifnge GPs -prescfibfng .- behaviou~4. An 
evaluation of the impact of first NICE guidelines on GP prescribing revealed 
that despite the recommendations to downscale PPI prescribing, prescribing 
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rates and costs increased. However, when the guidance coincided with 
information from other sources or with personal experience there was some 
evidence that technology appraisals triggered a change in prescribing. But 
that this was not always sustained. 
Grime et.af4 conducted a qualitative study using semi-structured interviews 
with 26 GPs to compare their perspectives of GPs and that of patients on the 
need for PPis, to examine the pressure to prescribe and to examine the 
effect of PPis on lifestyle. They found that GPs rated the efficacy of PPis 
more highly compared with patients. Half of the GP interviewees reproduced 
the stereotype of the demanding patient and of patients using PPis to support 
unhealthy lifestyles. GPs also underestimated patients concerns' about side 
effects, safety, and the effect of long-term use of PPis, and the willingness of 
patients to achieve the minimum effective dose by experimenting with their 
treatment. GPs felt that the pressure to prescribe PPis was outweighed by 
the pressure not to prescribe, and most GPs had responded to the call to cut 
the prescribing of PPis. Where strategies were employed to cut prescribing, 
these included the wholesale switching of patients on a treatment dose of 
one brand of PPI to a maintenance dose of a cheaper brand of PPI, the so 
called 'double switching'. In this study, the stereotypes of 'profligate 
prescriber', 'demanding patient', and 'adverse lifestyle', as explanations for 
the increase in the prescribing of PPis were not substantiated. The 
stereotype of patients demanding PPis may arise from GPs' internal pressure 
to prescribe being justified as pressure from patients. Labeling PPI patients 
as having a poor lifestyle can be a surrogate reason for justifying the 
reduction of PPI use49:54. 
1.3.3 Patients and PP/s 
There is a restricted literature on perceived benefits of PPis by patients 
although recent research has indicated poor concordance with therapy. 
Hung in et.af1 study caimed ·to ascertain the rates ana factors inffuenclng 
compliance amongst patients on long term PPis. The perceptions and 
attitudes of patients on long-term PPI therapy were evaluated by a validated 
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questionnaire and a prospective drug diary card determined compliance. The 
authors concluded that the compliance of patients on long term PPI therapy 
was related to the presence and severity of symptoms, and a personal 
preference about when to take the treatment. Also, this study indicated that a 
large proportion of patients did not understand the reasons for the 
prescription and appeared to lack the knowledge about how it worked. The 
authors felt that understanding of these factors is likely to be conducive to 
compliance and pointed to the need for research into ways of improving 
communication with patients. 
In a qualitative study of semi-structured interview with 82 patients on long-
term PPis, these were rated as being effective by them but less by GPs. 
There was concern expressed by patients about their long-term use, safety 
and side effects. Patients expressed a wish to experiment with reduction in 
doses and frequency of usage. The stereotypes relating to poor life style and 
"demanding patients" were rejected by this study54. 
Boath et a/. 34 in their study of 20 patients on long-term PPis obtained similar 
results. There was no evidence of patients demanding PPis, influenced 
through media, advertisement or social contacts. Although patients felt PPis 
were more effective than other drugs they had tried previously they 
expressed their concerns about stopping PPis or changing to another drug. 
Despite these reservations, the majority of patients interviewed said they 
would change if their general practitioner suggested it. PPis led some 
patients to abandon, or to not attempt, lifestyle changes34. 
1.3.4/mp/ications of long-term use of Proton Pump Inhibitors 
In addition to escalating costs two other factors are relevant to long-term 
treatment with PPis - firstly, their appropriateness in patients who are H. 
pylori positive, because of the risk of provoking increased acid suppression 
(discussed later in this chapter) and secondly, the risk of masking or delaying 
the diagnosis of upper gastrointestinal cancer. Griffin and Raimes55 in an 
editorial in the British Medical Journal in1998 under the heading of "Proton 
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pump inhibitors may mask early gastric cancer" advocated that all dyspeptic 
patients over 45 should undergo endoscopy before these drugs are started. 
They argued that the nihilistic approach adopted by many of gastric cancer 
as being an incurable condition was no longer tenable as this was curable 
diagnosed and treated early. Although the reasons for delay in the diagnosis 
of gastric cancer may be multifactorial, the authors felt that one element was 
the prescription of ulcer healing drugs before endoscopy. This article referred 
to the existence of two points at which the inappropriate prescription of 
proton pump inhibitors might delay or prevent the diagnosis of early gastric 
cancer. Firstly, rapid control of dyspepsia may lead the patient or general 
practitioner to underestimate the importance of this symptom, so referral for 
endoscopy is delayed or even deferred. Secondly, if the patient should later 
undergo a gastroscopy then the prior treatment with these drugs may mask 
the endoscopic signs and the diagnosis may be missed. On the basis of the 
then available evidence and unanswered questions about the effects of even 
short courses of proton pump inhibitors in patients with early gastric cancer, 
the authors emphasised the need for this message to be reinforced. 
Bramble et a/. 47 in a retrospective analysis identified 133 patients with upper 
gastrointestinal cancer. Of these, 116 had died, 31 from adenocarcinoma of 
the oesophagus and 85 from stomach cancer. They found that failure to 
reach the diagnosis of cancer at the initial gastroscopy was associated with 
prior acid suppression therapy. Only one of 54 (1 %) patients on no treatment 
or antacids alone was erroneously diagnosed as suffering from benign 
disease, whereas 22 of 62 (35%) patients treated with acid suppression were 
diagnosed as suffering from benign disease but at varying times later turned 
out to have adenocarcinoma. 
Panter et a/. 48 in a recent large cohort study analysed the primary care 
records of 747 patients diagnosed with upper gastrointestinal 
adenocarcinoma at one NHS trust in UK between 1991 and 2001. They 
found that patients with benign symptoms prescribed antisecretory drugs 
were referred later than those not on antisecretory drugs (P < 0.0001), as 
were patients with alarm symptoms (P = 0.0008). Prior use of antisecretory 
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drugs delayed diagnosis by 17.6 weeks (mean) but had no effect on tumour 
stage at diagnosis or survival. The authors concluded that prior antisecretory 
drug therapy was associated with delayed diagnosis of upper gastrointestinal 
adenocarcinoma irrespective of presenting symptoms. However, concerns 
that delays might adversely affect tumour stage or long-term survival were 
not substantiated in this study. 
However, according to some authors, it is desirable to endoscope all patients 
over the age of 45 to detect early gastric cancer56. This is because a 
significant proportion of patients with early gastric cancer experience only 
typical dyspeptic symptoms and not alarm symptoms 57. There is also some 
evidence that prescribing of powerful acid suppression drugs will heal early 
gastric cancers and abolish symptoms thus leading to delay in diagnosis and 
survival7;58. 
1.4 Gastro-oesophageal reflux disease (GORD) 
1.4.1 Definitions 
The 2004 NICE guidelines 17 state: "GORD refers to endoscopically -
determined oesophagitis or endoscopy negative reflux disease" 
The Genval consensus statement59, which has become a guidepost, stated 
that the term "GORD" should be used to include 
a) all individuals exposed to the risk of physical complications from 
gastro-oesophageal reflux or 
b) who experience clinically significant impairment of health-related well-
being (quality of life) due to reflux related symptoms, after adequate 
reassurance of the benign nature of the symptoms 
1.4.2 The prevalence of GORD 
It is useful to look at the prevalence data from the following two aspects; the 
prevalence of proven GORD and the community prevalence of GOR 
symptoms. 
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1.4.2.1 The prevalence of proven GORD (by investigations) 
In the UK, the prevalence of oesophagitis had remained constant at about 
20% between 1989 to 1994(Figs 3 & 4)60. However, case series data from 
endoscopy units seem to indicate that the prevalence has increased 
significantly over the last decade61 . The prevalence of oesophagitis can be 
nearly 50% in those with frequent reflux symptoms. Winters4 in his study of 
97 patients with frequent reflux symptoms found endoscopic reflux 
oesophagitis in 45% and Barrett's oesophagus in 12%. GORD increases in 
prevalence with age and is slightly higher in women as has been shown in 
the Fourth National Study of the Morbidity Statistics in General Practice62 
(Fig 5). 
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Figure 3. Diagnosis of oesophagitis, duodenal and gastric ulcer at 
endoscopy: England, 1989-1994, Source: Hospital episode Statistics60 
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Figure 4. Findings at Endoscopy: England 1994 Source: Hospital 
Episode Statistics60 
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Figure 5. First and new episodes of dyspepsia: England 1991-2 
Source: Morbidity Statistics in General Practice: Fourth National 
Study62 
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1.4.2.2 The prevalence ofGOR symptoms 
There are few published studies that describe the community prevalence of 
predominant GOR symptoms (heartburn, acid regurgitation) in isolation63:64, 
but there are several that describe global dyspepsia prevalence65-70. 
Prevalence rates thus vary depending on the definitions used (Fig 6), 
population studied, and the ethnicity and country of origin. 
Heading71 , in a systematic review, ascertained that in ten selected studies, 
the reported prevalence of upper abdominal symptoms (mostly upper 
abdominal pain or discomfort) ranged from approximately 8% to 54%, while 
the prevalence of heartburn and/or regurgitation ranged from 1 0% to 48% for 
heartburn, from 9% to 45% for regurgitation and 21% to 59% for both/either. 
The authors concluded that the most likely explanation for the broad range of 
prevalence reported was due to the variation in the definition of symptoms. In 
the case of heartburn and regurgitation, different understandings of these 
terms by different investigators and subjects may have contributed to the 
range of results. 
The community prevalence data of GORD symptoms may thus be affected 
by the definitions used. The following are the commonest quoted definitions 
involving dyspepsia; by including or excluding GORD they can greatly 
influence prevalence data. 
Rome 2 definition of dyspepsia72 excluded heartburn, while the 1988 working 
party and the British Society of Gastroenterology definitions73 definition 
includes patients with predominant heartburn. This difference in definitions 
explains the variation in prevalence rates between different studies (figure 6). 
The BSG definition73 
Dyspepsia defined as any symptom referable to the upper gastrointestinal 
tract, present for at least four weeks and including upper abdominal pain or 
discomfort, heartburn, acid reflux, nausea, and vomiting. 
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Rome 1 and 2 definition72 
Dyspepsia defined as discomfort centred in the upper abdomen and excludes 
patients with heartburn or acid reflux as their only symptom. Symptoms 
needed to be present for at least one month and at least one quarter of the 
time. 
"Dyspepsia" required pain or discomfort to be centred predominantly in the 
upper abdomen for at least 12 weeks in the last 12 months. 
Figure 6. Prevalence of adult dyspepsia by definition. Source: National 
Institute of Clinical Excellence, 200417 
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Figure 6 shows that if the BSG definitions were used, the mean dyspepsia 
prevalence rate, which includes heartburn, was 39% (23% to 49%). However, 
when the Rome definition that excluded predominant heartburn was used, 
the mean dyspepsia prevalence rate was 20% (10% to 29%). 
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The prevalence rates of reflux symptoms, essentially of heartburn and or acid 
reflux as available from various studies63;S4;?0;?4-82 are listed in Table 1. 
Table 1. Population surveys indicating prevalence of heartburn or acid 
regurgitation 
Author Country Type "Definitions Sample Prevalence 
Year of of size rate% (annual) 
prevalence reflux 
study symptoms" 
lsolauri Finland Population- questionnaire 1700 27 (heartburn) 
1995 based 45 
(regurgitation) 
Corder UK Population- Heartburn 3971 34 
1996 based questionnaire 
Locke USA Population- Validated 1511 19.8% (weekly) 
1997 based questionnaire 
Kennedy UK Community Heartburn, 3169 28.7 
1998,2000 sample acid 
regurgitation 
Tougas Canada Population- Validated 1036 Not 
1999 based questionnaire easily available 
Haque New Population- Validated 817 30 
2000 Zealand based questionnaire 
Agreus Sweden Population- Validated 1290 n/a in abstract 
2001 based questionnaire 
Louis Belgium Population- Interview 2000 28 
2002 based Re presence 
of heartburn 
Nader Brazil Population- Pre-codified 1263 48.2 
2003 based questionnaire 
Diaz-Rubio Spain Population- Telephone 1775 31.6 
2004 based survey 
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1.4.3 Can Gastro-oesophagea/ reflux disease be diagnosed clinically? 
The sensitivity, specificity and positive predictive value of symptoms patterns 
appear to correlate poorly with the dyspepsia sub types. These may be 
slightly worse for peptic ulcer disease in comparison to reflux oesophagitis 83-
86 [Table 2 ]. 
Table 2. Symptom evaluation and prediction of detecting endoscopic 
disease 
Symptom Evaluation indices Author, year 
Heartburn Sensitivity 71% Adang,1986 
Specificity 59% 
PPV38%, 
NPV 85% 
Reflux-like Sensitivity (58% to 62%) Talley, 1993 
symptom Specificity (70% to 82%) Muller-Hansen, 1998 
cluster PPV (24% to 51%) 
NPV (90% to 87%) 
Ulcer-like Sensitivity (31% to 62%) Talley, 1993 
symptom Specificity (71 % to 81 %) Muller-Hansen, 1998 
cluster PPV (24% to 40%) 
NPV (78% to 92%) 
In primary care, the presentation of heartburn is treated by some at least, if 
not most, general practitioners as being GORD. Such a view was supported 
by the publication of "An evidence-based appraisal of reflux disease 
management - the Genval Workshop Report" by Dent et a/. in which 
heartburn was identified as the pivotal symptom for the diagnosis of reflux 
disease59. When heartburn is the major or the sole symptom, gastro-
oesophageal reflux is the cause in at least 75-80% of individuals87;88. 
Evidence-based documentation of the positive predictive value of heartburn 
for reflux disease is lacking, in part because of the lack of an acceptable gold 
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standard for the diagnosis of reflux disease in the absence of oesophagitis. 
Heartburn is also the most common symptom of reflux disease, occurring in 
at least 75% of patients89. 
Because of a lack of "gold standard" reference diagnostic test for GORD, it 
has been suggested that application of such statistical techniques as latent 
class analysis and a Bayesian approach in future studies will give a much 
more realistic estimate of the accuracy of reflux symptoms for the diagnosis 
of GORD90. 
The use of routine diagnostic questionnaires in primary care has not been 
evaluated, although such questionnaires have been developed with content 
validitl1;92. The questionnaire developed by Shaw et a/.91 is a simple, brief, 
validated, self administered questionnaire. It comprises four domains 
(burning feeling behind stomach, pain behind breast bone, acid taste in the 
mouth, unpleasant movement of materials upwards from the stomach) and 
can be scored to indicate if GORD is likely. 
The sensitivity and specificity of the "acid-test" with the use of PPis is 
considered comparable to that of pH monitoring in the diagnosis of 
GORD93;94• 
1.4.4 Lifestyle associations with GORD 
Although few well-designed placebo-controlled trials have been conducted, a 
review of the literature indicates an appreciable efficacy of lifestyle 
interventions, which are founded on well-studied physiological determinants 
of gastro-oesophageal reflux. These include selective food and medicine 
avoidance, weight loss, smoking cessation and elevation of the head of the 
bed95. The role of obesity in the pathogenesis of the disease and provoking 
GORD is controversial; some epidemiological or observational studies have 
demonstrated a positive association96-103 while others l1ave ~shown no 'such 
correlation 104-107• The evidence of association at best seems to be weak, 
given that the odds ratio for most studies that show an association is less 
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than two. Concerning smoking and GORD some studies have shown a 
positive association97;108;109, others no or even a negative association96;102;106 
between current or ex-smokers and GORD. Concerning alcohol and GORD, 
there is weak evidence of any positive association between them. Even in 
studies that have shown a positive association97;102;108;109, the odds ratios has 
been less than two, indicating that any effect is likely to be small. Sleeping 
with the bed-head raised is commonly recommended as treatment for 
patients with troublesome GORD symptoms but there is sparse evidence for 
this advice110. There is also no firm evidence of any association between 
coffee, chocolate, and amount of fat intake and GOR0101 ;102;111 . 
1.5 H. pylori- the Story 
Figure 7. A 1 O,OOOx computer-aided design image of H. pylori showing 
curved shape and flagellae that enable the bacteria to propel 
themselves into the mucus lining of the stomach. Source: H. pylori 
Research Laboratory website: www.hpylori.com.au/ 
------
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Figure 8. A silver stain (Warthin Starry) of H. pylori (black wiggly lines) 
on gastric mucus-secreting epithelial cells (x1 000). This picture is of Dr. 
Marshall's stomach biopsy, taken 8 days after he drank a culture of H. 
pylori. This image is from the Helicobacter Foundation website: 
www.helico.com 
When scientists identified H. pylori in 1982 as an infectious agent responsible 
for peptic ulcer disease, it transformed the understanding of the microbiology 
and pathology of the human stomach. Before then, "no acid, no ulcer'' 
. 
succinctly described the accepted medical paradigm: stomach ulcers 
occurred when excess acid damaged the gastric mucosa, and treatment was 
aimed at reducing or neutralizing that acid. Those who believed in 
psychosomatic theories of illness postulated even further that overproduction 
of the ulcer-causing acid was stimulated as a response to life's stresses-
including overambitious mothers. We now know that duodenal ulcers largely 
result from a bacterial infection, and that they are readily curable by 
treatment with antibiotics 112;113. 
The story of the discovery of H. pylori sounds like a chapter from the book, 
"Microbe Hunters". Written in 1926 by Paul de Kruif, it chronicled the 
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discovery of the microbes causing the infectious diseases that ravaged the 
world's population of the time. The modern story is the tale of two 
investigators from Western Australia. One observed a microorganism under 
his microscope and refused to accept previous explanations for its presence; 
the other used himself as a guinea pig in order to satisfy Koch's postulates, 
which indisputably establish an organism as causative agent for a specific 
disease (i.e., a pathogen). In fact, it recalls the story of Robert Koch himself, 
who conducted his experiments far from the medical mainstream in rural 
Germany, finally convincing the reluctant Berlin professors in 1882 that the 
bacilli he had isolated and studied actually caused tuberculosis 114. 
The scientific breakthrough that involved H. pylori occurred in 1982 when J. 
Robin Warren and Barry Marshall isolated a new bacterium and showed that 
it caused gastritis and stomach ulcers, diseases that affect millions of 
humans worldwide. As happens with many scientific advances, this 
breakthrough initially gained its momentum from the creative insights of an 
independent investigator. 
Warren, a pathologist who examined gastric biopsies, also observed the 
curved rod-shaped bacteria under his microscope. After examining many 
such specimens, he realized that the bacteria were always present in tissue 
that showed signs of inflammation, that the number of organisms correlated 
with the degree of the inflammation present, and that they occurred in half of 
the routine gastric biopsy specimens he examined. Convinced that his 
observations were significant and merited further investigation, he kindled the 
interest of Barry Marshall, then a trainee in internal medicine, and together 
they set out to isolate the source of the infection. 
1. 5. 1 Perseverance and good luck 
The Australians were fortunate and their practice of careful observation paid 
off. Warren had noticed that the curved microorganisms he saw resembled 
Campylobactef, a tYpe of bacterium known to cause intestinal disea;e. Their 
laboratory used the selective growth conditions appropriate for 
Campylobacter, near 37°C with a low level of oxygen present. They tried, 
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without success, to grow the bacteria from stomach biopsies for more than a 
year until the cultures were inadvertently left in the incubator over the Easter 
holidays. This chance prolongation of the incubation period from the usual 
two days to six resulted in the successful growth and isolation of the 
bacterium. They had discovered serendipitously that Helicobacter species 
grew much more slowly than the other bacteria that were usually cultured in 
laboratories. 
Isolating H. pylori (or Campylobacter pyloridis, as it was originally called) was 
significant, but it still did not establish whether the bacteria were the cause of 
the inflammation with which they were associated or whether they occurred 
as a result of it. At first the distinction was unclear, because slides from 
autopsy specimens showed that the bacteria were present in many 
individuals with no history of ulcers. To confirm that H. pylori caused the 
gastritis and peptic ulceration, Marshall and another volunteer tried to fulfill 
Koch's third and fourth postulates by ingesting cultures of the bacteria. Both 
contracted gastritis, underwent endoscopy, and provided biopsies from which 
the suspected pathogen was re-isolated. This confirmed the connection 
between H. pylori and gastritis, but since neither scientist developed an ulcer, 
that link was still unproven. The connection between H. pylori and ulcers was 
eventually deduced from epidemiological studies showed an increased 
incidence of ulcers in persons infected with the bacteria 115-117. 
After Warren and Marshall published their work118;119, many other 
investigators were able to culture the bacteria from the stomachs of their 
patients who had gastritis and ulcers. This, combined with clinical 
observations indicating that antimicrobial therapy resulted in ulcer cures, 
made the weight of the evidence compelling. 
1. 5. 2 H. pylori and epidemiology 
The gastric bacterium H. pylori, although strongly associated with peptic ulcer 
disease and distal gastric cancer120;121 , is widely present in the population but 
causes no harm in the majority of patients (Figures 7 & 8). 
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Figure 9. Map showing percentages of world population infected with H. 
pylori as determined by epidemiological studies. This image is from the 
Helicobacter Foundation website: www.helico.com 
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H. pylori varies in prevalence widely with over 80% of Japanese and South 
American adults infected compared with approximately 40% in the UK and 
20% in Scandinavia (Fig 9). Local differences in prevalence occur where 
there has been substantial immigration from countries with a higher 
prevalence. 
The transmission mode of H. pylori infection is uncertain. Person-to-person 
and faeco-oral or oro-oral route seem likely although H. pylori is rarely 
cultured from faeces or saliva122. Acute H. pylori infection causes a vomiting 
illness and recent evidence suggests H. pylori may be transmitted through 
vomit123. 
Epidemiological evidence suggests that many individuals acquire the 
infection in childhood: social deprivation, household crowding and number of 
siblings appear important risk factors 124;125. 
The prevalence of infection increases with age, although this may be largely 
a cohort effect. Poorer socio-economic conditions 70 years ago meant most 
children were infected with H. pylori. While the majority of 70 year olds are H. 
pylori positive only 10-20% of children are infected today124. This is 
consistent with the reduction over time of H. pylori related diseases such as 
peptic ulcer and distal gastric cancer. 
1.6 H. pylori and GORD-Is there a link? 
Several and some potentially important and interesting reviews have been 
published over the last five years concerning H. pylori, GORD and PPis 
(Table 3). 
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Table 3. Review studies concerning H. pylori, GORD and PPis (1999-2004) 
Author, study Conclusion 
O'Connor,1999,review Relationship complex and confusing; test and treat young 
126 patients prior to long-term PPI 
Labenz, 1999, Long-term PPI therapy safe for >10years in H. pylori 
editorial127 positive and negative GORD but unsure regarding safety 
if treatment for 20 or 30 years. 
Martinek,2000,review PPis less effective in the absence of H. pylori in GORD; 
128 H. pylori may protect against GORD. 
Falk,2001,clinical Relationship confusing 
review129 
McColl,2004,comment Available evidence does not provide a clear answer 
ary13o concerning eradication of H. pylori in patients on long-
term PPI therapy for GORD. 
Vakil,2003, Role of H. pylori in GORD remains controversial 
review131 
Labenz,2001, Some evidence to support benefit of eradication prior to 
debate long-term PPI therapy for reflux. 
(protagonist) 132 
Tytgat,2001, Benefits of PPI therapy in GORD outweigh the risks. 
review133 
Dent,2001, Medico-legal risks and the adverse consequences of H. 
review134 pylori infection alone favour eradication in GORD patients 
on long-term PPI therapy. 
Gisbert, 1999, H. pylori and GORD seem to have a friendly relationship, 
review135 but may not be so when PPis enter the scene. 
McNamara, H. pylori infection does not seem to play a causal role in 
1999 review 136 I GORD. 
Axon,2004, GORD patients infected with H. pylori should be 
personal view 137 eradicated if long-term PPI therapy is required. 
Freston,2001, No evidence to test and treat for H. pylori in GORD 
debate (antagonist) 138 patients requiring long-term PPI therapy 
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From a clinical and general practitioner's perspective, the following areas are 
of relevance: 
Should GPs routinely test for H. pylori with view to eradication in patients with 
newly diagnosed GORD or those presenting with symptoms of heartburn and 
acid regurgitation? Should GPs offer routine "test and treat" policy to patients 
with GORD or GORD related symptoms and on long-term PPis? How do 
GPs perceive the relationship between H. pylori, GORD, Barrett's 
oesophagus, oesophago-cardiac and gastric cancers? 
In order to explore the above, the presence or absence of a link between H. 
pylori and GORD can be considered under the following headings: 
a) The prevalence of H. pylori in GORD b) The effect of H. pylori infection 
and eradication on GORD c) The effect of H. pylori infection and eradication 
on the effectiveness of PPis in GORD d) The effect of H. pylori in the 
presence of long-term PPis in accelerating gastric atrophy increasing the risk 
of gastric cancer 
1. 6. 1 H. pylori prevalence in the spectrum of GORD 
There have been conflicting reports of H. pylori prevalence rates in GORD 
patients compared to those without GORD. Some studies have reported no 
difference while others have ascertained lower H. pylori prevalence in 
patients with reflux disease, raising the possibility of a negative association 
between H. pylori infection and GORD. A review by O'Connor126 identified 
twenty six observational studies, thirteen which had a control group. The 
prevalence of H. pylori in GORD was 40% (16-88%) and in controls 50% (5-
82%). A meta-analysis published in a abstract form 139 ascertained a lower 
prevalence of H. pylori in GORD (OR 0.7, 95% Cl, 0.63-0.78). This negative 
association may be greater in studies assessing endoscopically proven reflux 
oesophagitis rather than symptom based diagnosis. The second meta-
analysis also drew attention to the fact that papers from the Far East showed 
a greater negative association than those from Western Europe, with those 
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from North America lying between the two. Such a negative association, it 
has been suggested may also extend to Barrett's oesophagus and 
oesophago-gastric adenocarcinoma 140-145. Thus both observational and 
epidemiological studies appear to suggest a protective role for H. pylori in 
GORD146. Further credence for the protective role has been provided by 
some authors indicating the less frequent occurrence of severe forms of 
oesophagitis in H. pylori positive patients 147;148. 
1.6.2 Effect of H. pylori infection and eradication on GORD 
1. 6. 2. 1 Duodenal ulcer patients 
Eradication of H. pylori in this group of patients may provoke de-novo 
oesophagitis. Labenz et.al first formally published evidence to this fact 
through a case-control study of successful (244) vs. failed (216) eradication 
therapy in duodenal ulcer patients 149. Life-table analysis estimated the risk of 
reflux oesophagitis within 3 years to be 25.8% in the cured group and 12.9% 
in those with on-going infection (p<0.0001 ). However, this study has been 
strongly criticised on methodological grounds as this was really a 
retrospective analysis of a series of double-blind, randomised trials in which 
patients with duodenal ulcer were treated with true eradication or placebo. A 
further study in the same year150 also arrived at similar results. 
However, since, several well-designed studies 151 ;152-155 have addressed the 
relationship between eradication of H. pylori in peptic ulcer patients and 
GORD. Nakajima and Hattori recently reviewed the data on the de novo 
development of GORD following eradication in peptic ulcer and concluded 
that there was no worsening of GORD following eradication therapy156. 
1.6.2.2 GORD patients 
Further credence for the protective role of H. pylori in GORD has been 
provided by some authors indicating the less frequent occurrence of severe 
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forms of oesophagitis in H. pylori positive patients 147;148. However, other 
studies have found no such difference143;157. 
Two well designed randomised control trials 158;159 have failed to show any 
significant impact of eradication on the duration of oesophageal pH less than 
4, time to relapse with symptoms or endoscopic relapse of oesophagitis. A 
further randomised trial published in abstract form specifically addressed this 
question in 232 endoscopy-negative or Los Angeles grade A oesophagitis 
patients in the UK. The author of this study showed no influence of 
eradication therapy on cumulative relapse rates of reflux disease at 12 
months 160. Indeed, there is no published studies to-date that has shown any 
worsening of GORD symptoms or oesophagitis following eradication in 
GORD patients. 
1.6.2.3 The "normal population" 
Two double-blind, randomised controlled trials with large sample sizes and 
adequate follow-up periods have assessed the impact of H. pylori eradication 
on dyspepsia in the community. Both concluded that symptoms of epigastric 
pain, heartburn and acid-reflux were less frequent in the eradication group at 
the end of the study161 ;162 . 
1.6.3 Effectiveness of proton pump inhibitors in GORD and H. pylori infection 
In healthy volunteers infected with H. pylori, proton pump inhibitors are more 
effective acid-suppressants and raise intra-gastric pH significantly more in 
comparison to those who are uninfected. Several studies have arrived at this 
conclusion using different PPis 163-166. It has been suggested therefore that 
such findings would have clinical applications in the management of GORD 
patients with PPis. 
-one large study aetermiried that healing rates using 4omg of pantoprazole at 
8 weeks were significantly higher in oesophagitis patients infected with H. 
pylori (p=0.004)167 but another study reported no difference147 in the dose of 
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PPI required to maintain relief of symptoms and healing of oesophagitis 
(p=0.05). Carlsson et a/. specifically addressed this question by evaluating 
data in 1350 patients with GORD from three double-blind, randomised 
controlled trials. They concluded that in the 36% of patients infected with H. 
pylori, the risk of relapse was significantly lower during maintenance therapy 
with omeprazole compared to uninfected patients. However, healing of 
oesophagitis and relief of symptoms was similar in the two groups. 
1. 6.4 Long-term PP/s for GORD, H. pylori and upper Gl cancer 
It is now well accepted that H. pylori infection in the stomach is strongly 
associated with the development of chronic atrophic gastritis 168;169, itself a 
precursor for gastric adenocarcinoma 170. 
Valle et a/ 169 in a long-term retrospective assessment over 32 years, found 
that the prevalence of corpus atrophic gastritis rose from 15% to 38% in 85 
H. pylori positive individuals; in comparison this finding rose by 12% (0 to 2) 
in 17 H. pylori negative individuals. Kuipers et a/168 likewise found that the 
frequency of atrophic corpus gastritis increased over a mean period of 11.5 
years from 24% to 45%, an annual rate of increase of 2%, in comparison to 
0.3% without H. pylori infection. Other studies have ascertained similar 
results 171 ;172. 
PPis can suppress over 80% of gastric acid secretion 173. Several earlier 
studies have shown an increase in the incidence of atrophic gastritis, up to 
25%, in patients with peptic ulcer or reflux oesophagitis and on long-term 
maintenance PPI therapy followed up between 1 to 5 years 174-176. 
Subsequent studies, however, suggested that PPI therapy related changes in 
the topography and severity of chronic gastritis is largely confined to those 
who are infected with H. pylori. 
Kuipers et a/177 studied patients from two separate cohorts who were being 
treated for reflux oesophagitis. 72 patients were treated with fundoplication 
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and 105 treated with omeprazole (20 to 40 mg once daily). In both cohorts, 
the patients were followed for an average of five years (range, three to eight). 
After fundoplication, the patients did not receive acid-suppressive therapy. 
The presence of H. pylori was assessed at the first visit by histological 
evaluation in the fundoplication group, and by histological and serologic 
evaluation in the omeprazole group. The patients were not treated for H. 
pylori infection. Before treatment and during follow-up, the patients 
underwent repeated gastroscopy, with biopsy sampling for histological 
evaluation. Among the patients treated with fundoplication, atrophic gastritis 
did not develop in any of the 31 who were infected with H. pylori at base line 
or the 41 who were not infected; one patient infected with H. pylori had 
atrophic gastritis before treatment that persisted after treatment. Among the 
patients treated with omeprazole, none of whom had atrophic gastritis at 
base line, atrophic gastritis developed in 18 of the 59 (30%) infected with H. 
pylori (P<0.001) and 2 of the 46 (4%) who were not infected (P=0.62). The 
authors concluded that patients with reflux oesophagitis and H. pylori 
infection treated with omeprazole are at increased risk of atrophic gastritis, 
6.1% annually, compared to 0% in those not treated with omeprazole and 
treated by anti-reflux surgery. This study has been criticised for its 
methodological weakness and patient selection 126. Similar results were 
obtained by other authors 178;179. In contrast, Lundell et.a/ did not find 
evidence of accelerated development of atrophic gastritis in patients on long-
term omeprazole180, though the results have been challenged by some 
authors 181 :182 who have ascertained that in fact, H. pylori infected patients did 
develop accelerated moderate to severe atrophy. 
Several other studies have found no evidence of acceleration of corpus 
atrophy in H. pylori individuals on long-term PPI therapy for reflux disease 183-
185. A very recent randomised study by Kuipers eta/. examined progression 
of atrophy in of H. pylori infected subjects with reflux oesophagitis on PPI 
therapy. They ascertained that despite being on PPis for 3 years or more, no 
progression to atropny was observed in any subject186. 
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The changing patterns of H. pylori gastritis in long-standing acid suppression 
was elegantly documented in a recently conducted prospective, double-blind 
trial187. The authors ascertained the effect on gastric histology of 12-month 
maintenance treatment with omeprazole in H. pylori-positive GORD patients 
randomly assigned to either an eradication or omeprazole-alone regime. A 
control group of 20 H. pylori-negative GORD patients also received 
omeprazole throughout the study period. Biopsies taken at baseline and at 
12 months were graded "blind" by a single observer according to the updated 
Sydney System. The 41 H. pylori-positive subjects with grade B or C 
oesophagitis were randomly assigned (20 to omeprazole alone, 21 to 
eradication) and 33 subjects completed the 12-month study. There was a 
significant decline in antral chronic inflammation in initially positive patients 
between baseline and end in both the eradication group (p =.035) and the 
omeprazole-alone group (p =.008). However, corpus chronic inflammation 
increased in the omeprazole-alone group {p =.0156) but decreased in the 
eradication group. The change toward corpus predominance between 
baseline and end for the omeprazole-alone group was highly significant (p 
=.0078). Furthermore, 5 of 11 in the omeprazole-alone group developed mild 
corpus atrophy, compared to 0 of 8 who had undergone H. pylori eradication. 
The change in frequency of corpus atrophy between the two groups was also 
significant (p =.02). The authors concluded that in H. pylori-positive subjects 
with GORD, long-term acid suppression lead to a shift from antral- to corpus-
predominant gastritis and an increase in corpus atrophy that could be 
prevented by prior eradication. It was recommended that H. pylori infection 
should be eradicated prior to long-term acid suppression with proton pump 
inhibitors. 
The incidence of gastric cancer is falling while that of lower oesophago-
cardiac adenocarcinoma is rising in the UK. This trend started well over three 
decades back (Fig 1 0) and preceded the introduction of PPis. The incidence 
of GORD in the developed world has risen dramatically since 1975, whilst 
over the same period duodenal ulcer has rapidly declined (fig 11) 146 
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The decline in the in the prevalence of H. pylori in the developed world in the 
201h century is likely to be responsible for the current statistics regarding 
duodenal and gastric ulcers. This may also at least in part explain the fall in 
gastric cancer rates. Remarkably, the presence of H. pylori may reduce the 
risk of developing other types of cancer, such as oesophageal 
adenocarcinoma.The same biological effects of H. pylori that predispose 
people to gastric cancer are likely to protect them from oesophageal 
cancer 146;188. 
Axon has recently suggested that the increased prevalence of gastro-
oesophageal reflux disease is a result of rising acid secretion in the general 
population, which, in turn, is a consequence of the increased linear height (a 
predictor of acid secretion)189;190. The greater acid secretion could also 
explain the decline in the prevalence of H. pylori and perhaps account for the 
inverse relationship between H. pylori and gastro-oesophageal reflux 
disease 137. 
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Figure 10: Incidence of gastric and oesophageal cancer in England and 
Wales 1979 to 1997. Source: Office of National Statistics 
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Figure 11.0pposing time trends of peptic ulcer and reflux disease (Gut 
1998;43: 327-33) 
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1. 7 Proton pump inhibitors-"the marketing story" 
1. 7. 1 Impact 
PPis are classified under the group of "blockbuster drugs". By definition, such 
super drugs are potent in their action, relatively harmless, recognised by the 
majority of medical fraternity for their highly beneficial effect and influence 
commonly occurring medical condition or conditions. 
"Blockbuster drugs share a variety of common features, among which is the 
"tendency to create entirely new markets". For example, an early "informed" 
estimate of the potential market size for the hypothetically "perfect" peptic 
ulcer drug was thirty-five million dollars. Based on current sales, however, 
this hypothesis has underestimated the actual market demand for 
omeprazole by about 400-fold. Similarly, prior to the introduction of the 
"retired" blockbusters chlordiazepoxide and diazepam (Librium TM and 
Valium ™), the market for minor tranquilizers in the treatment of anxiety and 
neurosis did not exist. Thus, once an emerging blockbuster seems to be 
therapeutically working, it is not unusual for diagnostic rates of the disease for 
which it is indicated and efficacious to actually increase. Top blockbuster 
drugs generally have or appear to have a high margin of safety191 . 
The advent of PPis has had a tremendous impact on several fronts; from 
patients and the medical fraternity to academia and research, creation of jobs 
to corporate decisions of pharmaceutical industries, financial and stock 
market buoyancy to the sponsoring of national and international meetings, 
creation of vociferous PPI lobbies, from GPs and Primary Care Trusts to 
Regional Health Authorities, National Patient Action Teams, Modernisation 
Agencies and the Department of Health. 
Such widespread and global impact, however, has only been possible 
because of the successful and clever marketing strategy deployed by the 
pharmaceuticals and aimed primarily at GPs. So good has been the influence 
of such sale technique, that despite guidelines from the National Institute of 
Clinical Excellence and pressures from PCTs and Pharmaceutical Advisors, 
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the rise and rise in the prescribing of PPis has been unstoppable33:34. In 
2003, £402 million was spent on PPis in England and Wales, an increase of 
£30m over 2002 and increase of nearly 600% over the last decade. 
1. 7. 2 Marketing strategy 
The success of PPis in the market place is not just the result of its 
pharmacological and clinical properties but due a combination of factors; 
recognition of the need to develop a potent agent, of a niche market for such 
a product, the involvement of key stakeholders in pre-clinical and post-
marketing studies, accompanying fortuitous events in the form of H. pylori, 
and ability to influence the "gatekeeper''-the grass root GPs of their potency, 
safety and cost-effectiveness. Campaigning, including invitations to GPs, 
specialists and other allied health professionals to national and international 
drug launches and related meetings helped to catapult a successful drug 
from the perspective of shareholders and the industry. Globally, in year 2000, 
$297.6billion was spent on drugs, of which anti-ulcer drugs was the leading 
category with 5% of the total expenditure. The old adage that "second onto 
the market is best" proved uncannily accurate for ranitidine, which through a 
combination judicious and aggressive marketing and backed up by research 
undertaken by key players, became established as the class leader amongst 
H2RAs. A similar strategy has not gone wrong for lansoprazole, which has 
overtaken omeprazole in terms of sales and share of primary care 
prescribing (Table 4). 
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Table 4 Top UK pharmaceutical products, 2002. Source: Association of 
British Pharmaceutical Industry 
product manufacturer Date Primary sector Hosp Total sales 
authorisation sales* £m sales £m £m 
Zocor MSD May89 300.73 9.95 310.67 
Lipitor Pfizer Jan 97 232.68 5.02 237.70 
Zoton Wyeth Apr94 211.16 17.87 229.03 
lstin Pfizer Jan 90 166.42 3.81 170.23 
Losee AZ Jun 89 151.74 11.03 162.77 
Zyprexa Eli Lilly Oct96 96.20 24.86 121.07 
Seretide GSK Mar99 111.73 3.82 115.54 
Lipostat BMS Sep90 106.33 3.53 109.86 
Tritace Aventis Mar90 100.35 3.98 104.33 
Serevent GSK Dec90 99.30 2.61 101.91 
Efexor Wyeth Jan 95 94.56 5.66 100.22 
Seroxat GSK Feb 91 92.46 3.70 96.15 
Zestril AZ Jun 88 79.65 1.53 81.17 
Flixotide GSK Mar93 74.17 1.98 76.15 
Omeprazole Generic Mar02 73.77 2.01 75.78 
Nexium(03) AZ 02 28.3 
Becotide GSK Oct72 48.44 1.14 49.59 
---------------- --
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1. 7.3 Drain on NHS resources - ''fact or fiction" 
The " fact" camp argue that PPis are inappropriately prescribed and poorly 
monitored by GPs, abused by patients to compensate for their life-style 
indiscretions, conflicting evidence provided by specialists and industry 
confuse GPs and the public, and that they are "unethically" promoted by 
sales representatives 192. All this therefore lead to high volumes of prescribing 
by GPs and a drain on NHS resources. Additionally, "a new and unnecessary 
importance and impetus" is given to a benign condition that hitherto 
responded to life style changes and use of antacids. It is estimated that there 
is potential saving of £50million each year if PPis were prescribed according 
to guidelines22 and that such savings in a cash-stripped NHS would be 
invaluable. 
The "fiction" camp takes the opposite view. They argue that in the main, PPis 
are appropriately prescribed and that any rationing of their prescribing 
freedom would result in unnecessary suffering by patients34. Patients with 
reflux symptoms have poor quality of life43 and PPis have dramatically 
improved this and it would be unethical to attempt to reduce or stop 
medications. Use of PPis by GPs has reduced hospital admissions, surgical 
procedures and oesophageal strictures30. There is also pressure to prescribe 
and maintain long-term prescribing 193. 
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Chapter 2 
The prevalence of H. pylori in Gastro-Oesophageal 
Reflux Disease: a systematic review 
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2.1 Abstract 
Objectives: To ascertain the prevalence of H. pylori in, and its association 
with, gastro-oesophageal reflux disease. 
Design: Systematic review of studies reporting the prevalence of H. pylori in 
patients with and without gastro-oesophageal reflux disease. 
Data sources: Four electronic databases were searched to November 2001. 
Experts in the field, pharmaceutical companies and journals were contacted 
for information on unpublished trials. Studies were reviewed according to 
predefined eligibility and quality criteria. 
Main outcome measures: Odds ratio for the prevalence of H. pylori infection 
in patients with gastro-oesophageal reflux disease. 
Results: Twenty studies were included. A 95% confidence interval for the 
odds ratio for H. pylori prevalence was 0.47, 0.78 indicating a lower 
prevalence in patients with gastro-oesophageal reflux disease. Substantial 
heterogeneity was observed between studies. Investigation of this indicated 
that location was an important factor, with much lower prevalence of H. pylori 
in patients with gastro-oesophageal reflux disease in East Asian studies, 
despite a higher overall prevalence of infection compared with Western 
Europe and North America. Year of study was not a source of heterogeneity. 
Conclusion: Despite study heterogeneity, there is significantly lower 
prevalence of H. pylori infection in patients with gastro-oesophageal reflux 
disease than in patients who do not have it, geographical location being the 
most important determinant; the higher prevalence of H. pylori infection in 
Asia was associated with lower prevalence in gastro-oesophageal reflux 
disease patients compared with Western Europe and North America. 
56 
2.2 Introduction 
Gastro-oesophageal reflux disease is a common condition affecting 25-40% 
of the population 194. It is managed essentially in primary care and is 
associated with the largest prescribing cost sector in the NHS195. Whilst there 
is good evidence that infection with H. pylori is the principal cause of peptic 
ulcer disease there is uncertainty about the organism's role in gastro-
oesophageal reflux disease. Treating H. pylori infection is effective in healing 
duodenal ulcers 196. The effect of eradication in patients with gastro-
oesophageal reflux disease is less clear, some reports suggesting that this 
might be counterproductive and that H. pylori infection might be protective 
against it142;197. However, the recent Maastricht 2 guidelines 198, on the 
management of patients with H. pylori infection, recommend eradication in 
patients with gastro-oesophageal reflux disease who are likely to require long 
term proton pump inhibitor therapy. This is on the grounds that profound acid 
suppression may accelerate the progression of H. pylori induced atrophic 
gastritis, increasing the potential risk of cancer. 
The evidence for an association between H. pylori and gastro-oesophageal 
reflux disease remains mixed and largely uncertain. Studies evaluating the 
effect of the presence or absence of H. pylori on gastro-oesophageal reflux 
disease have frequently suffered from design drawbacks and have given 
conflicting results 147;167. Fundamentally, it is not certain whether there are 
clear differences in H. pylori prevalence between patients with and without 
gastro-oesophageal reflux disease as several studies have, again, giving 
conflicting results 157;199-202. 
A rigorous systematic review was conducted of the available studies to 
establish the overall prevalence of H. pylori in gastro-oesophageal reflux 
disease and to determine if this is significantly different from those without. 
This information is important for providing a definitive answer as to whether 
gastro-oesophageal reflux disease patients differ and to quantify the extent of 
the infection in them. This topic is also of particular relevance because of the 
large numbers of patients in the community taking long term proton pump 
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inhibitors, mostly for reflux. The determination of H. pylori status in these 
patients has hitherto not been a clinical issue; gastro-oesophageal reflux 
disease is commonly diagnosed and treated in primary care on the basis of a 
clinical history alone. 
2.3 Methods 
2.3.1 Search strategy 
Studies to November 2001 fulfilling the eligibility criteria listed in Box 1 were 
suitable for inclusion regardless of publication status. Studies were identified 
by searching four electronic databases (Medline, Embase, Cinahl and 
Cochrane) using subject terms and text words, by reviewing bibliographies of 
retrieved studies, by contacting recognised experts in six countries, and 
pharmaceutical companies (see below). General medical and major 
gastroenterology journals over the previous year were also scanned. 
2.3.2 Assessment of eligibility and trial quality 
Gastro-oesophageal reflux disease was defined according to published 
definitions93;203-205;205 . This comprised two categories, both in patients who 
had heartburn or reflux as the predominant symptoms. The first was the 
presence of endoscopically defined oesophagitis and the second, where 
endoscopy did not reveal visible oesophagitis, positive pH monitoring test 
results and /or histological oesophagitis. 
Two investigators independently reviewed all identified papers according to 
the eligibility and quality criteria. Abstracts were only included if they met the 
eligibility criteria. Where disagreements occurred a third reviewer was 
involved and the majority view taken. The quality of trials was evaluated 
according to the predefined criteria (Box 1 ). The quality assessments focused 
on whether the methods used for obtaining cases and controls, data 
collection, and H. pylori testing were stated. 
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BOX1 
Eligibility and quality criteria 
General 
Studies that used a comparator, control or reference group 
A. Cases (Gastro-oesophageal reflux disease) 
• All should have undergone gastroscopy 
• Patients with endoscopically proven oesophagitis, included 
• Patients with normal oesophageal appearances on endoscopy, who had 
confirmation of gastro-oesophageal reflux disease either by pH studies or with 
positive histology, included. 
• Patients with non-ulcer dyspepsia in whom other confirmation of gastro-
oesophageal reflux disease by pH studies or oesophageal histology were not 
available, excluded 
• Patients with normal endoscopy and typical reflux symptoms but confirmation by 
pH studies or histology not available or confirmed, excluded. 
• Patients known or discovered to have Barrett's oesophagus, excluded. 
• Patients with confirmed peptic ulcer disease, excluded 
• Patients who had received proton pump inhibitors within the previous 2 weeks or 
H. pylori eradication, excluded 
B. Comparator group (one or more of the following) 
• Normal endoscopy and absence of gastro-oesophageal reflux disease symptoms 
• Healthy asymptomatic volunteers 
• Absence of pathological reflux on pH monitoring 
• Normal endoscopy and absence of histological oesophagitis 
C. Quality criteria 
• Documentation of how cases were obtained 
• Appropriateness of comparator 
• Similar data collection for cases and comparator group 
• Similar H. pylori testing for cases and comparator group 
• Basic data adequately described 
• Statistical methods described and significance levels assessed 
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2.3.3 Details of searches for studies of H. pylori prevalence in gastro-
oesophageal reflux disease (gastro-oesophageal reflux disease). 
Medline, EMBASE, CINAHL, Cochrane (Controlled Trials Register and 
database of systematic reviews) electronic databases were explored using 
broad search strategies to identify all studies and trials determining H. pylori 
prevalence in gastro-oesophageal reflux disease. Searches were run from 
1983 for Medline and CINAHL and from 1988 for EMBASE until May 2000. A 
final search of Medline and Embase was undertaken in Nov 2001. 
Gut, Gastroenterology, British Medical Journal, Lancet, New England Journal 
of Medicine and Alimentary Pharmacology and Therapeutics from 1998 were 
hand searched. In addition, the content of major gastroenterological and 
general medical journals for the year up until the end of Oct 2001 was 
routinely reviewed. Members of the Cochrane Upper Digestive and 
Pancreatic Group, editors of Alimentary Pharmacology and Therapeutics and 
Gut as well as experts in the field of H. pylori and gastro-oesophageal reflux 
disease concerning the systematic review were also contacted. 
The bibliographies of retrieved papers were also reviewed for relevant 
studies not identified by the database and hand searching. Pharmaceutical 
companies (Astra-Zeneca, Wyeth Laboratories, and Abbott Laboratories) 
were also contacted for any data on studies that had been published or were 
unpublished and in their archives. 
2.3.3.1 Tenns for H. pylori prevalence in gastro-oesophageal reflux disease 
MeSH search tenns 
(Gastro-oesophageal reflux disease and H. pylori related) 
H. pylori, gastroesophageal reflux, heartburn, esophagitis, esophageal 
stenosis, barrett esophagus, esophageal neoplasms. 
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Embase subject headings 
Campylobacter pyloridis, barrett esophagus, esophagus cancer, esophagus 
carcinoma, esophagus metastasis, esophagus tumor, reflux esophagitis, 
gastroesophageal reflux, esophagus stricture, heartburn. 
Textword search terms 
H. pylori, campylobacter pyloridis, campylobacter pylori, reflux, 
gastroesophageal, gastro-oesophageal, gastro AND oesophageal, gastro 
AND esophageal, GERD, gastro-oesophageal reflux disease, heartburn, 
esophagitis OR oesophagitis, stricture, esophageal OR oesophageal, barrett 
esophagus OR oesophagus, neoplasm OR neoplasms, cancer OR cancers. 
Selection Criteria 
(1) Subject 
Any relationship I association between Helicobacter pylori and oesophageal 
disease (i.e. Barrett's Oesophagus, Oesophageal Cancer, Reflux 
Oesophagitis, gastro-oesophageal reflux disease). Such a relationship could 
be mediated through a "third party", e.g. proton pump inhibitor treatment. 
(2) Study type 
Systematic review, Meta-analysis, RCT, Any other type of clinical trial, Case-
controlled study, Cohort-study (retrospective or prospective), Cost-analysis 
study based on the, above types of study, Biomedical I Biological study 
(human, animal, biochemical, genetic etc.), Qualitative research study. 
The following study types I publication types were DISCARDED 
Case report, personal literature review, expert opinion, consensus report 
(unless based on selected types of study), editorials, letters. Selection was 
been an iterative process. Database records were reviewed independently by 
both the author of this thesis as well as another research associate. 
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Disagreements were discussed and a consensus reached. Complete articles 
were obtained for items that passed the selection criteria or for items where 
there was not enough information in the database record to make a decision. 
The full articles were then reviewed against the selection criteria for a second 
time. 
2.3.4 Experts contacted for systematic review 
Dr H H Tsai, UK, Prof. P.Malfertheiner, Germany, Dr AG Fraser, New 
Zealand, Prof. J. Labenz, Germany, Dr N. Murai, Japan, Dr N. Vakil, USA, 
Prof. K. Haruma, Japan, Prof. B. Tepes, Slovinia. 
2.3.5 Data extraction 
Data were extracted from eligible studies on a standardised form and this 
was checked by a second investigator. Data concerning the prevalence of H. 
pylori in various grades of oesophagitis and endoscopy negative reflux 
disease was recorded as reported but the overall prevalence of H. pylori in 
gastro-oesophageal reflux disease was used for analysis. 
2. 3. 6 Data Synthesis 
Each of the 20 studies was summarised according to its odds ratio206• For 
this review, an odds ratio of less than one indicates a higher prevalence of H. 
pylori amongst control patients than amongst gastro-oesophageal reflux 
disease patients. We pooled the study results using a fixed effect (Mantei-
Haenszel) model, which was assessed using a test of homogeneity and a 
funnel plof07 . Following the finding of substantial heterogeneity, we used a 
random-effects model208 to pool the odds-ratios. The statistical analysis was 
performed using the free package R, 208 and the rmeta subpackage 
contributed by Thomas Lumley. 
------------------------------------------------
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2.4 Results 
The initial search identified 654 articles but, after scanning titles and 
abstracts, only 45 were found that evaluated H. pylori prevalence in gastro-
oesophageal reflux disease. Thirty-five of these met the eligibility criteria. 
Further detailed scrutiny excluded sixteen of these 143;147;178;199;202;209-21 9. 
Despite meeting the eligibility criteria, one further study 220 was excluded 
because of significant overlap with another study by the same lead author 221 ; 
also the proportions between the two studies were so close that there was 
virtually no difference in results. This left 20 for final consideration 141 ;145;157;222-
237 (Appendix 3). These contained a total of 4,134 patients, of whom 58.5% 
were in control groups. 
2. 4. 1 Studies included in the systematic review 
Details of studies are given at the end of this chapter following Discussion. 
2.4.2 Studies excluded from the systematic review 
Details of studies are given at the end of this chapter following Discussion. 
2.4.3 Prevalences of H. pylori infection (Table 1) 
Because these studies were conducted in different settings with different 
background prevalences of H. pylori, an overall difference in prevalence rates 
is of limited value. However, from the studies considered, the average 
prevalence of H. pylori infection in gastro-oesophageal reflux disease was 
38.2% (range, 20-82%) and in the comparator group 49.5% (range, 29-
75.6%). 
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Table 1. Prevalence of H. pylori: odds ratio for each study, (95% 
confidence intervals). Studies are arranged in decreasing order of odds 
ratio. 
Author Hp Sample Hp Sample Odds Lower Upper 
(country, comp* size GORD size ratio 95% 95% 
year) comp* GORD 
Csendes 38 190 40 136 1.67 1.00 2.78 
(Chile, 
1997) 
Newton 9 25 15 36 1.27 0.44 3.63 
(UK, 1997) 
Pieramico 19 49 24 54 1.26 0.58 2.77 
(Italy, 
2000) 
Gisbert 23 44 32 56 1.22 0.55 2.69 
(Spain, 
2001) 
Hackelsber 89 227 50 130 0.97 0.62 1.51 
ger 
(Germany 
1998) 
Manes 80 200 37 105 0.82 0.50 1.33 
(Italy, 
1999) 
Vaezi 25 60 39 108 0.79 0.41 1.51 
(USA, 
2000) 
EI-Serag 55 148 36 116 0.76 0.45 1.27 
(USA, 
1999) 
Goldblum 13 27 24 58 0.76 0.30 1.90 
(USA, 
1998) 
Varanasi 89 257 24 86 0.73 0.43 1.25 
(USA, 
1998) 
64 
Liston 27 33 28 37 0.69 0.22 2.21 
(UK, 1996) 
Vicari 26 57 30 84 0.66 0.33 1.32 
(USA, 
1998) 
Schubert 17 42 9 31 0.60 0.22 1.62 
(USA, 
1999) 
Fallone 37 78 27 81 0.55 0.29 1.05 
(Canada, 
2000) 
Werdmuller 204 399 34 118 0.39 0.25 0.60 
(Holland, 
1997) 
Shirota 17 28 26 73 0.36 0.15 0.88 
(Japan, 99) 
Wu (Hong 73 120 21 66 0.30 0.16 0.57 
Kong, 
1999) 
Mihara 47 70 26 70 0.29 0.14 0.58 
(Japan, 
1996) 
Haruma 145 190 39 95 0.22 0.13 0.37 
(Japan, 
2000) 
Koike 126 175 59 175 0.20 0.13 0.31 
(Japan, 
1999) 
*Comp = comparator group 
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Figure 1. The prevalence of H. pylori; odds ratio and 95% confidence 
intervals. 
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Figure 1 plots these odds ratios and 95% confidence intervals. Large boxes 
indicate studies with small standard errors (essentially larger sample sizes). 
The vertical dotted line indicates no difference between groups. Four 
studies222;225;232;233 show higher prevalence amongst the gastro-oesophageal 
reflux disease patients, but not significantly so, except marginally, for the 
Csendes study222• The remaining studies indicate lower H. pylori prevalence 
amongst gastro-oesophageal reflux disease patients, significantly so for six 
studies 157;221 ;228;231 ;235;237. The pooled (Mantei-Haenszel) odds ratio is 0.58, 
95% Cl (0.51, 0.66), indicating quite strong evidence of lower H. pylori 
prevalence amongst gastro-oesophageal reflux disease patients. The 
heterogeneity test gives X"2 = 83.01, df=19, P<0.001. 
0 
~ 
U5 
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Figure 2. Size and effect of results from eligible studies 
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Figure 2, which shows a funnel plot for the analysis, provides no clear 
evidence of publication bias: nor would we expect any in this context. 
Because of the presence of substantial heterogeneity, the studies were also 
pooled using the DerSimonian-Laird random effects model. This gave a 
summary odds ratio of 0.60, 95% Cl (0.47, 0.78), weaker but still strong 
evidence of lower H. pylori prevalence amongst gastro-oesophageal reflux 
disease patients. 
The statistical heterogeneity was investigated by year of study (no effect) and 
by location. Five of these 221 ;228;231 ;235;237 involved patients from East Asia, 
seven 157;225;227;229;230;232;233 from USA/Canada, seven 141;145;223;224;226;234;236 
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from Western Europe. One further study222 originated from Chile. Figure 1 is 
arranged to show the locations of the studies and indicates some similarities 
in results for neighbouring studies. Analysing the results for the three main 
groups separately, we find: for Western Europe an odds ratio of 0.76, 95% Cl 
(0.61,0.96), test for heterogeneity: X"2= 14.01, df=6, p=0.030). From Figure 
1, it seems that the Werdmuller study 157 dominates the analysis. Repeating 
the analysis excluding this study leads to an odds ratio of 0.97 95% Cl 
(0.75,1.27), test for heterogeneity: X"2= 1.8, df=5, p=0.88. We conclude that 
the evidence for Western Europe is equivocal. For North America the odds 
ratio is 0.70 95% Cl (0.55,0.9), test for heterogeneity: X"2 = 0.92, df=6, 
p=0.99. This suggests that there is evidence for lower H. pylori prevalence 
amongst gastro-oesophageal reflux disease patients in North American 
studies, and consistently so. 
For Eastern Asia the odds ratio is 0.24 95% Cl (0.19,0.32), test for 
heterogeneity: X"2= 2.36, df=4, P=.670. This suggests that there is very 
strong evidence for lower H. pylori prevalence amongst gastro-oesophageal 
reflux disease patients in Eastern Asian studies, and consistently so. 
The Csendes study222 , from South America, appears anomalous compared 
to the others. These results suggest that the major portion of the differences 
amongst studies can be explained by differences in location. Some of the 
remaining heterogeneity may be a product of clinical heterogeneity238. 
However it was not straightforward to explore these studies further to identify 
covariates to explain the clinical heterogeneity. 
2.5 Discussion 
The results indicate that there is significantly lower prevalence of H. pylori in 
patients with gastro-oesophageal reflux disease than in patients without, 
geographical location being the important determinant of this conclusion. 
The results of our systematic review were based on studies all of which had a 
comparator group. Despite this, there were significant differences between 
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studies in relation to type of study (prospective/retrospective case-control, 
trial), study population, identification of cases and controls, inclusion and 
exclusion criteria, matching of cases and controls and H. pylori testing 
methods. The results need to be interpreted with caution. 
The majority of subjects included were having endoscopy for clinical reasons 
and did not thus constitute a population group per se, although three 
community-based studies227;228;230 were discovered. Ascertaining the 
prevalence of H. pylori was thus necessarily dependent on a proportion that 
was being investigated for suspected lesions. However, this is unlikely to 
have substantially compromised our overall results because our eligibility 
criteria excluded patients with gastro-oesophageal reflux disease symptoms 
who had negative endoscopy or negative pH testing. 
Given that there was substantial heterogeneity observed between studies, 
we acknowledge issues about the appropriateness of reporting a pooled 
odds ratio. Our exploration of the heterogeneity suggests a possible 
difference in prevalence of H. pylori in gastro-oesophageal reflux disease 
between East Asia and North America I Western Europe; a single study from 
South America 222 gave an exceptionally higher prevalence. At first sight 
these results indicate that the prevalence of H. pylori in gastro-oesophageal 
reflux disease is lower in countries where the prevalence of H. pylori in the 
general population is higher. The reasons for this are unclear and may be 
related to dietary or genetic factors. Of the 20 studies included in the 
analysis, four reported a higher prevalence amongst those with gastro-
oesophageal reflux disease, but in only one of these222 was the difference 
statistically significant. The reasons for this are uncertain but may at least 
partly be related to factors such as study design, selection of cases and 
controls and method of H. pylori testing. Again, presenting data as pooled 
estimates of odds ratios for different groups of countries may give the 
misleading impression of post-hoc confirmatory analyses but we strongly feel 
that there is a location effect evident hi these data, arrd that the prevalences 
have different patterns within locations. 
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H. pylori prevalence in males and females were not separately analysed. 
These data were not obtainable in many studies and where available, there 
was no reported difference in prevalence between sexes. Barrett's 
oesophagus was excluded in relation to H. pylori because it was felt this 
merited a systematic review in its own right. 
The clinical relevance of this lower H. pylori prevalence in gastro-
oesophageal reflux disease is unclear. Some studies 142 have suggested that 
H. pylori may indeed be protective against gastro-oesophageal reflux disease 
and that those infected with H. pylori may have less severe gastro-
oesophageal reflux disease. 197. There is also conflicting evidence about the 
effect of H. pylori infection on the efficacy of proton pump inhibitors. One 
study 167 found that patients with gastro-oesophageal reflux disease and H. 
pylori infection responded significantly better to proton pump inhibitors. In 
contrast, another trial found that H. pylori negative patients did not need 
higher doses of acid suppression with proton pump inhibitors to maintain 
symptomatic and endoscopic disease remission. There is evidence that in 
the presence of long-term acid suppression with proton pump inhibitors, H. 
pylori induces atrophic gastritis 177 and recent guidelines have advocated 
eradication in patients on long-term proton pump therapy198. Our findings 
contribute to the ongoing debate whether or not H. pylori should be 
eliminated in patients with gastro-oesophageal reflux disease, and describes 
the size of the potential problem. 
These results do not enable definitive comment on the benefit or possible 
detriment from H. pylori eradication in patients with gastro-oesophageal 
reflux disease; a further review regarding this is in preparation. The 
systematic review findings add insight into the understanding of the complex 
relationship between H. pylori and gastro-oesophageal reflux disease. 
Clearly, more, well designed, prospective, large-scale, case-control studies 
and trials are required both to uncover the epidemiological relationship 
between H. pylori and gastro-oesophageal reflux diseclse · as well as to 
determine the clinical implications of this association. 
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Details of included studies 
Author, reference, year and type of study: Werdmuller157, descriptive and 
prospective. 
Participants: Consecutive patients undergoing upper Gl endoscopy for 
upper abdominal complaints or reflux symptoms. Cases (n= 240, of which 
118 patients with proven gastro-oesophageal reflux disease included. Rest 
with hiatus hernia and no RE or with 80 excluded). Reference group 
(n=399): Normal endoscopy and presumed absence of typical reflux 
symptoms. 
Intervention: Upper Gl endoscopy, Hp testing by histology (H&E stain), 
culture, quick urease test and serology (not all four tests in every patient). 
Outcome: Hp prevalence in gastro-oesophageal reflux disease (29%), in 
reference group (51%). 
Comments or conclusions: We assumed from the details given that 
patients in the reference group do not have reflux disease. 
Author, reference, year and type of study: Koike221 , Case-control, 
prospective. 
Participants: Patients were self and physician referred. Cases (n=175): RE 
patients. Controls: Age-sex matched, randomly selected, who visited the 
hospital, were asymptomatic, and had normal endoscopy. 
Intervention: Upper Gl endoscopy. Hp testing by histology, rapid urease 
test and serology. Atrophic gastritis assessed by updated Sydney system, 
and serum PG measured. 
Outcome: Hp prevalence in gastro-oesophageal reflux disease (34%), in 
control (72%). 
Comments or conclusions: 
Author, reference, year and type of study: Csendes222 Case-control, 
prospective, prevalence study. 
Participants: Cases (n=136): Patients with chronic gastro-oesophageal 
reflux disease (RE, ENRD) symptoms of at least 3years' duration. Controls 
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(n=190): Patients needing endoscopy none of who had symptoms of gastro-
oesophageal reflux disease. 
Intervention: Upper Gl endoscopy in cases and controls, Hp testing by 
histology. pH-metry in all cases of gastro-oesophageal reflux disease, no 
pH-metry in controls. 
Outcome: Hp prevalence in RE, ENRD, BO and controls. No difference in 
Hp prevalence (NS) between RE (32%), ENRD (25%) and controls (29%). 
Also no difference in age and sex distribution 
between reflux and controls. 
Comments or conclusions: Exclusion of peptic ulcer not clearly stated. 
Author, reference, year and type of study: EI-Serag223, Descriptive, 
prospective. 
Participants: Patients referred for elective upper Gl endoscopy. 
Cases (n=154, of which 116 patients were included, 38 excluded because of 
80): all patients with erosive oesophagitis. Controls (n=148): Patients with 
normal endoscopy and absence of gastro-oesophageal reflux disease 
symptoms. 
Intervention: Upper Gl endoscopy in cases and controls, Hp testing by H/E 
stain. 
Outcome: Hp prevalence in gastro-oesophageal reflux disease (31 %), in 
control (43%). 
Comments or conclusions: This study was looking at the protective effect 
of corpus gastritis against RE. We excluded Barrett's from our analysis. 
Author, reference, year and type of study: Fallone224, Descriptive, 
prospective. 
Participants: Patients scheduled to have upper Gl endoscopy. Cases (n= 
327, of which 81 patients with gastro-oesophageal reflux disease included. 
Rest were Classified into four groups; NUD, DU, GU, and therefore excluded. 
Patients with gastro-oesophageal reflux disease consisted of RE and ENRD. 
Comparator group (n= 78): These were p'atiemts in whom there were no 
GERD symptoms and the indications for endoscopy were multiple, all had 
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normal oesophagus or findings unrelated to gastro-oesophageal reflux 
disease. 
Intervention: Upper Gl endoscopy; Hp testing by histology and culture; 
detection of specific genes or gene sequence within Hp and detection of 
CagA antibodies. 
Outcome: Hp prevalence in gastro-oesophageal reflux disease (33%), in 
comparator group (48%). Prevalence of CagA, CagE, vacA 81 genotypes 
and CagA antibody determined in cases and comparator group. 
Comments or conclusions: Some patients with ENRD but reflux not 
proven may have been included in our prevalence data. This study 
concluded that gastro-oesophageal reflux disease was associated with a 
significantly lower rate of vacA 51 genotype than controls. 
Author, reference, year and type of study: Gisbert 225 Descriptive, 
prospective, prevalence. 
Participants: Consecutive patients undergoing24-hour oesophageal Ph 
monitoring in the motility unit because of symptoms suggestive of gastro-
oesophageal reflux disease. Cases (n= 56): Typical gastro-oesophageal 
reflux disease symptoms and positive Ph findings. Controls (n=44): gastro-
oesophageal reflux disease symptoms but negative Ph findings. 
Intervention: Upper Gl endoscopy, 24-hour oesophageal Ph monitoring and 
Hp testing by histology and rapid urease test. 
Outcome: Hp prevalence in gastro-oesophageal reflux disease (57%), in 
control (52%). 
Comments or conclusions: Comparator group may represent NUD 
patients. 
Author, reference, year and type of study: Goldblum226 Case-control, 
prospective. 
Participants: Cases (n=58): patients with classic gastro-oesophageal reflux 
disease symptoms enrolled into the study. Control {n=27): Patients 
undergoing endoscopy for reasons other tlian gasfr<:>-oesophageal reflux 
disease symptoms, 80, PUD or dyspepsia. 
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Intervention: Upper Gl endoscopy in cases and controls; Hp testing by 
histology (H& E and Giemsa stain) and serology. 
Outcome: Hp prevalence in gastro-oesophageal reflux disease (41%), in 
control (48%). Prevalence of carditis and IM of the cardia in cases and 
controls was also determined. 
Comments or conclusions: This study also concluded that cardia 
inflammation and cardia IM are associated with Hp infection. 
Author, reference, year and type of study: Hacklesberger227 Case-control, 
prospective. 
Participants: Cases (out of 171, 130 [n] were included, remaining 41 had 
associated PUD): consecutive Caucasian patients undergoing elective 
endoscopy. Controls (n=227): asymptomatic volunteers or patients attending 
for other reasons and without any gastro-oesophageal reflux disease 
symptoms. 
Intervention: Upper Gl endoscopy in cases only. Hp testing by histology 
and rapid urease test in cases 13C -UBT 
Outcome: Hp prevalence in gastro-oesophageal reflux disease (38%), in 
control (39%). 
Comments or conclusions: Different methods of Hp in cases and controls. 
No endoscopy in controls. 
Author, reference, year and type of study: Haruma228 Retrospective 
case-control. 
Participants: Of the 6205 patients undergoing upper Gl endoscopy between 
defined periods, 229 were defined as having RE. Of these, 95 (n) met the 
authors' inclusion criteria. Controls (n=190): healthy, asymptomatic, age-sex 
matched selected from among 608 healthy individuals who had undergone 
routine health care check for gastric cancer. 
Intervention: Upper Gl endoscopy in cases and controls; Hp testing by 
Giemsa stain and serology. Inflammation, atrophy and IM were evaluated 
using updated Sydney system. Serum gastrin and PG concent~ations were 
also determined. 
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Outcome: Hp prevalence in gastro-oesophageal reflux disease (41%), in 
control (76%). 
Comments or conclusions: The authors found significant low prevalence 
of Hp in RE in patients over 60, but not under 59 years of age when 
compared with age-sex matched controls. 
Author, reference, year and type of study: Manes23° Case-control, 
prospective, prevalence. 
Participants: Cases (202 of which 105 [n] patients with proven gastro-
oesophageal reflux disease included): Consecutive patients with typical 
GERD symptoms lasting more than 6 months. Peptic ulcer cases excluded. 
Controls (n=200): 1) healthy asymptomatic blood donors and 2) functional 
non-specific abdominal complaints with normal endoscopy except for signs of 
chronic gastritis. 
Intervention: Upper Gl endoscopy in cases only. Hp testing by histology I 
rapid urease test in cases and serology in controls. 
Outcome: Hp prevalence in erosive RE (32%), ENRD (62%) and control 
group (40%). Also patterns of gastritis, Hp colonisation and dyspepsia 
symptoms in ENRD andRE compared. 
Comments or conclusions: We excluded 80 (as stated in our protocol) 
and also ENRD (not proven to have gastro-oesophageal reflux disease) from 
our analysis. Different methods of Hp testing in cases and controls, no 
endoscopy in controls. 
Author, reference, year and type of study: Mihara231 Case-control, 
prospective, prevalence. 
Participants: Cases (n=70): Patients with RE. Control (n=70): Age- sex 
matched, no gastro-oesophageal reflux disease symptoms and normal 
endoscopy. 
Intervention: Upper Gl endoscopy, Hp testing by Giemsa stain and 
serology, gastritis and atrophy scores and serum pepsinogen levels. 
Outcome: Hp ,prevalence in gastro'"oesophageal reflux disease (37%), in 
control (67%). Gastritis, atrophy scores and serum PG1, PG2 levels and 
ratios in cases and controls were also determined. 
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Comments or conclusions: Abstract. 
Author, reference, year and type of study: Newton232 Case-control, 
prospective, prevalence. 
Participants: Cases (83 of which 25[n] patients with proven gastro -
oesophageal reflux disease included): patients referred for endoscopy 
divided into four groups. (RE, DU, RE+DU, 80). Controls (n=25): 
asymptomatic patients with anaemia referred for endoscopy. 
Intervention: Upper Gl endoscopy in cases and controls. Hp testing by 
histology and CLO test. 
Outcome: Hp prevalence in gastro-oesophageal reflux disease (42%), in 
control (36%). Hp colonisation and distribution assessed in different patient 
groups. 
Comments or conclusions: We excluded 80, DU and DU+RE for our 
analysis. 
Author, reference, year and type of study: Pieramico233 Case-control, 
prospective. 
Participants: Cases (122, of which 54[n] patients with proven gastro-
oesophageal reflux disease included, 68 ENRD patients excluded because 
reflux not proven): Consecutive patients referred for gastro-oesophageal 
reflux disease symptoms to the endoscopy unit. Controls (n=49): Patients 
who underwent endoscopy in the same period as cases for reasons other 
than gastro-oesophageal reflux disease symptoms, Barrett's oesophagus, 
active or previous PUD, gastric or oesophageal neoplasms or dyspepsia 
Intervention: Upper Gl endoscopy in cases and controls; Hp testing by 
Giemsa stain in cases and controls. 
Outcome: Hp prevalence in gastro-oesophageal reflux disease (44%), in 
control (38%). 
Comments or conclusions: Grade 0 (ENRD, 68 patients)) were not proven 
to have gastro-oesophageal reflux disease, hence we excluded them from 
our analysis. 
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Author, reference, year and type of study: Schuberf34 Descriptive, 
prospective. 
Participants: All consenting patients referred for endoscopy between 
defined periods. Cases (170, of which 31[n] proven gastro-oesophageal 
reflux disease patients included). Rest were classified into several diagnostic 
groups (DU, GU, NUD, gastritis, duodenitis) and therefore excluded. Control/ 
comparator group (n=42): Patients with absence of gastro-oesophageal 
reflux disease symptoms and normal endoscopy. 
Intervention: Upper Gl endoscopy; Hp testing by histology, rapid urease 
test and culture. 
Outcome: Hp prevalence in gastro-oesophageal reflux disease (26%), in 
comparator group (40%). 
Comments or conclusions: Some patients with ENRD but reflux not 
proven may have been included in our prevalence data 
Author, reference, year and type of study: Shirota235 Descriptive, 
retrospective. 
Participants: Random selection of cases and controls from among patients 
who underwent upper Gl endoscopy between defined periods. Cases 
(n=73): RE (mild, severe). Controls (n=28): Normal endoscopy and 
presumed absence of gastro- oesophageal reflux disease symptoms. 
Intervention: Upper Gl endoscopy, Hp testing by culture, urease test and 
serology, serum pepsinogen levels and oesophageal manometry. 
Outcome: Hp prevalence in gastro-oesophageal reflux disease (36%), in 
controls (61 %). Pepsinogen 1 to pepsinogen 2 ratios determined to assess 
severity of atrophic gastritis. 
Comments or conclusions: We assumed from the details provided that 
patients in the control group did not have gastro-oesophageal reflux disease 
symptoms. The authors concluded that a low prevalence of Hp might result in 
a milder grade of atrophic gastritis and consequently exacerbate RE. 
Author, reference, year and type of study: Vaezi145 Descriptive, 
prospective. 
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Participants: Patients undergoing upper Gl endoscopy. Based on pre-
endoscopy questionnaire and endoscopy findings, patients were grouped into 
cases: gastro-oesophageal reflux disease (n=1 08), short and long-segment 
Barrett's and controls (n=60). Control patients had normal endoscopy and no 
gastro-oesophageal reflux disease symptoms. 
Intervention: Upper Gl endoscopy. Hp testing by Giemsa stain, serology to 
determine lgG response to Hp whole cell antigen and to CagA using ELISA. 
Outcome: Hp and CagA prevalence in cases (gastro-oesophageal reflux 
disease, SSB, LSB) and controls. Hp prevalence in gastro-oesophageal 
reflux disease (36%), in control (42%). 
Comments or conclusions: The paper concluded that CagA positive Hp 
strains might protect against Barrett's. We excluded patients with Barrett's 
from our analysis. 
Author, reference, year and type of study: Varanasi236 Descriptive, 
retrospective. 
Participants: Review of records of all patients {>18yrs) who had upper Gl 
endoscopy and rapid urease testing. Cases (n=54): gastro- oesophageal 
reflux disease (RE or proven ENRD-typical symptoms of gastro-oesophageal 
reflux disease, normal endoscopy and histological esophagitis) and BO. 
Comparator (n=257): Normal endoscopy and presumed absence of gastro-
oesophageal reflux disease symptoms. 
Intervention: Upper Gl endoscopy; Hp testing by rapid urease test in all, 
histopathology and serology in some. 
Outcome: Hp prevalence determined in patients with and without gastro-
oesophageal reflux disease as well as well as stratifying for presence or 
absence of PUD in each group. Hp prevalence in gastro-oesophageal reflux 
disease (29%), in control (34%). 
Comments or conclusions: We excluded BO and cases of RE associated 
with PUD from our analysis. This study found no variability of Hp between 
different groups of RE. 
Author, reference, year and type of study: Vicari141 Prospective, case-
control. 
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Participants: Cases: patients with classic gastro- oesophageal reflux 
disease (153, of which 84[n]patients included and 59 with 80 excluded) 
symptoms enrolled into the study. Control: Patients undergoing endoscopy 
for reasons other than gastro-oesophageal reflux disease symptoms, 80, 
PUD or dyspepsia. 
Intervention:· Upper Gl endoscopy in cases and controls; Hp testing by 
histology (H& E and Giemsa stain) and serology. 
Outcome: Hp prevalence in gastro-oesophageal reflux disease (36%), in 
control (46%). CagA positivity status also determined in cases and controls. 
Comments or conclusions: Some patients with ENRD, but reflux not 
proven may have been included in our prevalence data. 80 excluded. 
Author, reference, year and type of study: Wu237 Case-control, 
prospective. 
Participants: Cases (1 06, of which we included 66[n] and excluded 40 with 
ENRD whose diagnosis of reflux disease were not proven): Patients with 
typical gastro-oesophageal reflux disease symptoms and RE. Control 
(n=120): Absence of gastro-oesophageal reflux disease symptoms, absence 
of dyspepsia and recruited from general medical clinics and day care centres 
without any evidence of Gl disease. 
Intervention: Upper Gl endoscopy in Hp positive cases, Hp testing by 
serology in cases and controls, Giemsa stain for Hp, H&E stain for gastritis, 
and intensity of inflammation and bacterial colonisation by the updated 
Sydney system in Hp positive cases. 
Outcome: Hp prevalence in gastro-oesophageal reflux disease (32%), in 
control (61%). Histological assessment of gastritis and Hp colonisation in 
gastro-oesophageal reflux disease was also studied. 
Comments or conclusions: We excluded the unproven refluxers (ENRD) 
from our review. 
Author, reference, year and type of study: Liston229 Descriptive, 
prospective, prevalence. 
Participants: Consecutive patients admitted for gastroscopy recruited 
regardless of the reasons for procedure. Main reasons were anaemia, reflux 
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symptoms and epigastric pains. Cases (n=37): RE (macroscopic or 
microscopic). Comparator group (n=33): Normal endoscopy and no 
evidence of histological oesophagitis. 
Intervention: Upper Gl endoscopy; Hp testing by histology, rapid urease 
test, serology and 13C-UBT 
Outcome: Hp prevalence in RE (76%), in comparator group (82%). Patterns 
of gastritis described in the two groups 
Comments or conclusions: Although exclusion of PUD had not been 
clearly stated, on reading the paper, we assumed this to be the case. 
Details of excluded studies 
Author, reference, year and type of study: Schenk 147 Cohort, prospective. 
Participants: Cases: >grade one oesophagitis, Barrett's and hiatus hernia. 
Outcome and Results: Hp prevalence in cases 39/88 (44%). No separate 
prevalence data on different categories. 
Reasons for Exclusion: No control group 
Author, reference, year and type of study: Cheng 199 Descriptive. 
Participants: Cases: patients undergoing paired biopsies of distal 
oesophagus and gastric antrum during endoscopy. 
Outcome and Results: Hp prevalence in cases, 11/27 (41%). 
Reasons for Exclusion: No control or comparator group. 
Author, reference, year and type of study: McCallum202 Abstract Case-
control 
Participants: Cases: reflux disease (all positive on Bernstein's test) 
Controls: asymptomatic, healthy, volunteers 
Outcome and Results: Hp prevalence in cases, 13/21 (60%), in controls, 
1120 (5%). 
Reasons for Exclusion: Control group did not meet eligibility and quality 
criteria. Wide difference in mean age between cases and controls (50:30). 
_ Numbers too small in each' group. 
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Author, reference, year and type of study: Abbas209 Case-control, 
retrospective 
Participants: Cases: uncomplicated oesophagitis. Controls: Barrett's 
Outcome and Results: Hp prevalence in cases 18/29 (62%). Hp 
prevalence in comparator 14/29 (48%) 
Reasons for Exclusion: Comparator group inappropriate for this systematic 
review. 
Author, reference, year and type of study: Oberg210 Descriptive and 
retrospective 
Participants: Cases: oesophagitis, Barrett's and ENRD 
Outcome and Results: Hp prevalence in cases 27/189 (14%). No separate 
prevalence data on different categories. 
Reasons for Exclusion: No control group. 
Author, reference, year and type of study: Sekiguchi211 Descriptive 
Participants: Cases: oesophagitis, grade one to four 
Outcome and Results: Hp prevalence in cases, 6/21 (29%). In grade one 
and two, prevalence was 6/12 (50%) and in grade three and four, 0/9 (0%). 
Reasons for Exclusion: No control group. Presence of ENRD in controls 
could not be excluded 
Author, reference, year and type of study: Macchiarelli212 Descriptive, 
retrospective, prevalence 
Participants: Retrospective pre-selection of cases presenting with typical 
gastro-oesophageal reflux disease symptoms that had undergone both 
endoscopy and 24- hr ph studies. 
Outcome and Results: Hp prevalence in patients divided into reflux (12/20, 
60%) and non-reflux (6/23=26%) groups based on abnormal and normal ph-
metry. 
Reasons for Exclusion: Number of cases and comparator too small. Peptic 
ulcer exclusion not stated. 
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Chapter 3 
The effect of H. pylori and its eradication on Gastro-
Oesophageal Reflux Disease in patients with 
Duodena~ Ulcers or Reflux Oesophagitis - a 
systematic review 
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3.1 Abstract 
Background: The effect of H. pylori in provoking or protecting against gastro-
oesophageal reflux disease is unclear and studies have given conflicting 
results. Recent guidelines recommend H. pylori eradication in patients on 
long-term proton pump inhibitors. There are no systematic reviews on this 
topic and no firm evidence base for recommendations concerning the 
association of H. pylori with, and the effects of eradication, on reflux disease. 
Aims: (a) To ascertain the effect of H. pylori eradication on gastro-
oesophageal reflux disease outcomes (reflux oesophagitis and heartburn) in 
patients with duodenal ulcer disease and (b) to ascertain the effect of H. 
pylori infection on reflux oesophagitis concerning heartburn, pH, severity, 
healing and relapse rates. 
Methods: Systematic review of electronic databases was undertaken to 
September 2003. Experts in the field, pharmaceutical companies and 
journals were contacted about unpublished trials. Studies were reviewed 
according to predefined eligibility and quality criteria. 
Results: Twenty-seven studies/trials were included in the systematic review. 
(a) Study variation rather than therapy influenced results in relation to the 
presence or absence of oesophagitis in patients with duodenal ulcer who 
underwent H. pylori eradication at 6-48 months follow-up (b) In patients with 
reflux oesophagitis no obvious differences were discovered in heartburn 
scores, 24-hour pH values, healing and relapse rates between H. pylori 
positive and negative cases. 
Conclusion: (a) There was no evidence to indicate that H. pylori eradication 
in duodenal ulcer disease provoked reflux oesophagitis or worsened 
heartburn; (b) there were insufficient data to draw firm conclusions about the 
impact of H. pylori in-patients with reflux oesophagitis. 
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3.2 Introduction 
There is controversy as to whether eradicating H. pylori leads to a worsening 
of reflux symptoms or of oesophagitis. Studies evaluating the occurrence of 
reflux oesophagitis or heartburn following eradication in duodenal ulcer 
disease have given conflicting results 149;155;239-241 . Labenz149, in 244 patients 
with duodenal ulcer disease, reported an increased prevalence of reflux 
oesophagitis following successful H. pylori eradication but McColl155, in 83 
patients, discovered improvement of reflux symptoms following successful 
eradication. 
There is also disagreement concerning the influence of H. pylori on gastro-
oesophageal reflux disease per se; some studies have reported no effecf42 
while others have reported some 143;243. H. pylori infection with the sub strain 
CagA is potentially protective against gastro-oesophageal reflux disease 
because it lowers intragastric acidity142. The predicted rank order for the 
presence of gastro-oesophageal reflux disease and its complications (peptic 
stricture, Barrett's oesophagus and adenocarcinoma of the gastric cardia) is 
highest in populations without H. pylori infection, less in those with H. pylori 
infection and least in those infected with CagA positive H. pylod 97• Some 
have reported a possible negative association between H. pylori infection and 
gastro-oesophageal reflux disease244. 
The effect of H. pylori infection on gastro-oesophageal reflux disease is also 
important in better understanding the influence of the infection on the 
success of acid suppression therapy. Holtmann et al167 found that patients 
with gastro-oesophageal reflux disease and H. pylori infection responded 
better to PPI treatment than those H. pylori negative. However, Schenk et 
al147 found that H. pylori negative patients did not need higher doses of 
proton pump inhibitors to maintain symptomatic and endoscopic remission 
compared with those who were positive. 
This is an important topic because gastro-oesophageal reflux disease is an 
increasingly common problem in clinical practice. The bulk of proton pump 
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inhibitor therapy use is for this41 ;42 , currently costing $ 640 million in the 
UK245. The potential costs of maintenance anti-reflux therapy need to be 
accounted for when evaluating the cost-effectiveness of eradication therapy. 
A test and treat strategy is now espoused, especially for younger patients 
with dyspepsia246;247 the majority of these will not have an ulcer and some 
are likely to have reflux disease. A systematic review of eradication in non-
ulcer dyspepsia indicated that eradication might be cost-effective with a 
clinical benefit to one in fifteen248. If H. pylori eradication is associated with a 
negative effect on gastro-oesophageal reflux disease this may result in the 
worsening of symptoms in some and increased management costs. 
The purpose of this study was to evaluate current data on the link between H. 
pylori and gastro-oesophageal reflux disease and to study any associations 
between the infection and gastro-oesophageal reflux disease symptoms. 
This review was driven by a number of current clinical issues concerning the 
relationship between H. pylori infection and reflux oesophagitis; this is topical 
because of questions as to whether clinicians should consider eradication in 
patients with gastro-oesophageal reflux disease prior to commencing proton-
pump inhibitors. 
The aim was to (a) ascertain the effect of H. pylori eradication on gastro-
oesophageal reflux disease outcomes (reflux oesophagitis and heartburn) in 
patients with duodenal ulcer disease and (b) ascertain the effect of H. pylori 
infection on reflux oesophagitis concerning heartburn, pH, severity, healing 
and relapse rates. 
A rigorous systematic review was conducted of studies and trials to 
determine (a) the effect of H. pylori eradication on heartburn and 
oesophagitis in patients with duodenal ulcer disease and (b) the effect, if any, 
of H. pylori infection on reflux oesophagitis. 
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3.3 Methods 
3.3.1 Search strategy 
Studies or trials to September 2003 fulfilling the eligibility criteria listed in the 
box below (Box 1) were suitable for inclusion in the review. The search 
process of studies identification was similar to the previous systematic 
review. This systematic review was conducted under two sections: 
(a) Patients with duodenal ulcer disease, H. pylori eradication and reflux 
oesophagitis outcomes (b) Patients with reflux oesophagitis and the effect of 
H. pylori infection. 
3.3.2 Assessment of eligibility and trial quality 
The process of assessment was similar to the previous systematic review. 
The quality assessment for studies and trials relating to duodenal ulcer 
disease focused on whether a clear description of outcomes relating to reflux 
oesophagitis and heartburn were provided. The methods used for selection 
of cases and controls, allocation, blinding to H. pylori result, and analysis 
were recorded. The quality assessment for studies or trials relating to 
patients with reflux oesophagitis patients focussed on whether similar 
grading, same or different endoscopists and H. pylori testing methods were 
used in positive and negative cases. The study design acceptable for this 
research were meta-analysis, randomised trials, cohort and case-control 
studies. 
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Box2 
Eligibility criteria for the two sections of the review 
General 
• Studies or trials that provided adequate information for the systematic 
review 
• Abstract without full journal publication, excluded 
(a) Duodenal ulcers, H. pylori eradication and gastro-oesophageal reflux 
disease outcomes 
• Patients with endoscopically proven duodenal ulcer, included 
• Intervention group received effective H. pylori eradication treatment with 
eradication confirmed (see below) 
• Comparison or control group received placebo or other drugs known not to 
eradicate H. pylori 
• Suitable H. pylori eradication treatments were 
~ Proton pump inhibitor dual treatment (proton pump inhibitor plus either 
amoxycillin or clarithromycin, for two weeks) 
~ Triple treatment (proton pump inhibitor, H2 receptor antagonist, or 
ranitidine bismuth citrate with two out of three of amoxycillin, 
clarithromycin, or 5-nitroimidazole, for at least one week, or bismuth salts 
with two out of three of tetracycline, amoxycillin, and metronidazole, for at 
least one week) 
~ Quadruple treatment (proton pump inhibitor plus standard triple treatment) 
• Minimum follow-up period for assessment, six months 
(b) gastro-oesophageal reflux disease and H. pylori infection 
• Endoscopically proven reflux oesophagitis, included 
• Endoscopy negative reflux disease, exclude 
Quality criteria 
General 
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Appropriateness and description of selection of cases and controls 
(a) Duodenal ulcers, H. pylori eradication and gastro-oesophageal reflux 
disease outcomes 
• Clarity and adequacy of information concerning oesophagitis and 
heartburn before and after eradication in cases and controls 
• Description of analysis stated (intention to treat or other) 
• Blinding to H. pylori result and allocation method stated 
• Lost to follow-up and percentage of participants excluded from analysis 
described 
(b) Gastro-oesophageal reflux disease and H. pylori infection 
• Grading of oesophagitis (same or different endoscopist) 
• Method of H. pylori testing before and after eradication 
3.3.3 Data extraction 
(a) H. pylori eradication in duodenal ulcer disease 
A single investigator extracted data from eligible studies on a standardised 
form which was checked by a second investigator, and outcomes recorded 
for the final assessment. We recorded heartburn and reflux oesophagitis 
outcomes before and after H. pylori eradication in duodenal ulcer disease 
patients as provided in the papers. We also obtained individual patient data 
from the authors as far as possible and recorded the following information 
concerning the number of patients with duodenal ulcer in whom reflux 
oesophagitis was present : (1) before and after H. pylori eradication, (2) 
before but not after eradication, (3) after but not before eradication and (4) 
neither before nor after eradication. 
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(b) Reflux oesophagitis and H. pylori 
The severity of the reflux oesophagitis in H. pylori positive and negative 
cases was recorded as reported. Heartburn values, endoscopic healing 
rates, use of acid suppression and relapse rates in the H. pylori positive and 
negative groups was also recorded. 
3.3.4 Quality of studies/trials included in review 
(a) H. pylori eradication in duodenal ulcer disease 
Amongst the fifteen studies 149;151 ;153-155;239-241 ;249-255 in this category, 
six151 ;153;239;249;250;253 were randomised controlled trials but were unable to 
obtain full or clear information on quality criteria (blinding, method of 
randomisation, concealment of allocation, masking of outcomes and drop-
outs) on these. There were also substantial differences between studies in 
study design, selection of cases, endoscopy assessments and recording of 
reflux disease symptoms. 
(b) Reflux oesophagitis and H. pylori 
Eight randomised controlled trials 147;158;159;167;256-259 were identified. Only 
one 158 provided clear and full information concerning blinding, method of 
randomisation, concealment of allocation, masking of outcomes and drop-
outs. 
3.3.5 Data Synthesis Methods used 
(a) Duodenal ulcer disease 
Logistic regression260 and Poisson generalized linear modelling261 were used 
to analyse data. Standard meta-analysis methods using odds ratios were not 
appropriate: few of the studies presented the full information required for 
such analysis, sample sizes were extremely unbalanced, and there were 
frequent counts of zero. Furthermore, the outcome variable was not one-
dimensional (improvement, no improvement) but two-dimensional (change in 
absence/presence of reflux oesophagitis). The focus was thus on the effect 
of eradication on presence or absence of reflux oesophagitis, taking into 
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account study and patient characteristics using more sophisticated statistical 
techniques. 
(b) Reflux oesophagitis and H. pylori 
Amongst the studies included, there were substantial differences concerning 
study design, methods, selection of patients and outcome measurements. 
Sample sizes were small in several studies. This was also true for the eight 
trials, which reported outcomes differently. It was not therefore possible to 
undertake any meaningful pooling of data. Data have been expressed from 
individual studies in the form of tables and narratively described. 
3.4 Results 
The initial search strategy was similar to the previous review and thus yielded 
the same results. But, after scanning titles and abstracts, only 52 were found 
that seemed to assess the influence of H. pylori on gastro-oesophageal reflux 
disease. On further scrutiny, seventeen of these studies did not address the 
research questions and were discarded. Twenty-eight studies met the 
eligibility criteria and were included in the systematic review (Appendix 4). Of 
these, fifteen 149; 151 ;153-155;239-241 ;249-255 in this category, six 151; 153;239;249;250;253 
evaluated the impact of H. pylori eradication on reflux oesophagitis or 
heartburn in patients with duodenal ulcer disease. Thirteen 143;147;157-159:167:256-
259;262-264 evaluated the effect of presence or absence of H. pylori on reflux 
oesophagitis in terms of severity, healing and relapse. Seven studies 141 ;265-270 
did not meet our eligibility criteria and were excluded. 
3. 4. 1 Studies included in the systematic review for eradication of H. pylori in 
duodenal ulcer disease 
Details of studies are provided at the end of the chapter 
3.4.2 Included studies for systematic review of impact of H. pylori on reflux 
oesophagitis 
Details of studies are given at the end of this chapter following Discussion 
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3.4.3 Studies excluded in the systematic review 
Details of studies are given at the end of this chapter following Discussion 
3.4.4 Results in patients with Duodenal Ulcer 
The numbers of patients who developed new oesophagitis following 
successful or failed eradication are shown in Table 1. Those in whom 
oesophagitis persisted following successful or failed eradication are shown in 
Table 2. There were few patients with reflux oesophagitis before the 
eradication treatment and there are doubts as to whether these patients were 
excluded in the studies. The reason for showing them is to indicate that the 
analysis was limited to patients definitely without reflux oesophagitis 
beforehand. This information was obtained directly from the authors in some 
cases. 
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Table 1. H. pylori eradication and development of new reflux 
oesophagitis in duodenal ulcer patients 
Author De-novo De-novo p,CI Follow-up 
Type oesophagitis oesophagitis [where period 
of study following following failed available] (months) 
successful eradication 
eradication (n,%), 
(n,%), 
Malfertheiner 11/153 (7%) 8/102 (6%) NS 6 
RCT 
Fallone 13/63 (21%) 1/24 (4%) P=0.10 (CI 4- 12 
RCT 29%) 
Rokkas 6/24 (25%) - NA 12 
RCT 
Bytzer 2/99 (2%) 3/105 (3%) NA 24 
RCT 
Befrits 8/79 (10%) 5/61 (8%) P=0.756 18 
RCT 
*Tepes 8/61 (13%) - 0.02 12 
Cohort 
Murai 15/327 (5%) 1/13 (8%) NA 6 
Cohort 
O'Connor 10/170 (6%) - NA 1 
Cohort 
Manes 5/70 (7%) - NA 12 
Cohort 
Kim 2/81 (2%) 3/39 (8%) p>0.05 26 
Cohort 
Hurenkamp 2/64 (3%) - NA 6 
Cohort 
La benz 32/244 (13%) 3/216 (3%) p< 0.001 17 
Case-control 
Hamada 3/74 (4%) 0174 (0%) NA 17 
Cohort 
-- --- -
*In Tepes study, the p value relates to companson w1th baseline data and follow-up at 12 
months. 
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Table 2. H. pylori eradication and persistence of oesophagitis in 
duodenal ulcer patients 
Author Persistent Persistent Oesophagitis Follow-up 
Type oesophagitis oesophagitis neither before (months) 
of Study after after nor 
successful failed after 
eradication, eradication, successful 
n(%) n(%) eradication 
(n) 
Malfertheiner 2/5 (40%) 0/5 (0%) 142 6 
RCT 
Bytzer 5/9 (55%) 2/11 (18%) 97 24 
RCT 
Tepes 2/2 (100%) - 53 48 
Cohort 
Murai 717 (100%) - 312 6 
Cohort 
Hurenkamp 4/7 (57%) - 62 6 
Cohort 
O'Connor 25/45 (55%) 2/4 (50%) 160 1 
Cohort 
No p value, odds rat1o or confidence mtervals available for the above data. 
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Figures 1 and 2. Estimates and 95% confidence intervals 
Figure 1 
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The data are graphed (Figures 1 and 2). Plotted for each study, are 
estimates and approximate 95% confidence intervals for the population 
proportion for (a) patients with successful H. pylori eradication who 
developed reflux oesophagitis (b) patients with no eradication treatment or 
failed H. pylori eradication who developed reflux oesophagitis, within the 
follow-up period (c) patients with successful H. pylori eradication who had 
reflux oesophagitis before and after treatment (d) patients with no or failed H. 
pylori eradication who had reflux oesophagitis before and after treatment. 
The graph implies that, regardless of the eradication group: (i) for patients 
without oesophagitis at the beginning of the study, the proportion of those 
developing oesophagitis is the same (ii) for patients with oesophagitis at the 
beginning of the study, the proportion of those with persisting oesophagitis is 
the same. The only notable relevant non-overlap occurs in the Labenz trial149, 
for which the proportion of patients developing oesophagitis appears higher 
in the eradication group. The studies are ordered by proportion for the 
eradicated group, and that not all studies provided the information needed to 
draw the confidence intervals. 
For the graph only, estimated population proportions and confidence intervals 
were obtained using the Agresti-Coull method271 , which is essentially the 
standard method but with two successes and two failures added to each 
sample. The standard method is known to be flawed272 , particularly where 
the population proportions are small. In Figure 2, three studies 151 ;249;255 show 
slightly smaller proportions of patients with persisting reflux oesophagitis in 
the groups with non-eradication of H. pylori. This is consistent with the 
findings in our previous systematic review which showed a negative 
association between H. pylori prevalence and reflux oesophagitis. These 
three studies (two RCTs and one cohort study) are providing full information 
for fuller statistical analysis allowing Poisson generalized linear 
modelling260of actual counts to explore relationships between the effects of 
H. pylori eradication and the presence or absence of oesophagitis before and 
after treatment. The categorical variables are; (A) presence or absence of 
oesophagitis before treatment, (B) presence or absence of oesophagitis at 
follow up, (E) eradication or non-eradication of H. pylori, (S) three studies. 
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Each combination of these categorical variables is associated with a count 
(Y) of patients in that cell. Using the standard statistical notation261 [section 
3.4], the minimal model is Y-T.E to fix the margins, and the model with 
intercept added is Y-T.E+A*B. We examined the two candidate explanatory 
variables S, T and added these separately in turn. Study (S) appears far 
more relevant (deviance 48.08, df 6, Chi-square test P<<0.001) than 
Treatment (T) (deviance 10.90, df 3, Chi-square test P=0.010), so we form 
the model Y-T.E+A*B+(A*B).S. This model has residual deviance 7.96 on 9 
df, suggesting a satisfactory fit. Adding Treatment (T) to the model does not 
prove useful (deviance 4.1 0, df 3, Chi-square test P=0.25). We concluded 
that differences with respect to oesophagitis before and after eradication or 
non-eradication reflect study variation rather than treatment. Alternatively, the 
sample sizes for these studies were simply too small to confirm with any 
degree of statistical significance the smaller proportion of patients with 
persistence of reflux oesophagitis in the non-eradication group. 
A less satisfactory approach, but one which is feasible and does take into 
account all the data, is to use logistic regression analysis260 to model the 
proportion (P) of patients who had oesophagitis at follow-up. The explanatory 
variables are (S) study, (T) treatment, (R) whether or not the patient had 
oesophagitis before treatment, (F) the follow-up time in months, taking as 
appropriate the midpoint of a follow-up range. (S) was included because 
account had to taken of the fact that there would be variation between 
studies. (F) was included because it was suspected that longer follow-up 
periods may allow more patients to develop reflux oesophagitis. The 
treatment variable was amended by more finely describing non-eradication. 
For four of the studies 151 ;151 ;153;249;250, non-eradication took the form of a 
placebo offered to patients. For five of the studies 149;154;240;251 ;255, non-
eradication represented failed eradication. We wished to determine not only 
whether there were differences between eradication and non-eradication but 
also whether there were differences between no treatment and failed 
treatment. 
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For the modelling, the baseline variable R was included in every model to 
account for the presence or absence of oesophagitis before treatment. This 
model has residual deviance 110.61 on 30 df, clearly inadequate. Each of the 
candidate explanatory variables was added, separately in turn. Study S was 
by far the most important (deviance 61.49, df 12, Chi-squared test 
P<<0.001), followed by treatment (deviance 14.67, df 2, Chi-squared test 
P=0.001). Follow-up time (deviance 0.72, df 1, Chi-squared test P=0.397) did 
not appear relevant and was not considered further. Thus (S) was added to 
the model and refit. Adding treatment to the model did not improve it 
(deviance 3.82, df 2, Chi-squared test P=0.148); however there appeared to 
be an interaction effect between study and treatment (deviance 19.33, df 7, 
Chi-squared test P=0.007). Inspection of the model coefficients showed that 
this was entirely due to the low proportion of patients with reflux oesophagitis 
for the Labenz trial149, a feature evident from the graph (Figure 1 ). Excepting 
this peculiarity, it was concluded that, conditional on pre-treatment presence 
or absence of oesophagitis, eradication (successful, failed, or not applied) 
was not related to later presence or absence of reflux oesophagitis. The final 
model, which has residual deviance 36.78 on 16 df, P=0.002, does not quite 
adequately explain all the variation. It is an open question as to what other 
sources of heterogeneity are involved. 
It was not possible to obtain individual patient data for heartburn in most 
studies. Therefore the group of patients with heartburn before and after 
successful and failed eradication are presented in Table 3. The results 
appeared to show a trend towards improvement in heartburn following 
eradication; successful (range, 0-32%) or failed (range, -3 to 27%). In two 
studies250;253, the authors appeared to have selected duodenal ulcer patients 
with no heartburn at baseline. The proportion of such patients in the two 
studies reporting heartburn after successful eradication was 29% (18/63) and 
37% (9/24) respectively while following failed eradication, 8% (2/24) patients 
in one stud/50 complained of heartburn. Life-table analysis (Kaplan-Meier) of 
the cumulated risk of developing heartburn after eradication was significantly 
lower (log rank test, p< .001) according to another study153. 
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Table 3. H. pylori eradication and heartburn and in duodenal ulcer 
patients 
Author Heartburn before Heartburn before p,OR,CI 
Type (B) and after (B) and after (A) [where 
of study (A) successful failed eradication, available] 
eradication, n/n n/n (%) 
(%) 
Malfertheiner 288/911 (32%) 8 123/318 (39%) 8 p<0.0001, 
RCT 109/911 (12%) A 80/218 (25%) A OR 0.48 (0.34-
0.68) 
*Vakil 37/64 (58%) 8 92/178 (52%) 8 p=0.331 
RCT 12/51 (23%) A 41/161 (25%) A 
**McColl 36/86 (42%) 8 - NA 
Cohort, 15/86 (17%) A 
no control 
***Hurenkamp 30/71 (42%) 8 - p>0.05 
Cohort, 25/71 (35%) A 
no control 
****Manes 23/70 (33%) 8 - NA 
Cohort, 23/70 (33%) A 
no control 
La benz 74/244 (30%) 8 65/216 (30%) 8 NA 
Case-control 61/244 (25%) A 72/216 (33%) A 
In *Vakil study, seven patients had heartburn before and after, five after but 
not before, and 21 before but not after eradication. 
In **McColl study, 18 patients had heartburn before and after, three after but 
not before, and 18 before but not after eradication. 
In ***Hurenkamp study, 16 patients had heartburn before and after, seven 
after but not before, and 14 before but not after eradication. 
In ****In Manes study, 17 patients had heartburn before and after, 6 after but 
not before and 6 before but not after eradication. 
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3.4.5 Results in patients with Reflux Oesophagitis 
Given the diversity of outcomes in the included studies it was not possible to 
conduct any form of formal statistical analysis. A summary of results are 
therefore described from the various studies and the interpretation is 
presented as a narrative review in this section and in the discussion. 
Four studies 143;147;157;264 specifically addressed the association of H. pylori 
status to the severity of oesophagitis (Table 4). In the study by Schenk, the 
median Savary-Miller score was higher in those without the infection (3 vs. 
2). Two studies 157;264 seemed to indicate that severe forms of oesophagitis 
may be less common in the presence of H. pylori infection. Of the two studies 
that also determined the cagA status, the Warburton-Timms study with 
adequate sample size showed that in the presence of this strain, chances of 
developing severe oesophagitis are significantly lower in comparison to its 
absence (p<0.0001 ). 
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Table 4. H. pylori status and severity of oesophagitis 
Author Hp+ve Hp-ve, p,OR,CI CagA+ve CagA -ve p,OR,CI 
Type mild,mod mild, mod [where mild,mod mild,mod [where 
of (MM),% (MM),% available] (MM),% (MM),% available] 
study severe(S), Severe(S), severe(S), Severe(S), 
% % % % 
Warburt MM80% MM79% N8 MM86% MM69% OR 0.57, 
on- 820% 821% 814% 8 31% (0.41-
Timms [n=120] [n=192] [n=77] [n=42] 0.80); 
De script p=0.0001 ive 
Werdmu MM79% MM74% NA 
ller 8 21% 8 26% 
Descript [n=34] [n=84] 
ive 
Wu MM 86% MM 68% p=0.022 MM 85% MM 46% NA 
Case- 8 14% 8 32% 8 15% 8 54% 
control [n=44] [n=96] [n=33] [n=11] 
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Table 5 presents the studies concerning H. pylori and healing of 
oesophagitis. Of the two studies that specifically addressed healing 167;263, 
one 167 ascertained that H. pylori positive patients healed significantly more 
than the negatives (96% v 92%, p=0.004). A long-term cohort study147 
ascertained that the median dose of omeprazole required to maintain healing 
was no different between H. pylori positive and H. pylori negative 
oesophagitis patients (p=0.05). 
Table 5. H. pylori and healing of oesophagitis with proton pump 
inhibitors 
Author H. pylori H. pylori p value, Cl Follow-up 
Type positive negative [where (months) 
of study and and available] 
healed healed 
Holtmann 323/335 469/511 p= 0.004 2 
RCT (96%) (92%) 
Soga 10/11 17/17 NA 5 
Case- (91%) (100%) 
control 
Table 6 presents the studies covering H. pylori status in reflux oesophagitis 
and relationship to pH, time to relapse of reflux symptoms and recurrence of 
oesophagitis. This table highlights the widely varying designs, methods and 
end points of the different studies. Despite this, none of the four 
studies 159;256;258;262 that evaluated 24-hour oesophageal pH measurements 
showed any significant difference between H. pylori positive and negative 
oesophagitis patients. In one of these studies258, the mean total percentage 
of time with pH < 2 was significantly higher in the H. pylori eradicated group. 
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Table 6. Relationship of H. pylori status in reflux oesophagitis to ph, 
time to relapse and recurrence of oesophagitis 
Author, H. H. H. Mean time Time to Endoscopic Follow-
Type pylori pylori pylori ph Relapse relapse up (mo) 
of study positive negative eradication <4 (days) ofOE 
RE RE (oeso) Pos:Neg: Pos:Neg: 
Pos:Neg Con(%) Con(%) 
p,CI p,CI p,CI 
Peters 28 30 N 15.8:16.1 - - 3 
Cohort p=0.96 
Tefera 25 23 y 9.4:9.6 - - 3 
Cohort pre- post- p=0.46 
eradication eradication 
Schwizer 16 13,29 y p> 0.3 54:100:110- 6 
RCT 14 placebo 13 [no p=0.046 
and post- ph p=0.018 
2 eradication values 
eradication and available] 
failures 29 controls 
Moayyedi 7 7,7 y - - 29%:29%:0% 12 
RCT 7 p=0.94 
post-
eradication 
and 
7 controls 
Hatlebakk 40 52 N - 200:300 - 12 
RCT p=0.70 
Adamek 55 100 y - - 31%:29% 12 
RCT 
*Wu 11' 14,post- y 6.8:6.7:6.4 - - 6 
RCT placebo eradication (week 0) 
[p=0.76] 
15, control 6.5:7.1:6.8 
(week 26) 
1[0.29] 
Stat1st1cal data (p value, 95% Cl) have been prov1ded where available. *The mean 
percentage of time the oesophageal ph was less than 3 and less than 2 was significantly 
increased in the group following eradication compared to placebo (p=0.02 and 0.01 ). oeso = 
oesophageal, con = control 
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One trial 159, with relatively small number of patients in each arm, determined 
that H. pylori eradication did not adversely influence the time for relapse of 
reflux symptoms. Another recent randomised trial158, with a small sample size 
of oesophagitis patients found no difference between H. pylori positive and 
negative cases in endoscopic relapse at 12 months. A further trial259 
comparing the efficacy of pantoprazole versus ranitidine in preventing 
relapse of oesophagitis also concluded that initial H .pylori eradication did not 
influence the outcome of the long-term treatment in the pantoprazole group. 
Four studies 167;256;258;262 evaluated heartburn (Table 7). Despite the variability 
of study designs, methods and outcome measurements, none identified any 
significant differences in heartburn assessments between H. pylori positive 
and negative oesophagitis patients, either at baseline or following eradication 
and acid suppression. 
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Table 7. H. pylori status and relationship to severity of heartburn 
Author H.pylori H.py/ori negative Heartburn Absence of heartburn 
type positive oesophagitis or reflux post acid 
of study oesophagitis (number score suppression 
(number of patients) H. pylori therapy% 
of patients) [Pos]:[Neg] H. pylori [Pos]:[Neg] 
p,CI p,CI 
Holtmann 323 493 - [89%]: [85%] 
RCT 
Wu 11 14(eradicated), [4.5]:[4.2,4.1] -
RCT 15 (control) (pre-treatment, 
p=0.75) 
[3. 7]:[3.8,3.9] 
(post-
treatment, 
p=0.54) 
Tefera 25 23 [2]:[1 1 -
Cohort p=0.01 
Peters 28 30 [1.18]:[1.27] -
Descriptive (pre-treatment, 
NS) 
[0.17]:[0.15] 
(post-
treatment, NS) 
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3.5 Discussion 
Duodenal Ulcer patients 
One needs to attach caution to the interpretation and the clinical significance 
of the findings. It is acknowledged that the heterogeneity between the studies 
with their varying periods of follow-up could have affected findings. It was not 
felt possible to provide any reliable data concerning possible beneficial effect 
of H. pylori eradication on the healing of associated oesophagitis in duodenal 
ulcer patients. This was because in several studies, associated endoscopic 
oesophagitis prior to eradication therapy was either absent or present for only 
small numbers. In spite of these weaknesses, this is the first systematic 
review to attempt to answer some of the controversial and clinically important 
questions around H. pylori eradication and its potential effect on gastro-
oesophageal reflux disease. 
In patients with duodenal ulcer disease, this systematic review indicated that 
following successful eradication of H. pylori there is no increased risk of 
provoking de-novo oesophagitis. Although there has been speculation that 
successful H. pylori eradication may provoke oesophagitis 149, analysis by two 
separate modelling methods have failed to substantiate this. Study variations 
appear to explain the differences in the presence or absence of oesophagitis 
rather than the effect of eradication per-se. There may also be other 
unexplained sources of heterogeneity. 
It was not possible to undertake any robust analysis concerning the effect on 
heartburn of H. pylori eradication, due to lack of individual patient data. The 
results were thus restricted in reporting study findings as "group data" for 
heartburn before and after eradication. Despite obvious heterogeneity 
between studies, there appeared to be a trend towards diminished 
prevalence of heartburn following eradication, successful or failed. 
The limitations of this finding are recognised; it is possible that patients in the 
two groups (successful vs. failed/non-eradication) were different or 
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comprised overlapping groups; it was not possible to establish this with 
certainty. The eradication treatment itself or other unknown factors may also 
have influenced heartburn. Furthermore the evaluation of heartburn was 
different in the various studies. Better-designed prospective studies of high 
methodological quality concerning heartburn assessment are required. 
The findings of this systematic review, indicating the lack of correlation 
between oesophagitis and H. pylori eradication in patients with duodenal 
ulcer disease, have clinical significance, especially in primary care where 
most patients are treated. It is unlikely that eradication should result in 
increased requirements for acid suppression or in complications from 
oesophagitis. The recent Maastricht-2198 guidelines recommend H. pylori 
eradication in patients with duodenal ulcer disease as well as those on long-
term proton pump inhibitors which are used mainly for reflux disease, on the 
basis that long-term prolonged acid suppression may accelerate atrophic 
gastritis. 
Reflux Oesophagitis patients 
In the second part of this systematic review concerning the effect of H. pylori 
infection on gastro-oesophageal reflux disease we were unable to undertake 
any statistical analysis because of a lack of studies with similar designs and 
comparable outcome measures. Only two randomised controlled trials 
158;159evaluated the effect of eradication in gastro-oesophageal reflux 
disease. Since the protocol of the Moayyedi study included patients with both 
proven and unproven gastro-oesophageal reflux disease, data from this 
study was presented as per the study eligibility criteria, from a small number 
of patients with only oesophagitis (data obtained directly from authors). The 
authors found no evidence that successful eradication had a deleterious 
effect on gastro-oesophageal reflux disease. Other studies included in the 
review failed to report any significant differences in the duration of reflux 
episodes demonstrated by 24-hour pH studies, heartburn scores, healing, 
remission and relapse rates and amount of proton pump inhibitor use 
between H. pylori positive and negative oesophagitis 167;256;258;262;263. Because 
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of significant heterogeneity between studies we accept that a beneficial effect 
of the presence of H. pylori on gastro-oesophageal reflux disease cannot be 
excluded, although this seems unlikely. Well-designed, prospective trials with 
adequate numbers of patients are required to determine the effect of H. pylori 
eradication on oesophagitis and heartburn. 
In conclusion this review asserts that the eradication of H. pylori in patients 
with duodenal ulcer disease does not provoke oesophagitis and there 
appears to be no obvious worsening of heartburn. In relation to the effect of 
H. pylori on reflux oesophagitis although further well designed trials are 
required the infection does not appear to cause an increase in severity of 
gastro-oesophageal reflux disease following eradication therapy. 
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Details of included studies 
Author, reference, year Manes252 2001 
Type of study and methods Cohort study, no control arm. Blinding: none 
described. Masking of outcomes: primary outcome (gastro-oesophageal 
reflux disease symptoms) assessment by investigator at follow-up interviews 
not aware of results of original symptom questionnaire at entry. 
Randomisation: none described. Drop-outs: reasons stated. 
Participants Single-centre study, Italy. Sample: 70 patients. Sample 
selection: endoscopy proven DU patients who are Hp positive on rapid 
urease test and/or histology. Eradication confirmed by 13C-UBT. 
Intervention Duration of therapy, 1 week. Eradication therapy. OAC, dosage 
and frequency described. Concomitant medication: not described. A further 
course of eradication therapy (type not described) was given if Hp test still 
positive at 4 weeks. 
Eradication rate: not described. 
Outcome gastro-oesophageal reflux disease and abdominal symptoms 
score (validated questionnaire using a four-point scale). Follow-up: 12 
months. 
Comments or conclusions RO and typical gastro-oesophageal reflux 
disease symptoms excluded 
Author, reference, year Hurenkamp241 2001 
Type of study and methods Cohort study, no control arm. Blinding: none 
described. Randomisation: to three different durations (4, 7 or 10 days) or 
eradication regimen. Method of randomisation: not described. Masking of 
outcomes: not described. Drop-outs: described. 
Participants Two-centre study. Netherlands. Sample: 75 patients. Patient 
selection: endoscopy proven PU (old or new) patients. Tests for Hp positivity 
at entry not described. Hp eradication confirmed by histology and 
bacteriology or U BT. 
Intervention Duration of therapy. mixed (4, 7 or 10 days). Eradication 
therapy. OMC. Dosage and frequency. described. Concomitant medication: 
for the first three weeks, tapering doses of acid-suppressant drugs until 
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completely stopped. Type, dosage, method of tapering: not described. 
During follow-up: concomitant antacids, OME or H2-RA allowed. Eradication 
rate: 100%. Follow-up: 6 months. 
Outcome Mean daily acid-suppressant drug intake. Prevalence of gastro-
oesophageal reflux disease (reflux symptoms and oesophagitis). 
Comments or conclusions Analysis per protocol. 
Author, reference, year Fallone2502000 
Type of study and methods RCT. Blinding: patients, investigations and 
endoscopists blinded to eradication or placebo therapy. Masking of outcome: 
assessments not stated. Randomisation: no description of method of 
randomisation or concealment. Drop-outs: reasons stated (side effects, 
failed to follow-up). 
Participants Single-centre trial: Canada. Sample: 98 patients. Patient 
selection: Consecutive endoscopy proven DU patients with Hp infection on 
histology or culture. Patients confirmed to have healed DU and Hp infection 
on biopsy included for randomisation. 
Intervention Duration of therapy. not stated. Eradication arm: BMA. 
Control arms: BMP or MPP Dosage, frequency not stated. Numbers of 
patients in each arm not stated. Only overall eradication rates provided and 
not individual eradication rates in each arm. 
Outcome (a) gastro-oesophageal reflux disease symptoms (structured 
assessment of digestive symptoms). (b) Endoscopic RO © gastro-
oesophageal reflux disease symptoms or RO. Follow-up: 12 months. 
Comments or conclusions Analysis per protocol. Concomitant gastro-
oesophageal reflux disease symptoms or RO excluded. 
Author, reference, year Malfertheiner1512002 
Type of study and methods RCT. Blinding: Double blind as to the 
treatment given, not placebo controlled. Outcome of eradication therapy 
masked to the patient but not to the investigator. Masking of other outcome 
assessments (heartb-urn, RO): not stated. Ranaomisation: No description of 
method of randomisation or concealment. Drop-outs: Follow-up as per 
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protocol. ITT approach used for all analyses. Patients with unknown post-
treatment Hp status excluded from analysis. 
Participants Multi-centre trial: Canada, Czech Republic, France, Germany, 
Ireland, Norway, Poland, Sweden, and UK. Sample: 1497 patients. Patient 
selection: Current DU, GU, past DU. Method of selection: not stated. 
Positive screening test for Hp by Helisal mandatory. Pre treatment tests 
were UBT and histology or UBT and culture. Patients with concomitant 
gastro-oesophageal reflux disease symptoms or RO requiring treatment 
excluded. 
Intervention Duration of therapy. one week to 12 weeks. Eradication arm: 
OAC, OMC or OAM. OAM tested at different doses and frequency. Control 
arm: 0, AC or MC. Numbers of patients in either arm not clearly stated. 
Only overall eradication rates provided and not individual eradication rates in 
each arm. 
Outcome (a) Heartburn prevalence and severity (generic Iikert scale) at 
baseline and at last visit. (b) Reflux oesophagitis prevalence (no grading 
used) at baseline and at last visit (only in patients with 6 months follow-up). 
Comments or conclusions Details obtained from author. Concomitant 
gastro-oesophageal reflux disease or RO excluded. 
Author, reference, year Labenz 149 1997 
Type of study and methods Cohort study. Blinding: Endoscopists blinded 
to Hp status, none described. Masking of outcomes: none described. Drop-
outs: not described. Protocol included two arms; (a) patients with cured and 
(b) patients with persistent Hp infection who were followed-up prospectively. 
Participants Multi-centre study. Nine German centres. Patient sample: 460 
patients. Patient selection: Patients with a history of relapsing or complicated 
DU. Hp negative DU patients were those in whom the infection had been 
cured immediately before inclusion in the study. Hp positive DU patients 
were those who had participated in clinical trials with a treatment arm without 
antibiotics or had been resistant to treatment. Hp infection absent if both 
rapid urease test and histology negative. 
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Intervention Duration of therapy. Not stated. Cure arm: Bismuth, Bismuth 
and amoxycillin, OA, OC, bismuth plus M plus tetracycline, OCM or OCA. 
Infection arm: Not stated. Follow up: 
Outcome RO: Grading (1-4) Gastritis: Grading (0-3). 
Comments or conclusions Patients with concomitant RO excluded. 
Author, reference, year McColl1552000 
Type of study and methods Cohort study. Blinding: Outcome of 
eradication therapy results blinded to patient or investigator. Masking of 
primary outcome assessment (GDSS): not stated. Study protocol did not 
require to include control arm or to undertake follow-up endoscopies in all 
patients. Drop-outs: reasons provided. Analysis on patients successfully 
followed-up (per protocol). 
Participants Single-centre study. UK. Sample: 118 patients. Patient 
selection: Patients referred to dyspepsia clinic. Patients with active DU and 
or GU [unrelated to NSAID use] and Hp infection (14C UBT, rapid urease test 
and histology) included in the study. 
Intervention Duration of therapy. OMA for 2 weeks (dosage and frequency 
stated). In penicillin allergy patients tetracycline used. Of those successfully 
eradicated, 16 patients received two courses of treatment. Of 11 patients 
with persistent infection, five had two or more courses of treatment. 
Outcome Median dyspepsia score (GDSS). Predominant gastro-
oesophageal reflux disease symptoms (heartburn). Follow-up: 1-3 years. 
Comments or conclusions No separate analysis of DU and GU patients. 
Author, reference, year Rokkas253 2001 
Type of study and methods Randomised, open labelled study. Method of 
randomisation stated. Blinding: endoscopists blinded to therapy. Histologists 
blinded to patients' condition. Masking of outcome assessments: described. 
Drop-outs: numbers given but no other details. Analysis per protocol and 
excluded drop-outs. 
, - Participants Two;.centre study. Greeee. Patient sample: 50 PU patients. 
Patient selection: consecutive, successfully treated Hp positive patients. 
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Method of Hp assessment at entry: not clearly stated. Hp cured if UBT 
negative. Hp relapse assessed by rapid urease test and histology. 
Intervention Duration of therapy. eradication therapy not described. 
Treatment arm: OME for 12 months. Control arm: no treatment. Frequency 
and dosage stated. Concomitant therapy. not described. Hp relapse rates 
not described. 
Outcome Incidence rates for heartburn and oesophagitis during follow-up. 
Gastritis scores. Follow-up: 12 months. 
Comments or conclusions Concomitant RO excluded. liT analysis not 
described. We excluded NUD patients included in this study from our 
analysis. No separate data for DU, GU patients. 
Author, reference, year Tepes254 1999 
Type of study and methods Cohort study. prospective. Blinding: None 
described. Outcome assessments: masking not described. Drop-outs: lost 
to follow up mentioned. 
Participants Single-centre study. Slovenia. Patient sample: 63 patients. 
Patient selection: Hp positive DU patients after successful eradication. At 
entry, Hp positive if rapid urease test, biopsy and culture positive. Cure of Hp 
confirmed if biopsies and cultures negative. 
Intervention Duration of therapy. mixed. CBS and AMO for 4 weeks along 
with MET for 2 weeks or CBS, AMO and MET for 2 weeks. Frequency and 
dosage of each drug described. Concomitant medications: anti ulcer drugs 
received by some patients during follow-up. Type, frequency and dosage not 
described. Hp eradication rates: NA. 
Outcome Ulcer recurrence rates. Oesophagitis rates at entry and follow-up. 
Follow-up: 2-4 years. 
Comments or conclusions Concomitant RO included. 
Author, reference, year Hamada 154 2000 
Type of study and methods Cohort study. Blinding: Investigators and 
patients not blinded to eradication therapy. Histologist blinded to diagnosis, 
Hp status and therapy regimen. Outcome assessments (RO and symptoms): 
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not masked. Drop-outs: not described. Study protocol had two arms; (a) 
eradication arm and (b) age, sex and disease match control arm. 
Participants Single-centre study: Japan. Patient sample: 592 patients. 
Patient selection: in the eradication arm, consecutive patients with PU or 
gastritis undergoing eradication for Hp. In the control arm, randomly selected 
patients attending the hospital during the same period. Hp status confirmed 
by three tests prior to inclusion; rapid urease, histology and serology. Hp 
eradication confirmed by three tests; histology, rapid urease test and UBT. 
Intervention Duration of therapy: mixed. Eradication arm: OAC (dosage, 
frequency stated). Further therapy with OME for seven weeks in GU, five 
weeks in DU, and no further therapy in gastritis patients. Control arm: OME 
(dosage stated) for eight weeks in GU, six weeks in DU and no medication in 
gastritis. Eradication rates: 78% in eradication arm, not stated in control arm. 
Follow-up: 17 months. 
Outcome RO: grading (LA classification A-D). corpus gastritis scores. 
Comments or conclusions Patients with concomitant RO excluded. 
Author, reference, year Murai240 2000 
Type of study and methods Cohort study (retrospective). Blinding: None 
described. Masking of outcomes: none described. Drop-outs: not described. 
Protocol did not include control arm. 
Participants Single-centre study, Japan. Patient sample: 451 patients (347 
with PU disease). Patient selection: Not described. Hp infection considered 
to be present if positive by at least two of four methods; histology, rapid 
urease test, serology and UBT. 
Intervention Duration of therapy: OCA or LCA at varying doses for 7 or 14 
days. 
Outcome (a) RO (LA classification) (b) Mean reflux scores (heartburn and 
retrosternal discomfort) using Iikert scale. Follow-up: 6 months, 
Comments or conclusions Retrospective study. No separate data on DU 
and GU patients. Paper considered PU and NUD patients. We excluded 
NUD as per our protocol. 
Author, reference, year O'Conno~55 2001 
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Type of study and methods Cohort study. Control arm: none. Blinding: 
Pathologist blinded to clinical details and biopsy site. Masking of outcomes: 
none described. Drop-outs: only three patients did not attend for re-
endoscopy, reasons not given. 
Participants Single-centre study. Ireland. Patient sample: 244 patients with 
PU disease (DU, 223 and GU, 21). Patient selection: Consecutive patient 
groups with endoscopy proven, Hp positive PU. Hp positive and negative 
status defined by present or absence of Hp on CLO and histology. 
Intervention Duration of therapy. Mixed. Type of eradication therapy: CBS, 
tetracycline, MET; OMC; OM+cefaclor; LMC. Dosage and frequency: 
described. Concomitant medication: not described. Eradication rates: 
described. Follow-up: 1 month. 
Outcome (a) Prevalence rates of oesophagitis in Hp positive PU patients. 
(b) Incidence rates of RO in eradicated and non-eradicated PU patients. 
Comments or conclusions Short-term follow-up only. 
Author, reference, year Kim251 2001 
Type of study and methods Prevalence and cohort study (prospective). 
No control arm. Blinding: none described. Randomisation: None described. 
Masking of outcomes: none described. Drop-outs: minimally described. 
Participants Single-centre study, Korea. Patient sample: 250 patients (120 
completed follow-up). Patient selection: consecutive patients with endoscopy 
proven DU or GU who are Hp positive. Hp positive if at least two out of four 
tests (rapid urease, microscopy, histology, culture) positive. Hp negative if all 
four tests negative. 
Intervention Duration of therapy. 1 or 2 weeks. Type of eradication therapy. 
(1) CBS, tetracycline or amoxycillin, MET. (2) OAC. Dosage and frequency: 
described. Concomitant medication: not described. Eradication rates: not 
described. Follow-up: eradicated patients, 26+-17 months, non-eradicated 
patients, 18 +-14 months. 
Outcome Prevalence rates of RO in Hp positive and negative DU and GU 
patients. Incidence rates of RO in eradicated and non-eradicated DU and 
GU patients. 
Comments or conclusions Patients with concomitant RO excluded. 
116 
Author, reference, year Befrits 153 2000 
Type of study and methods RCT. Blinding: double blind to therapy used. 
Randomisation method: proportion stated but method not described. 
Masking of outcomes: not stated or described. Drop-outs: exclusions 
described but no information concerning any drop-outs. 
Participants Single-centre study. Sweden. Patient sample: 165 patients. 
Patient selection: endoscopy proven active DU who are Hp positive. Hp 
positive if histology or microbiology positive and negative if both negative. 
Intervention Duration of therapy. mixed. Type of therapy. eradication arm 
received OA and control arm received omeprazole. Dosage and frequency: 
described. Eradication rates: stated. Concomitant medications: not 
described. Follow-up: median 18 months. 
Outcome Oesophagitis rates comparison in eradicated and non-eradicated 
groups. Life-table analysis of the cumulated risk of developing heartburn in 
the eradicated and non-eradicated groups. 
Comments or conclusions RO and heartburn requiring treatment 
excluded. Group data concerning heartburn in the eradicated and non-
eradicated patients not available. 
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Author, reference, year Bytze~49 2000 
Type of study and methods Randomised, placebo controlled, double blind 
trial. Blinding: Hp status blinded to patients and clinicians. Microbiology 
results blinded from clinicians. Pathologists blinded from clinical data. 
Blinding of therapy from patients and investigators not clearly described. 
Randomisation: method described. Masking of outcomes: described. Drop-
outs: reasons described. 
Participants Multi-centre study. Denmark. Patient sample: 276 patients. 
Patients selection: endoscopy proven active DU. Hp positive if any one of 
(UBT, histology, culture) three tests positive. Hp negative if all three tests 
negative. 
Intervention Duration of therapy. mixed. Eradication arm: OAM for 2 
weeks, then OME until ulcer healing for up to 16 weeks followed by OME 
placebo for 12 months. Control arm: OME until ulcer healing for up to 16 
weeks followed by OME maintenance for 12 months. Dosage, frequency 
described. Concomitant therapy. not described. 
Outcome (a) Stoppage of therapy for any reason. (b) gastro-oesophageal 
reflux disease (symptoms, RO) assessment. Follow-up: 24 months. 
Comments or conclusions Per protocol analysis. 
Author, reference, year Vakil239 2000 
Type of study and methods Randomised, placebo controlled, double blind 
trials (four). Blinding: patients and endoscopists blinded to treatment arm 
and results of Hp tests. Randomisation: method not described. Masking of 
outcome: assessments not described. Drop-outs: numbers stated but 
reasons not given. 
Participants Multi-centre study. 125 centres in USA. Patient sample: 242 
patients. Patient selection: endoscopy proven, uncomplicated DU patients 
who are Hp positive. Hp positive if rapid urease test, culture or histology 
positive. Hp negative if two of three tests negative; histology, culture, rapid 
urease test. 
Intervention Duration of therapy. not described. Eradication arms: RBC+A 
or RBC+C. Control arms: RBC or A or Cor placebo. Dosage, frequency: not 
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described. Concomitant therapy. Occasional antacid use allowed during 
follow-up. Eradication rates: 24% at 6 months. Follow-up: 6 months. 
Outcome Rates of heartburn and epigastric pain and severity (4 point 
ordinal scoring system). Hp eradication rates. 
Comments or conclusions Patients with concomitant RO excluded. Also 
GU patients excluded. 
Author, reference, year Tefera262 1999 
Type of study and methods Cohort study. no control arm. Randomisation: 
not applicable. Blinding: none described. Masking of outcomes: None 
described. Drop-outs: no patient dropped out of the study. 
Participants Single-centre study. Norway. Patient sample: 25 patients. 
Patient selection: currently untreated consecutive Hp positive patients with 
chronic recurrent heartburn or acid regurgitation and grade 1 or 2 RO. Hp 
positive at entry if rapid urease test positive. Hp negative after eradication if 
UBT negative. PU patients excluded. 
Intervention Duration of treatment: 10 days. Eradication therapy. RBS, 
oxyTc, MET. Frequency and dosage: described. Concomitant therapy. none 
commented upon. 24 hour pH recordings before and after eradication. 
Follow-up: 12 weeks. 
Outcome Median %pH time < 4 over 24 hours. Median heartburn score. 
Comments or conclusions Small sample. Grade 3, 4 patients excluded. 
No follow-up endoscopy. 
Author, reference, year Peters256 1999 
Type of study and methods Data collected as part of randomised double-
blind prospective trial on the effect of acid suppression on Barrett's 
epithelium. Randomisation: method described. Masking of outcome: not 
described. Drop-outs: lost to follow-up and protocol violation stated. 
Analysis on evaluable patients. 
Participants Three-centre trial: Netherlands. Patient sample: 68 patients. 
Patient selection: endoscopic and histology proven Barrett's and documented 
acid reflux. Hp status assessed by serum lgG ELISA at baseline and 24 
months. 
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Intervention Duration of therapy: 12 months. Acid suppression therapy: 
OME or ranitidine. Frequency. dosage stated. 24-hour pH at baseline and 3 
months. 
Outcome Mean time proportion (%) pH < 4 hours. Mean symptom scores 
(grade 0-3 for heartburn, regurgitation, dysphagia and odynophagia). 
Comments or conclusions Exclusion of associated PU not explicit. Hp 
testing by serology only. 
Author, reference, year Hatlebakk257 1997 
Type of study and methods Double-blind randomised trial: of two doses of 
maintenance therapy with lansoprazole for patients who are symptom free 
and have healed RO. Method of randomisation: not described. Blinding: to 
therapy described. Masking of outcomes in relation to Hp status not part of 
protocol. Drop-outs: none. 
Participants Single-centre trial: Norway. Patient sample: 103 patients. 
Patient population: symptom free patients with grade 1 or 2 (Berstad) healed 
RO following use of 4 weeks of healing doses of LAN. Hp assessed by UBT. 
PU excluded. 
Intervention Duration of therapy. 12 months. Type of therapy: LAN. 
Dosage, frequency: stated. Concomitant therapy. not described. Follow-up: 
12 months. 
Outcome Relapse rates: symptoms (grade 0-3 for heartburn, regurgitation 
and dysphagia) and or grade 1 or more RO. 
Comments or conclusions C14 UBT. 
Author, reference, year Holtmann 167 1999 
Type of study and methods Double-blind comparison of parallel groups. 
Blinding: described. Masking of outcomes: not described. Drop-outs: details 
and numbers of patients excluded from the study described. Analysis: mainly 
per-protocol population. 
Participants Multi-centre study. Germany. Patient sample: 971 patients. 
Patient population: endoscopy confirmed RO (SM grade 2 and 3). Hp status 
assess by UBT. PU excluded. 
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Intervention Duration of therapy: mixed (4 or 8 weeks). Type of therapy: 
pantoprazole. Dosage and frequency: stated. Concomitant therapy: 
antacids allowed. Follow-up: 4-8 weeks. 
Outcome Hp prevalence rates. Comparison of healing rates and relief of 
symptoms in Hp positive and negative patients. 
Comments or conclusions Intention to treat analysis not undertaken for 
main outcome measures. Grade 1 and 4 RO excluded. 
Author, reference, year Schwizer159 2001 
Type of study and methods RCT. Blinding: double-blind, placebo 
controlled trial. Masking of outcome assessments: not described. 
Randomisation: described. Drop-outs: reasons fully described. 
Participants Multi-centre study: Switzerland, Germany and Australia. 
Sample: 70 patients. Patient selection: Patients with heartburn, acid 
regurgitation or both for more than 4 weeks and proven reflux disease (RO or 
pathological 24-hour oesophageal ph monitoring). Hp status at entry and exit 
established by histology, UBT and serology. 
Intervention Duration of therapy: similar. Type of therapy: eradication arm: 
LAC or LPP for 1 0 days, followed by LAN for 8 weeks. Control arm: LAN for 
8 weeks. Frequency and dosage: described. Concomitant therapy: antacids. 
Type and dosage: not described. Follow-up: 6 months. 
Outcome Median time to first relapse (based on detailed gastro-
oesophageal reflux disease symptom assessment using questionnaires). 
Comments or conclusions Name of questionnaire used and its validity and 
reliability not described. Analysis "as effectively treated", not ITT. 
Author, reference, year Wu258 2002 
Type of study and methods RCT. Blinding: not stated, not placebo 
controlled. Masking of primary and secondary outcomes following 
eradication (oesophageal ph, reflux symptom score, RO): not stated. Drop-
outs: No information provided, follow-up for 26 weeks. 
Participants Single-centre trial: Hong Kong. Patient sample: 40 patients. 
Patient selection: Consecutive patients with weekly attacks of gastro-
oesophageal reflux disease symptoms associated with endoscopic RO. Hp 
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status confirmed by both biopsy urease test and culture. PU patients 
excluded. 
Intervention Duration of therapy: 2 weeks. Eradication arm: OAC for 1 
week, then omeprazole for 7 days. Control arm: omeprazole for 2 weeks. 
Hp-ve RO arm: omeprazole for 2 weeks. 24-hour oesophageal pH-metry 
before and 26 weeks after treatment. Follow-up: 26 weeks. 
Outcome Mean total percentage of time pH< 4, 3 and 2. Symptom scores 
(Iikert scale for frequency and severity). Endoscopic RO (graded by modified 
SM). 
Comments or conclusions Small number of patients in each group. 
Author, reference, year Moayyedi158 2001 
Type of study and methods RCT. Blinding: double blind, single dummy, 
parallel group trial. Outcome assessments masked and method stated. The 
additional third arm not masked. Randomisation: Method described. Drop-
outs: reasons fully described. 
Participants Two-centre trial: UK. Patient sample: 57 (grade A 
oesophagitis). Patient selection: patients over 17 years with recurrent 
heartburn as a dominant complaint for at least 12 months and at least 
moderate symptoms for a minimum of 2 days in the previous 2 weeks with 
normal endoscopy or grade A oesophagitis. Grades B-D, peptic ulcer 
excluded. At entry Hp status positive if UBT and at least one biopsy based 
test (rapid urease test or histology) positive, negative if both negative. Hp 
eradication assessed by UBT at 3, 12 months. 
Intervention Duration: 12 months. Eradication arm: OCT for one week. 
Placebo arm: omeprazole and two placebo antibiotics for one week. 
Additional third arm: open labelled omeprazole for 8 weeks (dose, frequency 
described). Patients in the eradication and placebo arms received additional 
treatment for further 7 weeks with omeprazole (dose, frequency described). 
Outcome Primary. Relapse rates and time to first relapse of gastro-
oesophageal reflux disease symptoms arms. Prevalence of heartburn and 
RO rates at 12 months follow-up. 
Comments or conclusions As our protocol included endoscopic 
oesophagitis patients only, we excluded ENRD (heartburn symptoms and 
normal endoscopy) patients from this study for our analysis. 
122 
Author, reference, year Soga263 2000 
Type of study and methods Prospective randomised, case-control 
comparative study: randomised to two types of acid suppression therapy. 
Method of randomisation: described. Blinding: None. Masking of Hp status 
and outcomes: not described. Drop-outs: reasons for exclusion stated. 
Analysis on patients who completed the study. 
Participants Single-centre trial: Japan. Patient sample: 71 patients. Patient 
selection: patients with suspicion of upper GIT lesions and grade A-D 
oesophagitis. Active PU excluded. At entry, Hp status assessed by histology 
and culture. 
Intervention Duration of therapy. 8 weeks. Type of therapy. one arm 
received OME and another arm received FAM. Dosage and frequency: 
stated. Endoscopy at entry and at 5 months. 
Outcome Healing rates: comparison between OME and FAM arms as well 
as between Hp positive and negative patients. Remission rates. 
Comments or conclusions Exclusion of previous healed peptic ulcer not 
described. No data on remission rates comparison between Hp positive and 
negative patients. 
Author, reference, year Werdmuller157 1997 
Type of study and methods Descriptive, prospective. Randomisation: not 
applicable. Blinding: none described. Masking of outcomes: none described. 
Controls: reference group with normal endoscopy. Matching: not described. 
Participants Consecutive patients undergoing upper Gl endoscopy for 
upper abdominal complaints or reflux symptoms. Cases (n=240, of which 
118 patients with proven gastro-oesophageal reflux disease included. Rest 
with hiatus hernia and no RE or with BO excluded). Reference group 
(n=399): Normal endoscopy and presumed absence of typical reflux 
symptoms. 
Intervention Upper Gl endoscopy, Hp testing by histology (H & E stain), 
culture, quick urease test and serology (not all four tests in every patient). 
Outcome Hp prevalence in gastro-oesophageal reflux disease (29%), in 
reference group (51%). 
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Comments or conclusions We assumed from the details given that 
patients in the reference group do not have reflux disease. 
Author, reference, year Wu264 2000 
Type of study and methods Descriptive, case-control. Randomisation: not 
applicable. Blinding: endoscopist blinded to Hp status. Masking of outcome: 
not applicable. Controls: age-sex matched non-reflux patients with Hp 
infection. Drop-outs: none described. 
Participants Single-centre study Hong Kong. Patient sample: 140 patients. 
Patient selection: Consecutive ethnic Chinese patients with reflux disease 
and proven endoscopic erosive oesophagitis. PU excluded. 
Intervention Endoscopy at entry to assess oesophagitis by Savary-Miller 
method. Hp status assessed by rapid urease test and histology. cagA by 
western blot. Age-sex matched Hp positive controls for cagA testing. 
Outcome Prevalence rates in Hp positive and negative oesophagitis (grades 
1, 2, 3 and 4). CagA prevalence rates in erosive oesophagitis and non-reflux 
controls. 
Comments or conclusions Authors also described rates in non-erosive 
reflux disease. 
Author, reference, year Warburton-Timms 143 2001 
Type of study and methods Descriptive, retrospective, prevalence. 
Randomisation: not applicable. Blinding: Anti-CagA antibody determined 
without prior knowledge of H. pylori or oesophagitis status. Control group: 
none. 
Participants Single-centre study UK. Patient sample: 1485 patients. 
Patient selection: Unselected cohort of patients attending for routine 
endoscopy in 1986. 
Intervention Oesophagitis graded according to Blackstone. H. pylori 
assessed by histology, culture and biopsy urease test. CagA serology 
determined by p 120 cagA ELISA kit and validated in some by western blot. 
Outcome Hp prevalence rates in oesophagitis (mild, moderate, severe). 
Anti-CagA antibody rates in normal, mild, moderate and severe oesophagitis. 
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Comments or conclusions Data recorded in 1986 described in 2001. 
Endoscopy performed by difference grades of clinicians. 
Author, reference, year Adamek259 2001 
Type of study and methods RCT. Blinding: double-blind in regards to acid 
suppression treatment (pantoprazole or ranitidine) but blinding to Hp status 
not described. Masking of outcomes: not described. Method of 
randomisation: stated. Drop-outs: reasons described. Analysis: ITT. 
Participants Multi-centre trial: Germany. Patient sample: 396 patients. 
Patient selection: pre-selected sample of patients with Savary I Miller stage 2 
reflux oesophagitis. PU excluded. 
Intervention H. pylori assessed by histology, culture and biopsy urease test. 
Duration of therapy for healing of oesophagitis: 8 weeks. Type of therapy: 
Pantoprazole, dose and frequency stated. Hp eradication regimen: 1 week 
PCM. Duration of maintenance therapy 12 months. 
Outcome Time to endoscopic proven recurrence of reflux oesophagitis in 
the two treatment arms. Sub-set analysis of influence of presence or 
absence of Hp on oesophagitis relapse rates in the pantoprazole group. 
Comments or conclusions Endoscopy performed by different clinicians at 
various locations. The primary objective of the trial was to compare the 
efficacy between two drugs in the prevention of relapse of oesophagitis 
following healing of oesophagitis with pantoprazole. 
Author, reference, year Schenk 147 1999 
Type of study and methods Cohort study (prospective). Randomisation: 
none described. Blinding: pathologist blinded to clinical and endoscopic 
data. Masking of outcomes: none described. Drop-outs: reasons not fully 
described. 
Participants Single-centre study Netherlands. Patient sample: 137 
patients. Patient selection: patients referred to clinic with symptoms 
suggestive of reflux disease and endoscopy proven oesophagitis of grade 1 
or more. Hp positive if histology and culture positive. 
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Intervention Duration of therapy. variable but not clearly explained. Type 
of therapy: OME, dosage and frequency variable depending on symptoms. 
Follow-up: 56.6 months (mean). 
Outcome (a) Severity of oesophagitis in Hp positive and negative patients. 
(b) Efficacy of OME to maintain disease remission (relief of symptoms and 
endoscopic signs of oesophagitis). 
Comments or conclusions Exclusion of PU note clearly stated. 
Details of excluded studies 
Author, reference, year Fraser268 1998 
Type of study and methods Cohort study. Retrospective and prospective. 
Blinding: not part of protocol, not described. Masking of outcomes: not 
stated. Drop-outs: not described. 
Participants Patients who attended for dyspepsia and were successfully 
treated for Hp. 
Outcome and results Hp reinfection rates. Symptom assessment 
(proportion with symptoms, mean symptom score and global assessment). 
GU patients had significantly better results in comparison to DU patients. 
Reason for exclusion No firm data regarding heartburn pre-eradication. 
Author, reference, year Carlsson266 1997 
Type of study and methods Post-hoc analysis of 3 RCTs comparing effect 
of short and long-term treatment with acid suppression therapies vs. placebo. 
Blinding: Hp status blinded to investigators. Masking of outcomes: not 
described. Drop-outs: not described. 
Participants Patients with RO and ENRD. 
Outcome and results Influence of Hp status on the response to treatment 
with anti-secretory drugs and symptomatic relapse on cessation of therapy. 
Healing of oesophagitis and relief of heartburn similar in Hp positive and 
negative patients. Relapse rates off therapy similar but time to relapse on 
maintenance therapy favoured Hp positive patients. 
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Reasons for exclusion Abstract without full information. Sub-group data 
concerning RO patients not available. Hp assessment not by the same test 
in all patients. Exclusion criteria not described. 
Author, reference, year Laine267 2002 
Type of study and methods Cohort study (prospective). Blinding: patients 
and investigators blinded to results of Hp following eradication. Masking of 
outcomes: not described. Drop-outs: nil. 
Participants Patients with primary complaint of dyspepsia who are Hp 
positive on rapid urease test or histology. 
Outcomes and results Hp eradication rates 48/61 (79%). Heartburn was 
present at baseline in 22 cured patients. At 6 months follow-up, it persisted 
in 13 and resolved in nine. Nine patients developed new heartburn. Quality 
of life measurements (QOLRAD) before and after successful eradication 
described. 
Reasons for exclusion No data concerning endoscopic diagnosis. 
Author, reference, year Murthl65 1998 
Type of study and methods Cohort study. No control arm. Blinding: none 
described. Masking of outcomes: not described. Drop-outs: described. 
Participants Hp positive DU patients who have been successfully 
eradicated (confirmed by rapid urease test and histology). 
Outcomes and results Comparison of serum gastrin and antral G and D-
cell density in patients who did and did not develop RO. 
Reasons for exclusion Abstract, small sample size, patient selection 
method not stated, duration of follow-up not described. 
Author, reference, year Vicari141 1998 
Type of study and methods Case-control. Blinding: not part of protocol. 
Participants Reflux disease patients defined as those with frequent 
heartburn or acid regurgitation 4 weeks before endoscopy. Control patients 
were undergoing endoscopy for other reasons. 
Outcomes and results Hp prevalence rates lower (34%) in reflux patients 
compared to controls (46%). CagA in controls (42%), reflux disease (37%). 
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Reasons for exclusion Did not satisfy our eligibility criteria (no data on 
proven oesophagitis). Controls not matched in numbers. 
Author, reference, year Hatlebakk270 1999 
Type of study and methods RCT. Blinding: described. Masking of 
outcomes: not described. Drop-outs: described. Intention to treat analysis 
described. 
Participants 483 untreated patients with complaints of heartburn 3 days a 
week, with at most grade 1 reflux oesophagitis. 
Outcome and results Adequate control of heartburn was achieved after 4 
weeks in 71% of patients taking omeprazole, 22% taking cisapride and 18% 
taking placebo. Patients taking omeprazole who were positive for H. pylori 
achieved adequate control of heartburn more often than patients who were 
negative for H. pylori (86% v 65%, P<0.02). Severity of heartburn and mean 
number of days with heartburn decreased more in patients taking 
omeprazole than in those taking placebo or cisapride (P<0.0001 ). 
Reasons for exclusion This trial was aimed to determine the ideal 
treatment for heartburn in patients with minimal or no oesophagitis. 
Eradication of H. pylori was not part of the protocol. 
Author, reference, year O'Conno~69 2001 
Type of study and methods Cohort study. Blinding: not part of protocol. 
Masking of outcomes: not described. Drop-outs: described. 
Participants Patients with endoscopy proven, Hp positive PU ulcer that had 
been successfully eradicated of Hp. 
Outcomes and results Hp recurrence rates, dyspeptic symptoms 
(epigastric pain, heartburn and belching) and use of anti-secretory therapy. 
Follow-up: 6.1 years (mean). Hp recurrence rate 6.6%. Dyspeptic symptoms 
in 42 (69%), heartburn in 27 (44%) patients. 
Reasons for exclusion No data concerning heartburn rates pre-eradication. 
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Chapter 4 
The use of Proton Pump Inhibitors: an exploration of 
the attitudes, knowledge and perceptions of General 
Practitioners 
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4.1 Introduction 
Proton pump inhibitors, potent suppressors of gastric acid, are commonly 
used for a variety of upper gastrointestinal disorders, especially gastro-
oesophageal reflux disease. They constitute the largest single sector of 
primary care prescribing, amounting to £300m annually in UK21 . Research 
from the North of England suggests that 0.5% of the population is on long-
term repeat prescriptions for proton pump inhibitors, mainly for gastro-
oesophageal reflux disease (56%) or dyspepsia (32%)42 . 
Chronic gastrointestinal reflux symptoms may be associated with an 
increased risk of developing oesophageal cancer6;273 but most patients with 
gastro-oesophageal reflux and dyspepsia could potentially be managed with 
more economic alternatives and/or lifestyle changes93.Guidelines from the 
Government advisory body the National Institute for Clinical Excellence22 
indicates that patients with mild gastro-oesophageal reflux disease, non-ulcer 
dyspepsia or non-acid-related symptoms should not be treated with proton 
pump inhibitors. 
Proton pump inhibitor prescribing has increased markedly since their launch; 
as an example, in one NHS region (West Midlands) there was a 456% 
increase in five years from 199234. It is unclear as to why the prescribing of 
proton pump inhibitors is on the increase since there is no evidence of 
sharply increasing morbidity from gastrointestinal conditions34. A better 
understanding of the prescribing practices of general practitioners could help 
reduce costs. However, there is relatively little research depicting the 
patterns of PPI prescribing by individual general practitioners, the extent of 
variations between them and the factors influencing their prescribing 
decisions. The aim of this study was to gain a better understanding of the 
prescribing behaviour of general practitioners by exploring their knowledge, 
understanding, perceptions and attitudes towards proton pump inhibitors. A 
qualitative approach using focus groups was chosen as the most effective 
means of undertaking this. 
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4.2 Methods considered 
In order to obtain the stated aims, the use of questionnaires, semi-structured 
interviews and focus groups were considered as possible other methods. It 
would have been difficult to ascertain and interpret the thought processes of 
general practitioners through questionnaires alone without prior information 
from a qualitative approach. The design of questionnaires for this type of 
study would have been complicated requiring a validation exercise and 
requiring constructs from qualitative methods. Questionnaires might have 
reached a larger audience and have provided quantitative information but 
would not have formed the first phase in understanding the thinking of 
prescribing general practitioners. 
It would have been possible to use semi-structured interviews, which provide 
detailed and easily decipherable information. This could have been obtained 
even from those general practitioners too "shy" to express their views in a 
group setting. However, in a one to one setting, sensitive, personal and 
controversial views are not necessarily shared easily. Interviews would also 
have been more time consuming and relatively expensive. 
Focus groups lend themselves ideally to this type research274. The nature 
and quality of information required for this kind of study can be arguably 
superior when peers are brought together to interact contextually. Focus 
groups create an atmosphere of inquisitiveness and debate between 
colleagues, and can challenge opinions and ideas through mutual interaction. 
By bringing professional colleagues together, focus groups provide an 
opportunity for understanding diverse views and opinions and can create a 
learning atmosphere. The chief drawback of focus groups is related to their 
organisation, the need for initiative and the communication skills required to 
bring professionals together. Practical difficulties in getting interested general 
practitioners to attend can be a problem. In the focus group, the facilitator 
has to ensure equal opportunities for opinions to be voiced, especially by the 
non-dominant participants -this can be a challenge. 
131 
4.3 Participants and recruitment 
A stratified random sampling strategy (to give a representative male/female 
ratio) was used to recruit the first batch of 19 participants for the focus group 
sessions. Fifty general practitioners were randomly selected from a register 
of practising general practitioners, provided by East Riding Health Authority. 
Of these, 30 general practitioners were initially contacted by telephone and 
then invited to participate by letter. Twenty five agreed to take part. However, 
six later withdrew due to prior commitments. None of this group was 
previously known to the principal researcher. A further convenience sample 
of ten general practitioners, who were known to the researcher in a 
professional and/or social capacity were also then recruited (Appendix 1 ). 
To contrast the views of recently qualified doctors and academic general 
practitioners a purposive sampling strategy was used to recruit the remaining 
participants. Fifteen out of 18 general practitioner registrars, currently training 
in the Hull and East Yorkshire, agreed to take part. Five out of eight 
academic general practitioners attached to the Centre for Integrated Health 
Care Research, University of Durham also participated. 
Thus, from a total of 67 who were invited to participate, 49 (33 male and 16 
female) agreed to take part (Appendix 2). Table 1 shows the characteristics 
of those general practitioners who volunteered and also those who declined 
to participate. Participants received a small honorarium in appreciation of 
their support. 
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Table 1. Participant and non-participant characteristics 
Participant/practice Agreed to Refused/unable 
characteristics participate to participate 
N=49 N=18 
Age (range) 26-62 27-63 
Sex (mlf) 33/16 11/7 
Small practice (less 3/46 1/17 
than 2 partners) vs. 
group practice 
Inner city and urban 26/23 11/7 
vs. rural practice 
Training and 24/25 7/11 
academic vs. non 
training or non 
academic 
4.4 Setting and procedures 
Five focus groups were arranged. Three of the groups were co-facilitated by 
a non-clinical researcher (VF), one by a practice secretary (lW) and one by 
the author RR. One of the focus groups was held in the post-graduate 
teaching room of the local hospital, three in the research seminar room of the 
local research network and one in the seminar room of the Centre for Health 
and Social Services at the University of Hull. Table 2 shows the 
characteristics of each focus group. 
VF has experience of qualitative research and undertaken workshops in 
focus groups. ASR briefed VF about the project and provided the material 
necessary to ensure facilitation of the focus groups. TW worked in ASR's 
practice and had no formal research experience but had some knowledge of 
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acid suppression drugs. ASR provided TW with in-house training. She 
assisted ASR in the organisation, note-taking, and transcribing of the focus 
group material. 
Table 2. Focus groups' characteristics 
Characteristics One Two Three Four Five 
Numbers 15 11 8 10 5 
Age Range 26-40 33-62 35-56 35-59 40-60 
M/F 9/6 9/2 6/2 5/5 4/1 
Sampling Purposive Stratified Stratified Convenience Purposive 
Type ofGPs Registrars Mixed* Mixed* Mixed* Academic 
Duration 45mins 50mins 45mins 55mins 50mins 
.. 
*Mixed 1nd1cates that General practitioners came from a vanety of backgrounds (tra1ner/non 
trainer, academic/non academic, inner city /urban/rural) 
Participants were given a brief explanation of the format of the meeting. The 
researcher facilitated the focus group in an unobtrusive manner, intervening 
only to ensure that all the expected issues were covered and in sufficient 
depth. To stimulate discussion, each focus group was also asked to 
formulate a management plan for a hypothetical case study. Sessions lasted 
approximately 45 to 55 minutes and were audio taped (with participants' 
consent) for transcription. 
4.5 Data coding and analysis 
An iterative approach following grounded theory principles275 was applied to 
data coding. Analysis began after the first focus group to allow expected and 
emergent themes and concepts to be incorporated and explored in 
subsequent focus groups. A constant comparative approach276 (Green, 1998) 
was adopted to ensure that both commonalities and contradictions were 
identified from transcripts. 
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The transcripts were coded independently by RR and VF to increase the 
reliability of the study. The coders agreed no new concepts were occurring by 
the end of the fifth focus group, suggesting 'saturation' had been achieved 
(Glaser & Strauss, 1967). Analysis of the data was aided by use of the 
computer software QSR NUD.IST 4.0 (non-numerical unstructured data-
indexing search and theory building). 
4.6 Respondent validation 
All participants were sent a copy of their focus group transcript summary. 43 
(88%) replied and none disagreed with their focus group transcript 
information. Three participants partially acknowledged the transcript data and 
provided feedback information. 
4. 7 Findings 
The emergent themes lent themselves to classification in the following three 
broad areas with sub themes. a) The understanding of the function of proton 
pump inhibitors and their use b) Prescribing issues c) The risks and benefits 
of proton pump inhibitors. 
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The understanding of the function of proton pump inhibitors and to 
their use 
(i) General practitioners perceptions of proton pump inhibitors 
Proton pump inhibitors were perceived to be an important group of drugs, 
considered extremely effective in relieving upper gastrointestinal symptoms. 
This was a recurrent theme. Although most general practitioners felt that 
proton pump inhibitors were a big leap, there was also the opinion that they 
may be "too good", possibly indicating, paradoxically, that this might be a 
drawback. Generally, it was felt proton pump inhibitors were well tolerated 
with very little by way of noticeable or reported side effects. Many participants 
shared the feeling of proton pump inhibitors being "over-effective", leading to 
difficulty in their withdrawal and reluctance by patients to stop them. Much 
discussion centred on the ethical, clinical and cost issues surrounding this; 
some participants felt that the difficulty in stopping proton pump inhibitors 
was not a problem. This indicated a more relaxed attitude towards proton 
pump inhibitor prescribing linked to the perceived benefits and symptomatic 
relief these drugs brought. Equally, there seemed to be a dilemma in 
attitudes towards the overall use of proton pump inhibitors. Some felt very 
uncomfortable that proton pump inhibitors were used rather blindly for 
"everything" whilst others appeared comfortable and guilt-free about their 
acknowledged, somewhat blanket use of these drugs. 
Many of the general practitioners perceived that patients felt so well on 
proton pump inhibitors that both they and the patients were reluctant to 
attempt to stop them or to reduce dosages. Patients thought to feel 
apprehensive about making changes for fear of relapse of symptoms. 
However many feel that this might be because of lack of clear 
communication, sharing of information, and a need for better understanding 
of patients' ideas, expectations. 
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"they are miracle drugs, not the sort you expect to come along every year. 
" they have revolutionised the management of dyspepsia and especially reflux 
disorders .... but also for a change you feel as a GP you can really deliver something 
useful because you know it works" 
" Yes, but there is this real problem, isn't there, that proton pump inhibitors are too 
good ... I find it difficult to stop them once they are started. Patients aren't keen to stop 
or reduce the dose because they fear their symptoms will relapse" 
"In my personal experience, patients get hooked on proton pump inhibitors, it is 
a/most addicting like heroine and people appear to experience severe indigestion 
symptoms on attempting to stop them" 
"But you could argue that for any drug, including paracetamol, if you give this long 
enough. I have been able to withdraw or reduce proton pump inhibitors in several of 
my patients without any problems" 
"A/so that's a fear that you could maybe share with them" 
(ii) General practitioners' views of their patients' understanding of proton 
pump inhibitors 
Many of the participants felt that patients regarded their proton pump 
inhibitors as a lifestyle drug and that this encouraged their use. 
Participants debated the ethical and political correctness of prescribing 
proton pump inhibitors as a lifestyle drug. While many felt that they should 
not be used this way, there was a strong voice of opinion that challenged this 
attitude. To indulge in excessive food and alcohol and other lifestyle 
indiscretions was considered "normal" human behavior. As the quality of life 
in patients who experienced symptoms improves ~ith protem pump inhibitors, 
it was considered that some patients would continue to lead a "normal life of 
indulgence". 
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"I think one thing I'm conscious of perhaps that we're not stressing enough the 
lifestyle issues, because often a lot of the symptomatic people are heavy drinkers, 
eating curry every night and smoking forty a day and that perhaps we're making it a 
bit too easy for them if we are ... " 
"We can offer advice regarding healthy eating, smoking, drinking and we do this all 
the time anyway; but who are we to be the judge and jury? As far as I am 
concerned if proton pump inhibitors makes a big difference to their life, then I have 
no right to deny this". 
"Diarrhoea is a problem with some people. Some people will take it intermittently 
as in they'll have a heavy meal and they'll take their PPI and ... " 
"and eat salad the next day, they'll, that's their education, that's their 
understanding, because they don't want to restrict their life-style, and will put up 
temporarily with diarrhoea and they'll double up, if they'll take one or two, sort of self 
regulating ....... " 
(iii) The initiation and maintenance of proton pump inhibitors 
The age of the patient at presentation, the waiting time for a hospital 
appointment or for endoscopy, personal experience and confidence, the 
availability of guidelines and evidence were considered to influence decision-
making here. There was controversy with regard to the understanding of 
good practice and diverse opinions and justifications were expressed about 
how doctors initiated and maintained proton pump inhibitor therapy. Whilst 
the age of 45 years has been quoted as the "cut-off' for decisions regarding 
referral and investigations, many felt this to be inappropriate, even illogical 
and possibly dangerous. Many confessed to not making their decisions 
based on this, but their personal uncertainty about particular patients. 
There were differences in the views of the general practice registrars and 
some of the academic general practitioners, compared with the established 
and entirely service based participants. The former attended to be more 
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cautious in their comments regarding the initiation of proton pump inhibitors; 
often recreating the need for definitive diagnosis (presumably by 
investigation) or a tentative positive clinical diagnosis. The latter group 
favoured a more blanket like approach to proton pump inhibitor therapy. The 
overall impression was that all the established service based practitioners 
looking for an effective tool within the consultation setting, usable quickly and 
with a view to reducing overall workload including that from repeated 
consultations and in terms of referrals and investigations. A patient who 
responded positively fulfilled these requirements. However, there were many 
complex issues raised during this discussion including the need to be aware 
of the low yield from tests in younger patients and the fear of commencing 
long-term therapy shortly after the first encounter with the patient. 
With regard to use of endoscopy, there was more than one opinion both as to 
when this procedure would be requested as well as how the results might 
influence the initiation and continuation of therapy. A major influence on 
which type of drugs were used was the way in which the patient presented. 
This also influenced the decision about investigations and referral. This was 
an important finding because it offered an explanation about how general 
practitioners make management decisions in dyspepsia and reflux. 
"At the same time, if you've got someone who is very elderly then I'd be quite happy to 
start them on a PPI without endoscopy because, what's the point of endoscoping 
somebody if you're not going to do anything about the result?" 
"But that could be dangerous and may not stand up in court. All guidelines advocate 
endoscopy over the age of 45 years" 
"Each case has to be individually assessed in my opinion. As a GP, I have knowledge 
of the patient, his other health problems, his expectations etc. So my decision to refer 
or not for endoscopy is dependent not just on age" 
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Most general practitioners were prepared to use maintenance dose proton 
pump inhibitors in formally investigated as well as uninvestigated patients. 
The possibility of peptic ulcer disease as well as simple indigestion and 
heartburn were quoted as the main reasons as to why participants felt that 
many patients needed to be upgraded to proton pump inhibitors from 
previous medications like cimetidine. Patient related factors (ideas, concerns 
and expectations) also appeared to have an important influence in the use of 
maintenance proton pump inhibitors. Those who had persistent symptoms 
with reduced quality of life merited proton pump inhibitors even if their 
investigations were normal. 
(iv) H. pylori infection and the use of proton pump inhibitors 
The focus groups debated the value of testing for H. pylori in patients on long 
term proton pump inhibitors. Opinions were divided. The argument in favour 
of testing and treating rested on assumptions of relief of dyspepsia symptoms 
as well as the possibility of stopping proton pump inhibitors or switching to 
"milder" medications like antacids. It was felt by some that eradication of H. 
pylori must be a "good thing". However, many doctors expressed uncertainty 
of the value of testing for H. pylori in gastro-oesophageal reflux disease. The 
logistics and the economic consequences of this, as well as any possible 
unintended harm from eradication weighed on the doctors' minds. Members 
concurred that there were two sides to this argument and that the issue was 
unresolved. 
"but it is, it's to do with, you can have people with H pylori and people 
asymptomatic and then the two, the four squares overlap and it's that 
target group in the middle that you're worried about but there's lots of 
people with H pylori and no symptoms and no H pylori but lots of 
symptoms .. " 
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(v) Step-up, step-down or step-away? 
The understanding and attitudes towards step up or step down therapy 
appeared to be influenced by several factors: guidelines, consultant opinions, 
own experiences, post-graduate education meetings and commercial 
influences. One group of doctors expressed the need to "step-away" from the 
traditional model of step-up or step down. They argued that in the context of 
the majority of primary care consultations, it was a futile exercise and even 
inappropriate to be able to consciously consider the step-up or step-down 
approach. Patients often had multiple problems and decisions were often 
influenced by other factors, e.g. psychological and social issues, 
expectations of both patients and doctors, and the relationship between 
them. Thus, what appears to be a simple concept of down grading or 
upgrading therapy in response to symptoms was actually perceived as a 
difficult exercise. Part of this was the desire by many participants to avoid 
repeated consultations and the need to maintain the patient on the most 
effective dose. Dose reduction was seen as a one dimensional exercise by 
some, perhaps theoretically saving money in drug costs, but not accounting 
for the additional workload and possible detriment to the patient. 
"It is fine to talk about this here in a group, in isolation I mean ... but in reality this 
never is the case, is it, during GP consultation? We are always faced with multiple 
problems and proton pump inhibitors is just one issue ... that is why I think guidelines 
are just that, guidelines". I hardly ever consciously think about them or apply them 
during consultation, mostly it is irrelevanr' 
"But we are being asked to practice evidence-based medicine and there is pressure 
also from patients". But I must admit, I do treat several of the older patients 
empirically, may be with proton pump inhibitors simply because I feel that is the right 
thing to do at that time" 
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"Well that's exactly what we did, because my husband was on it and we couldn't get it 
so we got our GP to write out private 'scripts and we had to get them sent over and 
she gave us them" 
"I'm taking, (waits until everyone quiet) I'm taking Pariet (name of a PPI), it's brilliant, I 
would even pay fifty pounds for it" 
"I find it very difficult to deny it to my patients, being in the position myself. I've had an 
endoscopy which was normal, okay, it's not as bad as I have to take it every time, but 
it occasionally comes back as quite distressing in, I would say, maybe one or two 
weeks and then it's settles with a Pariet and I don't take the Pariet anymore and after 
few months or so it comes back. There was some research on that in the BMJ just I 
think January last year about putting patients er on er intermittently exactly the way I 
do with myself. And I would find it difficult to say to patients, well you've got it-
tough" 
b) Prescribing issues 
(i) Costs 
Proton pump inhibitors were considered to be expensive by many 
participants but this view was not universally shared. Although several 
participants voiced the need to involve patients about the issue of costs and 
expenses of proton pump inhibitors, others felt uncomfortable about raising 
this. 
Prescribing influences 
Several factors were identified to influence proton pump inhibitor prescribing. 
They included the use of guidelines and evidence, endoscopy results, 
commercial influence and marketing, prescribing behavior of doctors, cost, 
and introduction of different proton pump inhibitors. The repeated influence of 
marketing on prescribing behavior was considered to have an impact 
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positively on proton pump inhibitor prescribing and negatively on prescribing 
of other acid suppression drugs. 
" I think we are all sitting here and debating about this mainly because of the pressure 
on us by our pharmaceutical advisors not to prescribe Proton pump inhibitors because 
of cost implications to the NHS; I bet that this will not be an important topic in 2 years 
when Losee goes generic" 
"Alright, they're expensive but on the other hand do they save in hospital admissions 
for perforated ulcers or bleeding ulcers so in that sense, okay, your drugs budget is 
seen to go up but well but on the other side you're saving money for the NHS in hospital 
admissions" 
"Why not be honest and say, the NHS can't afford to keep giving you these drugs 
unless there's a very good reason, the patients understand that, and in this day and age 
they understand perfectly well about cost. It's quite an acceptable thing to say, 
(Russell said I think here) I'm sorry but these are an incredibly expensive if you need 
them, yes, but if you can do without them, and, cost wise, let's look again" 
"But then people often say everybody else is a tourist whereas I'm on my vacation, 
everybody else is excess traffic, but my car's essential so ... 
ii) Review of prescriptions 
The importance of formal review as opposed to ad-hoc or opportunistic 
review was a common topic of debate in all the focus groups. A point of 
contention was whether the repeat prescription review process should have 
inbuilt checks. For example this might restrict the number of prescriptions 
issued. The review process and follow-up of patients on maintenance proton 
pump inhibitors was highlighted to have several advantages. The "correct" 
way of communicating to the patient was considered to be important in 
helping to "sell the proton pump inhibitors in the right way" and help formulate 
negotiated management plan. 
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"It goes back to what I was saying at the beginning that Proton pump inhibitors 
have been pushed at us so much aren't they, you often, at that time in a 
consultation, you just, they just slip you by, you think well, what could he have, 
oh Proton pump inhibitors ... and there's nothing, you know if someone comes 
in with fairly mild symptoms or you know, someone you think might go away 
with gaviscon or cimetidine, I think we should step back a second and try and 
remember those, there's nothing wrong to try those first and if they don't work 
then .. " 
"With the newer ones coming out, every time you turn over a page, there's an 
advert for one of the newer ones, erm, you're seeing reps every other week, for 
them and saying how are you doing with the Proton pump inhibitors and 
sometimes you forget there are other things that are cheaper that might work 
just as well for that patient" 
"That's the same with all the statins, that the other drug companies will jump on 
the back, and say look, it was our, it was our statin that's proved to do x, y and 
z. And then we say all the statins are the same so" 
"But there is a danger, with any ongoing medication, that they're just ringing up for 
the repeat prescription and you just merrily sign it ... 
"Yes, but we are overburdened with work already, especially in our inner-city 
practice, none of my partners will have time to review all patients on proton pump 
inhibitors ... a lot of it may be waste of time anyway. 
"But- you can usually persuade people along the lines of well, you don't want to 
put these drugs into your sort of body for long term if you can avoid it though do 
you? You haven't had any problems for four years, why don't you try stopping it 
for a while, if there's a problem you go back on it, sort of approach. And most folk 
you can win round you know, with the idea of your long-term drug use, not a good 
thing 
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c) Risks and benefits of proton pump inhibitors 
Concern was raised about the risk of missing serious pathology. Concerns 
were expressed with regard to a) missed cancers at endoscopy, b) the 
masking of symptoms of cancer leading to delayed diagnosis and c) the 
possible risk of developing cancer when proton pump inhibitors are used 
inappropriately or in the long-term. 
On the other hand, many participants highlighted the benefits of proton pump 
usage. The anecdotal experience of some doctors suggested decreasing 
complications from severe reflux disease, the reduced prevalence of 
complications e.g. strictures, bleeding and perforation. The "vastly improved" 
quality of life, the virtual eradication of ulcer disease and its complications 
were problems where proton pump inhibitors played a significant role. The 
potential risk of litigation from a missed or a delayed diagnosis was the 
reason for some to institute early investigation, without the prior use of proton 
pump inhibitors. Patient choices and expectations were other determining 
factors. 
"Miracle all right, but too good of anything can be dangerous. Would just like to 
reiterate that, let me say they even work too well, what worries me is won't there be 
long term missed cancers?" 
"But there is no evidence to that or is there? 
" How do you know about harm, they have been around only for just over ten years" 
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"So that's the ten to fifteen percent we can't change erm but there is a hell of a lot of 
people who didn't have the investigations like endoscopy/Hp test etc, and why not, 
other people have been on them for three, four, five years (nods and murmurs of 
assent around the table) then you think, hold on a second, am I the first option? 
What if, a patient comes in and says (knocks five times loudly on table) 'I want my 
repeat prescription'? Are you then going to say, 'yes hold on a second, but we're, 
we're going to change it now, we going to stop this or we going to do a test', 'yes but 
doctor, why are you going to do a test?' 'Erm, well because we should have done that 
five years ago' 
" So, that is the risk of proton pump inhibitors being given long-term to patients without 
thinking through, yes, now you are concerned about litigation if anything is discovered 
on endoscopy" 
Responses to Case Vignettes 
The groups were asked to formulate a management plan for the following 
case scenario. 
"What I've got here is a fifty five year old lady, obese, smoker, recent onset 
epigastric pains and heart-bum, no sinister symptoms; meaning no loss of 
weight and no loss of appetite. She has tried antacids over the counter but 
with no relief of her symptoms. She has come to consult you". 
The participants agreed in the main that she should have an endoscopy, but 
were divided about her management whilst awaiting endoscopy. Some felt 
that she should be prescribed an H2 receptor blocker, some, proton pump 
inhibitors and others nothing other than antacids. Most felt that testing for H. 
pylori would not be of any value, because this was likely to be undertaken at 
endoscopy. Most agreed that her risk factors, diet and life style needed to be 
addressed. 
''The endoscopy is normal, and she comes back with similar symptoms of 
heartburn, what will you do?" 
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At this stage, the groups considered other diagnoses, but when informed that 
the problem was essentially one of endoscopy negative reflux, some 
suggested lifestyle measures and antacids only. They argued that a normal 
endoscopy indicated minor reflux or non ulcer dyspepsia. Others felt that 
there was no connection between the endoscopy findings and severity of 
reflux and that the symptoms were the main denominator to guide 
management. Hence a trial of proton pump inhibitors or H2 blockers was 
justified. 
4.8 Discussion 
Prescribing is a critical medical task. The majority of consultations take place 
in primary care and general practitioners are at the forefront of decision 
making about prescribing277-279. Primary care prescribing has been under 
scrutiny partly because of costs but also because of the need to link this with 
evidence280;281 . Primary Care Trusts have a specific remit to guide 
prescribing policies and to assist general practitioners. Thus, apart from 
clinical and quality issues, economic pressure on the NHS has been a major 
factor in provoking management guidelines, possibly in the belief that these 
will reduce prescribing costs. Proton pump inhibitors have been a major 
target for such guidelines because of their pre-eminance in the NHS 
prescribing bill. However, the factors leading to such wide scale prescribing 
as well as the reasons for variations in prescribing of proton pump inhibitors 
between doctors have been far from clear. 
The overall impression was that proton pump inhibitor prescribing and 
variations in such prescribing seemed to hinge on self-justified perceptions 
and attitudes, despite a uniform understanding of their nature and costs. 
There were a number of specific findings. Firstly, the participants had a good 
working knowledge of proton pump inhibitors - the way they work, their 
indications and their effectiveness. Furthermore, they were aware of potential 
problems from proton pump inhibitor usage, such as the possible masking of 
dangerous lesions and difficulties around patients commencing long-term 
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therapy from an intended single first prescription. The participants also 
recognised the dangers of patients developing other lesions whilst on long-
term therapy and the need for prescription monitoring. 
These latter issues were linked with long-term proton pump inhibitor usage -
either intermittently or on a regular basis and caused much anguish. 
Participants readily recognised the need to avoid "unnecessary" long-term 
treatment but were caught in the dilemma of wanting to ensure adequate 
symptom control and to avoid repeated consultations. Here the paradox of 
proton pump inhibitor efficacy became apparent - some felt that they were 
"too effective", thereby reducing inducement for patients to alter their lifestyle 
or to attempt to manage on other, possibly less efficacious drugs. 
Within this context, the concepts of step up and step down, whilst understood 
in principle, were not felt to be easily or practicably applicable in the 
consultation setting. Many general practitioners seemed reluctant to switch 
doses, preferring instead to maintain the patient on what they regarded as an 
"effective" dose. A corollary of this is that many might have accepted the role 
of other health workers in the practice, e.g. a pharmacist or a nurse, to 
undertake dose switching. However, this was not being explored in the study 
- with hindsight this would have been useful. 
The key to whether or not the patient ended up on long-term prescriptions 
seemed to stem from the initial prescribing decision. A single successful 
attempt at treatment for troublesome symptoms was likely to be associated 
with repeat prescriptions and eventual long-term therapy. The general 
practitioner registrars, who were still in training and presumably still 
influenced more by their hospital training as well as academic general 
practitioners appeared more circumspect about initiating proton pump 
inhibitor therapy. However, there was no way to confirm whether this would 
have been carried through into the pragmatic practice setting - most 
experienced service based participants opted for expediency and avoidance 
of further workload including consultations and investigations. Empirical 
proton pump inhibitor therapy was more likely amongst these participants. 
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These participants justified their prescribing on the basis of benefits to the 
patient, although it was likely that they were acting to save time and 
consultations. 
The role of H. pylori and proton pump inhibitors was not well understood or 
appreciated on an objective scientific basis. However, it has to be recognised 
that many of the links between H. pylori and reflux are circumstantial or even 
only theoretical. It is probably too early or too much to expect everyday 
clinicians to have a clear view about H. pylori eradication in patients with 
reflux who are likely to require long-term proton pump inhibitors. This has 
been espoused in the Maastricht 2000 guidelines 198 but has not taken root in 
everyday practice. In any case, there are no clear data from prospective 
studies on the effect of eradicating H. pylori in patients on long-term proton 
pump inhibitors for reflux disease. 
Attitudes towards guidelines concerning proton pump inhibitors, dyspepsia 
and gastro-oesophageal reflux disease were generally remarkably negative. 
Most did not use any national or local guidelines. Whilst nearly all the 
participants had come across step-up and step-down approaches to therapy, 
they did not consciously think or apply this in real life. This may reflect the 
general difficulty of implementing guidelines in practice and may apply more 
widely across a range of other therapeutic areas24. 
Underpinning all these concepts was the matter of costs49. Most participants 
accepted that the costs of proton pump inhibitors was high and recognised 
their dominant situation in the NHS prescribing bill. However, costs of 
individual proton pump inhibitors' have been dropping although the overall 
situation has been affected by increasing numbers of those on long-term 
therapies. On comparative cost basis proton pump inhibitors compare 
favourably will other long-term drugs such as the statins and the newer 
generation of anti-hypertensives. From these focus groups, despite 
awareness of cost, most participants did not base their prescribing decisions 
on this. A minority held the view that proton pump inhibitors were expensive, 
lifestyle drugs which ought to be paid for by the patients themselves. 
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The findings of this research are not necessarily transferable to other 
settings. However, the views discovered are likely to be common to general 
practitioners, not only in the UK, but to most other countries with a primary 
care based health system. As such the constructs uncovered are likely to be 
"transportable" to other settings. 
A factor that stood out in a field where knowledge and awareness is high was 
that most prescribing decisions were based on the dynamics of the individual 
consultation. General practitioners face many difficult tasks within relatively 
short consultation times. From this study there appeared to be no common 
factors that might have accounted for variations in prescribing between 
general practitioners but there were indications as to why there is an 
apparently high volume of proton pump inhibitor prescribing. Discussions 
hovered around the concept of "good" and "bad" prescribers but these could 
not be defined- the individual patient-doctor encounter remained, as is often 
the case, at the heart of the prescribing decision. 
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Chapter 5 
A survey of long-term Proton Pump Inhibitor 
Prescribing in General Practice 
Background, Aims, Methodology 
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5.1 Background 
5. 1. 1 The extent of Proton Pump Inhibitor (PPI) prescribing 
In the United Kingdom, PPI prescribing costs the National Health Service 
(NHS) over £300 million annually, and is rising282 (Fig 1 & 2). Despite an 
apparent slowing down of the rate of rise of prescribing in the last three 
years, there is mounting concern of the effects of these prescribing costs to 
the NHS. In particular, criticism has been levied at doctors, principally 
general practitioners(GPs), for inappropriate prescribing and inadequate 
review of patients49• One primary care studl2 ascertained that proton pump 
inhibitors were prescribed by general practitioners to a substantial proportion 
of patients with undiagnosed dyspepsia or unspecified "indigestion" - this 
runs contrary the views of those who favour tight indications for their use. 
There is a relative paucity of detailed published data on this topic. Since the 
publication of the first set of guidelines from the National Institute of Clinical 
Excellence (NICE)22 in 2001, there have been no identifiable primary care 
based studies that directly address this area. In particular, there is relatively 
little new information concerning variations in prescribing PPis between 
practices, and the consultation patterns, types and rates of investigations, or 
other characteristics of patients on long-term therapy, which might explain 
the extent, and patterns of PPI prescribing. 
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Figure 1. Cost of proton pump inhibitors (£ million) 1991-99, net cost 
England. [Source: Department of Health, Prescription Cost Analysis 
England 200221 
3500000 
3000000 
2500000 
£1000 
2000000 
1500000 
1000000 
500000 
0 
Cost of PPis(1991-99), Net Cost 
England 
1 2 3 4 5 6 7 8 9 
Year (1991-1999) 
153 
Figure 2. Trends in spending on antacids and ulcer healing drugs in 
England (1997-2002). Source: NHS Prescription Pricing Authority 
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Repeat prescriptions for acid suppression therapy represent an important 
proportion of health care resources. One UK study found that repeat 
prescribing rates varied between practices from 1.68% to 11 .11% of the 
practice population. This increased with age and was higher in men. Only 
41% of patients had a proven diagnosis of gastro-oesophageal reflux disease 
or peptic ulcer. A review of notes was the most frequent way (36%) stated by 
GPs as their method of renewing repeats of acid suppression therapy 35. As 
previously indicated research from northern England42 ascertained that 0.5% 
of the population was on long-term repeat prescriptions for PPis, mainly for 
reflux disease or non-specified "dyspepsia". 
A key recommendation from NICE22 was that the majority of patients with 
GORD should be managed with lower, maintenance doses of PPis. 
However, no Primary Care Trust (PCT) in England or Local Health Group 
(LHG) in Wales has actually achieved this 283 [Figure 3). 
Figure 3. The average percentage of drug units written for low-dose 
maintenance and healing doses of all PPis in the UK. Source: NHS 
Prescription Pricing Authority Data282 
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Erg land 
N Ireland 
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5. 1. 2 H. pylori and long-term PPI use 
Initial work from Kuipers from Holland and others 177;284-286 suggested that the 
use of long-term acid suppression therapy might increase the risk of 
oesophageal lesions, particularly carcinoma, but a number of papers have 
failed to substantiate this assertion287. The backdrop here is that the dramatic 
increase in the rate of oesophageal cancer is of the adenocarcinoma type 
with histological changes related to gastric cardia tissue, rather than 
oesophageal sqaumous tissue per se288;289• There have been reports that 
long-term PPI therapy may lead to mucosal atrophy spreading towards the 
oesophagus285. Paradoxically, there have been suggestions that H. pylori 
infection may actually be protective against oesophageal 
adenocarcinoma 141 ;143;143. There is also a suggestion that patients who have 
received eradication therapy may require higher than anticipated doses of 
acid-suppression drugs 167. The situation regarding either eradication of H. 
pylori in patients with or without oesophagitis is thus not equivocally clear and 
is potentially bewildering from the general practice viewpoint, where most PPI 
prescribing occurs. 
The Maastricht 2 guidelines, 198 on the management of patients with H. pylori 
infection recommended eradication in patients with gastro-oesophageal 
reflux disease when they were likely to require long term proton pump 
inhibitor therapy. This was on the grounds that profound acid suppression 
may accelerate the progression of H. pylori induced atrophic gastritis, 
increasing the potential risk of gastric cancer177 . 
5. 1. 3 Long-term PPI and Quality of Life measures 
Symptoms of reflux and dyspepsia affect several aspects of daily living290. 
Consequently, quality of life (Qol) is reduced in patients with oesophagitis 
and upper dyspepsia 291 ;292. The results from a multicentre clinical trial by the 
European Study Group on the quality of life in patients with gastro-
oesophageal reflux disease concluded that the quality of life was 
substantially impaired in patients presenting with reflux symptoms 293. This 
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was irrespective of whether the patients presented with endoscopy positive 
or endoscopy negative reflux disease. Quality of Life measures tended to 
normalise or improve during medical treatment or after surgery for reflux 
oesophagitis 293;294 . 
The consequences of H. pylori on dyspepsia or reflux symptoms and quality 
of life in non ulcer patients are unclear. Also, there are little data addressing 
disease specific symptoms or quality of life in primary care patients on long-
term PPis295. Nonetheless, this is an important area because the majority of 
PPI prescribing takes place in primary care and there is a need to evaluate 
and justify the cost consequences of such prescribing. 
5.2 Aims and Objectives 
This study set out to ascertain in a sample of general practices: 
a) the extent of long-term prescribing of PPis, b) the H. pylori status of 
patients in the above group, and c) the differences in the H. pylori positive 
and H. pylori negative patients in terms of their symptoms and well-being, 
their response to ongoing treatment and their comparative extent of usage of 
acid suppression therapy. 
The first stage aimed to ascertain the extent of long-term PPI prescribing by 
general practitioners, the reasons for such prescribing, any investigations 
undertaken, and variations in prescribing between practices and practitioners 
and possible reasons for such variations. The subsequent stages of the study 
were to establish the H. pylori status of these patients with a view to studying 
differences between them, and to quantify what proportion might need 
eradication under guidelines such as the Maastricht II. 
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The study was set within the context of the following pragmatic clinical 
questions: 
1. How important is H. pylori status in patients who are likely to receive long-
term PPI therapy, most probably for GORD? 
2. Should patients who are on established long-term therapy be tested for H. 
pylori status and receive eradication therapy? 
3. Should patients who are commencing PPis for GORD (some of whom are 
likely to remain on long-term treatment) have their H. pylori status 
established initially with a view to eradication therapy prior to treatment? 
The results of the study would potentially prepare the basis for an 
intervention study involving the eradication of H. pylori in long-terms users of 
PPis. 
5.3 Methodology 
The study was set in General Practices in Hull and East Yorkshire and used 
the gastrointestinal physiology laboratory at Castle Hill Hospital for 
conducting the H. pylori tests. 
5.3.1 About Hull 
Kingston-upon-Hull is located on the east coast of the U.K. approximately 
200 miles (320km) from London, Rotterdam and Edinburgh. Hull is located at 
the point where the river Hull (which starts in the Yorkshire Wolds) joins the 
Humber, twenty miles from the sea. It is the third biggest port in England after 
Liverpool and London and is sometimes described as 'the biggest fishing port 
in the world'. During World War two Hull suffered some of Britain's heaviest 
bombing and many buildings were later constructed. There are important 
ferry links to Zeebrugge and Rotterdam from Hull. 
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Basic demographics (Figure 4) 
Hull was originally a small settlement called Wyke, which belonged to the 
Cistercian abbey of Meaux near Beverley. In 1293 King Edward I purchased 
Wyke from the abbot of Meaux and built a town renamed Kingston-upon-Hull. 
Today the name Kingston-upon-Hull is more of an historic term and the place 
is known more commonly as Hull. King Edward had recognised Hull's 
potential importance as the site for a harbour and as a war base and in 1299 
he granted the town its first charter. Hull's strategic importance was 
recognised centuries after the reign of King Edward when in the English Civil 
War Hull was the first place to be openly hostile to King Charles I. More 
recently Hull has become the focus for local commercial activity for a large 
surrounding area. The population is relatively stable with a mix of affluence 
and deprivation. Hull has a population of 268,600 with an increase of 2.5% 
over the last decade, workforce of 115,350, unemployment of around 10% 
and a land area of 7.1 hectare. 
Deprivation (Figure 5) 
Kingston upon Hull remains the highest ranking (and therefore most 
deprived) Local Authority District in the region. Since the index of multiple 
deprivation was published in 2000, Kingston upon Hull has moved up six 
places to be now considered the sixth most deprived district in the country in 
terms of local concentration. The 'top three' in terms of deprivation in the 
region remain Kingston Upon Hull, Bradford and Sheffield296. 
Social class structure 
Hull's position in the division of labour by class is shown in the table below 
(Table 1). 
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Socio-economic classifications (All people aged 16 - 74) - 2001 
Census297 Table 1 
-· 
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Kingston upon Hull - Population density - Pensioners aged 65 and over 1999, by enumeration district 
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5.3.2 Ethical approval 
Ethical approval was obtained from the Hull and East Riding Local Research 
Ethics Committee, from the local hospital (Castle Hill Hospital) research 
section to undertake the 13C-Urea Breath Tests and from the Medical 
Protection Society. Clarification was also obtained from the ethical 
department of the British Medical Association concerning Caldecott 
regulations. 
5.3.3 Selection of Practices 
Practices in the area were contacted with information about the study. A 
purposive sample was used to ensure diversity of characteristics such as 
inner-city/urban vs. rural, single-handed vs. group and academic/teaching vs. 
non-teaching practices. For inclusion, practices had to have a computerised 
prescribing system; in Hull the proportion of this was 95% and this did not 
pose a practical problem. The lead general practitioner of each practice was 
contacted by telephone or by e-mail for an explanation of the study. ASR 
visited those practices, which provisionally agreed to take part. Full verbal 
and written explanation of the study (Appendix 5) together with a brief Power-
Point presentation was provided to all the practice doctors and to the practice 
manager. Signed consent was obtained from the lead GP of practices that 
agreed to take part. 
5. 3. 4 Data collection 
The practice manager and/or the lead partner of the participating practice 
searched their practice computer database using computerised search terms 
and provided ASR with a list of eligible patients on long-term proton pump 
inhibitors. ASR arranged with the practice managers mutually convenient 
times to allow him and/or a research facilitator (RF) to visit the practices, to 
have access to the computer and paper records. The data were entered into 
an Excel spreadsheet and handled in accordance with data protection 
guidelines as applicable at the time. The study was conducted in 2001/2 
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when further constraints imposed by the Caldecott regulations in terms of 
access to patient data were not in force. The data were reverse-anonymised 
for use. Key codes were available at each practice, enabling anonymisation 
to be reversed if identification was needed for specific reasons. 
Study information sheet and consent forms were sent by the participating 
practices to eligible patients explaining about the study, inviting them for the 
13C-UBT, and procedures concerning test results and actions to be taken if 
positive (Appendix 6). Eligible patients were those deemed by their practices 
as fit to take part in the study and excluded patients with one or more of the 
following conditions: Recent diagnosis of cancer or undergoing treatment for 
cancer, Terminal illness, Multiple serious pathology, Cognitive impairment 
and serious mental health disorder 
5.3.5 Tests administered 
Those patients who consented were invited by letter to attend for a C13 urea 
breath test at their local practice or at the Gastrointestinal Physiology 
Laboratory at the local hospital (Appendix 7). The tests were undertaken by 
WR, the senior technician at the laboratory. WR, who is also a qualified 
phlebotomist, took venepuncture specimens from consenting patients for 
CagA antibody tests. The breath tests kits were mailed by first post to a 
reference laboratory for analysis. The results were received directly by ASR. 
The blood specimens were stored as recommended, under appropriate 
storage conditions by CW, a consultant clinical pathologist at the local 
hospital for later batched analysis. 
5.3.6 Symptom and well-being assessment: 
At the time of the C13 breath urea test, participants completed three validated 
questionnaires: The Leeds Dyspepsia Questionnaire (Appendix 1 0), b) The 
Carlsson Dent GORD questionnaire (Appendix 11) and c) The EuroQol (EQ-
5D) questionnaire. 
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The participants were informed in writing of their breath test results along 
with an explanation of any further action that might have been required 
(Appendix 8 & 9) 
5.3. 7 Data handling and analysis 
All data were entered on to standard PC database packages (Excel and 
SPSS) for analysis. 
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5.4 Summary of Study types 
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Chapter 6 
A survey of long term Proton Pump Inhibitor 
Prescribing in General Practice 
Results: Part A 
Practice, practitioner and patient characteristics 
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6.1 Practices 
Data were collected from eight practices. Of these, five were located Hull, 
two in the nearby village of Cottingham and one in the East Riding market 
town of Beverley. The characteristics of the practices are illustrated in 
Table 1. 
The following denominators were compared between practices; Size, 
Location, Deprivation, Academic link, PCT link, General Practitioners with 
special interest (GPwSI). 
Table 1. Characteristics of practices 
Characteris A B c D E F G H 
tic 
Location Urba Urban Urban Inner- Market Rural Rural Inner-
n city town/rural city 
GP 4 4 (2/2) 5 (3/2) 3 (2/1) 3 (2/1) 2 1 (1/0) 5 (3/2) 
partners (2/2) (1/1) 
(MIF) 
Dep Low Medium Medium High Low Low Low High 
Patient list 6,900 7,021 8,250 6,400 5,800 3,832 2400 6,330 
Academic Yes No Yes No No No Yes Yes 
or 
research* 
GP y y N y N N y y 
with special 
interest** 
PCT link*** No Yes Yes No No No Yes Yes 
Dep = depnvat1on, PCT = pnmary care trust 
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*An academic link was defined as involvement by one practice in the teaching of medical 
students or being a training practice for GP registrars or nurse practitioners. A research link 
was defined as the practice engaging in NHS research as by being accredited as a research 
practice or by contributing to research through a declared route, such as a research 
fellowship. **General Practitioners with special interests (GPwSI) were defined as those 
doctors in practices that had a higher level of expertise in a particular area of primary care 
and were the lead in that field for their practice and/or were providing enhanced services to 
patients in their locality. ***PCT link was defined as the practice having a formal contract with 
the local PCT, such as a partner being a member of the PCT executive committee. 
Deprivation was defined based on the information given by the practice according to the 
Townsendindex 2~. 
6.2 Definition of long-term use of proton pump inhibitors 
The definitions were based on the criteria used by Hungin et al42. A long term 
prescription was defined as a repeat prescription for PPis which had been 
commenced at least 6 months previously and was obtainable by the patient 
without a further consultation with the general practitioner i.e., on a "repeat" 
basis. This is conventional practice in the UK for patients on long term 
therapy (e.g. for anti-hypertensives), usually with built-in supervision checks 
and has been labelled as the "authorised repeat prescription"299. Acute 
prescribing was excluded, the emphasis being on patients who were on 
established on therapy. A prescription unit was defined as a 28-day supply of 
the drug at the dose intended by the prescribing general practitioner. A four 
weeks supply of treatment was considered as equivalent to one course of 
treatment. 
6.3 Results 
A total of 811 patients from the eight practices with a combined population of 
46,933 were on long-term proton pump inhibitors, giving a mean rate of use 
of 1.73% (range 0.6-3.6%). Complete demographic and clinical data were 
available for 648 patients (80%). The mean age of all patients was 65.7 (sd 
15.0); females 68.3 (sd 14.3) and males 62.3 (sd 15.2). Demographic 
characteristics of the patients are described in Table 2, Figures 1 and 2. 
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Table 2. Demographic patient characteristics (n=648) 
Characteristic Male Female 
Number on long-term therapy (n, 286 (44%) 362 (56%) 
%) 
Mean age, SO, range 62.3, 15.2 68.3, 14.3 
Smoking% (yes/no/not known) 20,63,17 15,68,17 
Alcohol% (yes/no/not known) 51,21,28 28, 40,32 
BMI (mean), SO 28.3, 6.4 27.4, 4.5 
Figure 1. Age-sex distribution (n=648) 
Long-term PPis by age and sex 
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Figure 2. Patient characteristics by sex 
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6.3.1 Investigations 
Alcohol% BMI 
Upper gastrointestinal (GI) endoscopy had been performed in 412 (63%) 
patients, barium investigations in 41 (6%), both endoscopy and barium 
studies in 16 (2%) and no upper Gl investigations in 211 (32%) patients. The 
male/female distribution of the investigations is highlighted in figure 3. Nearly 
two-thirds (62%) of those not investigated were females. Overall, 28% of all 
males and 37% of all females did not have any upper Gl investigations. 
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Figure 3. Male/Female distribution of investigations 
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6. 3. 2 Individual Practice Data 
• Male 
• Female 
None 
Table 3 illustrates and compares the overall patient characteristics, rates of 
PPI use and endoscopy utilisation rates between practices. * Of a total of 210 
patients on long-term medications in practice A, complete patient data was 
obtainable by the researcher in 36 patients; however, the practice was able 
to provide data concerning their overall rates of PPI use and endoscopy 
utilisation. **BMI values were not available in 6 patients in practice A, 16 in 
practice B, 8 in practice C, 36 in practice D, I in practice E, 21 in practice F, 
21 in practice G and 64 in practice H. 
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Individual Practice data (Table 3) 
Practice Age Sex Rates Smoking Alcohol BM1** Upper Gl 
(mean, (male/ of status(%) status(%) (all/male lnx (%) 
sd) female) PPI (yes/no/ (yes/no/ /female) (Endo/ 
use not not [mean,sd] barium 
(%) known) known) studies/ 
Endo 
&barium 
studies 
/none) 
A* 66.5, 15.1 14/22 2.9 17/75/8 67/11/22 27.1,4.8 33/3/3/61 
25.5,2.0 
28.3,5.8 
B 64.7, 14.3 36/51 1.2 17/78/5 33/18/49 28.6,4.5 63/6/2/29 
29.0,3.7 
28.3,4.9 
c 65.0,15.1 37/58 1.2 19/78/3 51/39/10 26.8,6.3 82/0/0/18 
25.8,4.4 
27.5,7.3 
D 67.2, 16.1 18/18 0.6 33/44/23 31/38/31 - 70/0/0/30 
E 65.4,14.6 38/43 1.39 12/85/3 52/46/2 28.5,6.6 60/5/0/35 
28.4,6.4 
28.5,6.7 
F 70.8, 12.1 24/18 1.09 7/55/38 38/17/45 25.7,4.1 67/2/7/24 
25.7,4.0 
25.8,4.6 
G 72.1, 13.6 19/22 1.70 2/41/57 21/15/64 26.6,2.7 68/0/5/27 
26.1 ,2.1 
27.2,3.4 
H 64.0,15.9 101/129 3.6 23/55/22 33/36/31 28.4,5.2 49/4/3/43 
27.2,4.2 
28.8,5.8 
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6. 3. 3 Long-term PPI use vs. Endoscopy utilisation 
Figure four shows the correlation of long-term PPI rates to endoscopy 
utilisation rates between practices. The Spearman's correlation coefficient 
was - 0.551 indicating a possible negative correlation but not achieving 
statistical significance. 
Figure 4. Correlation between PPI prescribing rates and endoscopy 
utilisation rates 
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Rates of long term PPI prescribing varied between practices and Figure 5 
illustrates some of the practice characteristics and corresponding rates. 
Figure 5 Variations in prescribing rates and practice characteristics 
Explanations of terms: Size = More or less than 3 full time GPs per practice, Dep (L) = low 
deprivation, Dep (M/H) = medium or high deprivation, inner-city/rural/urban = location of 
practice, Acad = academic 
177 
6.4 Discussion 
This cross-sectional survey showed shows that long-term proton pump 
inhibitors were used in 1. 7% of all patients in primary care. Overall, 
prescribing in females was greater than males (56%vs44%). The mean age 
was higher in females (68vs62years). More than half of the long-term 
prescribing (53%) was in the 50 to 74 year age group (Fig 1). In the younger 
age group (25 to 49 years) long-term prescribing was similar in rate in both 
sexes. After the age of 50 years, more females than males received long-
term PPI therapy (48%vs36%). 
There are a limited number of studies in the literature with regard to long-
term proton pump inhibitors in primary care. The average rate of use of long-
term therapy in primary care in our study is higher than previously quoted 
figures42 of 0.3% to 0.55% between practices. Boutee5 in a primary care 
study on repeat prescribing of acid suppression drugs found that rates varied 
between practices, from 1.68% to 11.11%. Most of the repeat prescribing 
was for H2-receptor antagonists. Repeat rates increased with age and were 
higher in men than in women. 
In a Dutch study300 on long-term acid suppressant therapy in family practice, 
the authors reported overall usage rates of 2%, which included H2-receptor 
antagonists. However, the definition of "long-term" acid suppression in their 
study was based on the use of medications for more than 12 weeks where as 
we used six months as a criterion. In a North of England studl01 the authors 
reported average rates of 3.7% usage of acid-suppression drugs (H2-
receptor antagonists or proton pump inhibitors) amongst general practices. 
However, data provided was for both acute and chronic prescribing. A study 
from London51 undertaken in seven general practices identified 0.82% of the 
population to be on long-term acid suppression defined as being on 
treatment for six months or more and another from Scotland52 ascertained 
repeat prescribing rates of 4.4% for ulcer healing drugs in general practice 
population. Of these, 4.2% were for H2 receptor antagonists and 0.2% for 
PPis. 
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The mean age of patients on long-term PPis in our study was similar to other 
studies42;51 ;301 ;302. The mean age was similar across the eight practices (64-
72, sd 12-16) as was the spread of age groups. The highest number of 
patients on long-term PPis was consistently between 50-74 years. 
Although more females received therapy in all practices except one (Practice 
F), this did not necessarily reflect higher rates of use, as this depended on 
the male/female distribution in individual practices. Our data indicated rising 
rates of maintenance PPI use with advancing age. Figure one demonstrates 
a normal distribution curve; the rates of PPI use in those over 75 years is 
higher than those below 75, despite less overall prescribing in the over 75s. 
The relevance of age-sex profiles in the understanding of rates of PPI use is 
highlighted in another UK studl01 . They ascertained that prescribing of 
antacids and ulcer-healing drugs varied systematically with patient age and 
gender. Consequently the authors concluded that evaluation of crude 
prescribing rates without reference to patient demography was unreliable as 
a guide to levels of usage. A study from Cornwall and the Isles of Scilly35 
confirmed that repeat rates of use of acid suppression drugs increased with 
age and rates were higher in men. 
Variations in prescribing 
General Practitioners vary in their repeat prescribing of medications 
generally,299;303 and this variation is also reflected in the prescribing of long-
term PPis. In our study, there was a six-fold (0.6%-3.6%) variation 
prescribing between practices. As far as we are aware, there is only one 
another study42 that has specifically investigated rates of long-term PPI use 
and the authors of this study found a two fold variation. Both were conducted 
in North-East of England. The most likely explanation of the differences could 
be attributed to the fact that our study done five years later simply reflects 
cumulatively increasing PPI usage. Other factors such as demography of 
practices304, data collection methods, adequacy of computerised records and 
other unknown factors could also have contributed to the differences. 
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One study44 ascertained a 23-fold variation in the prescribing of PPI between 
GPs, but no specific distinction between acute and chronic prescribing was 
undertaken at a practice level. Nevertheless, this study found on forward 
multiple regression analysis, that 23% of the prescribing variations could be 
explained when the GP was a member or fellow of the Royal College of 
General Practitioners and the practice was fundholding. We attempted to 
explain the variations in prescribing between general practices by mapping 
the demographic characteristics of each practice (Table 1, Figure 5). It was 
not possible to explain with any level of certainty, the differences in 
prescribing rates between practices based on our findings of any of the 
practice demographic characteristics, alone or in combination. To undertake 
any form of linear logistic regression modelling, the sample size of practices 
would have to be much greater than the present study. Being closely linked 
to the PCT and urban location offered some explanation in the consistency of 
prescribing between only two practices (DC and CJ). Although significant 
differences in age and sex distribution between practices if these existed 
might partly explain the diversity of prescribing, this was not actually the 
case. 
Other patient characteristics (Table 3, Figure 2) 
Smoking 
About two thirds of males (63%) and females (68%) were current non-
smokers (never smoked, or ex-smokers). The smoking status was not 
recorded or retrievable from the records of 20%, and 16% were current 
smokers. No obvious differences in any aspect of smoking status were 
observed between males and females. The proportionate distribution of 
smoking history in the different practices is shown in table 3. 
Alcohol use 
Two fifths (41%) were noted to be users of alcohol; males (52%) and females 
(25%). Just over a quarter (28%) did not drink or drank very occasionally and 
in just under a third (31 %) the information was not recorded or retrievable 
from the records. Thus nearly twice as many males as females drank alcohol. 
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The proportionate distribution of alcohol history in the different practices is 
shown in table 3. 
Body Mass Index (BMI) 
The overall mean BMI did not differ between males and females. Amongst 
individual practices, the mean BMI between the two sexes was also very 
similar in values (Table 3). 
Upper gastrointestinal investigations 
Overall, just over two thirds of patients (69%) had undergone investigations 
and in 31% no upper Gl procedures had been undertaken. Of those 
investigated, upper gastrointestinal endoscopy had been undertaken in all 
except 6% in whom a barium meal had been used. Between practices, 
utilisation of investigations ranged from 33% to 82%. 
Resource utilisation by investigations may be dependent both on practice 
demographic characteristics and that of the population served.304. Goudie52 
and colleagues ascertained in their study on repeat prescribing of ulcer 
healing drugs in general practice that 21% with uninvestigated dyspepsia 
were on repeat therapy. In another study, 24% of patients with non-specified 
or uninvestigated dyspepsia42 were on repeat PPI therapy. 
Practices in our study varied considerably in their utilisation of endoscopy but 
this was not surprising given the significant variation in their PPI repeat 
prescribing rates. One might reasonably expect that practices with high 
endoscopy utilisation rates would have lower prescribing rates and vice-
versa, indeed such a correlation was found in one study from London304• 
Despite possible evidence of such association in our study, it is likely that 
other factors may have influenced decision making as regards to referrals for 
endoscopy. 
The significant variation in the prescribing and endoscopy referral rates 
between practices is likely to be more than just a reflection of the differences 
in the practices' demographic characteristics or the population served. 
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Explanations are more likely to be found in the prescribing and referral 
behaviour of individual GPs; some of these factors are complex, even 
idiosyncratic and not amenable to numeric explanations. 
6.6 Conclusion 
The overall rate of long-term PPI prescribing was 1.73%. This 
epidemiological study of repeat PPI prescribing in a cross section of general 
practices with varying location and demographic characteristics, ascertained 
a significant six-fold variation in repeat prescribing rates. Utilisation of 
endoscopy was also considerably different between practices. 
6. 7 Research Process 
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CHAPTER 7 
A survey of long term Proton Pump Inhibitor 
Prescribing in General Practice 
Results: Part B 
Patterns of use 
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7.1 Introduction 
It was ascertained that the long-term prescribing of PPis varied six-fold 
between practices. The description and discussion of these findings were 
detailed in Chapter 6. 
This chapter explains the patterns of use of PPI in practices; types of PPis 
used, dosage, duration of use, results of investigations carried out and the 
recorded indications for the use of the PPis. Consulting patterns and 
diagnostic categories are also explored. The findings are linked to the use of 
health care resources including costs to the practice and projected costs to 
the Primary Care Trusts and the National Health Service generally. 
7.2 Results 
Fig 1 illustrates the overall prescribing pattern of various PPis. Omeprazole 
and lansoprazole together accounted for 89% of the total prescribing. In 
terms of the number of patients on long-term therapy, both drugs were 
equally prescribed (45% and 44%). However, lansoprazole was more 
frequently prescribed at maintenance doses (60%) compared to omeprazole 
(22%). Table 1 compares the prescribing pattern of individual practices. 
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Fig 1. Type and strength of PPI prescribing 
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Table 1. Patterns of PPI prescribing in practices (% of patients on long 
term PPis) 
Practice OME, mg LAN , mg RAB, mg PAN, mg ESO, mg 
10, 20, 15,30 (%) 10, 20 (%) 20, 40 (%) 20, 40 (%) 
40(%) 
A 25,32,6 15, 10 0,5 1,2 3,0 
B 8,25,6 30,17 0,0 0,5 9,0 
c 15,27,6 26,21 0,1 0,3 0,0 
D 8,30,7 29,7 0,4 0,4 10,0 
E 1,24,9 30,21 0,3 6,6 0,0 
F 7,22,6 25,22 0,9 5,3 0,0 
G 8,31 ,4 26,22 0,4 0,1 4,0 
H 7,33,11 27,19 0,0 0,0 2,1 
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Table 2 and Figure 2 compare practices the maintenance vs. the treatment 
doses prescribed of the two most commonly used PPis, omeprazole and 
lansoprazole. The commonly accepted low dose maintenance for 
omeprazole is 10 mg, for lansoprazole 15mg; treatment doses for 
omeprazole are 20/40mg and for lansoprazole 30/60mgm, all taken once 
daily. 
The mean ratio of maintenance to treatment dose maintenance prescribing 
for omeprazole was 0.38, sd 0.19, but the variation between practices was 
130 fold (0.005 to 0.65); for lansoprazole 1.68, sd 1.01, the variation being 
four fold between practices (1.12 to 4.14). 
Table 2. Maintenance dose vs. Treatment dose 
Practice Omeprazole Lansoprazole 
M/T ratio M/T ratio 
A 0.65 1.5 
B 0.25 1.76 
c 0.45 1.23 
D 0.21 4.14 
E 0.005 1.42 
F 0.25 1.13 
G 0.22 1.18 
H 0.15 1.12 
M=maintenance dose, T=treatment dose 
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Figure 2. Maintenance dose vs. Treatment dose 
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7.2.1 Indications for prescribing long-tenn PPis 
7. 2. 1. 1 Diagnostic Categories 
General practitioners recorded a variety of diagnostic terms: indigestion, acid 
reflux, heartburn, atypical chest pain, epigastric and abdominal pain, "wind", 
dyspepsia, gastritis, gastro-oesophageal reflux and hiatus hernia. I 
categorised these terms into diagnostic groups, based wherever possible on 
known investigation results. Where more than one pathology was identified 
from upper gastrointestinal investigations, the diagnosis was defined by the 
predominant condition and or the most frequently used term in the GP 
records. Uninvestigated patients were categorised into diagnostic groups 
based on information available from the records and the frequency of 
diagnostic terms used. 
The following categories were identified (Fig 3) 
Dyspepsia (uninvestigated or, non-ulcer), GORD (Reflux Oesophagitis, 
Endoscopy Negative Reflux Disease or uninvestigated), Gastro-protection 
(investigated or uninvestigated), Hiatus Hernia (investigated or 
uninvestigated), Duodenal Ulcer, Gastric Ulcer, Barrett's oesophagus and 
Stricture. 
GP 
36% 
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Figure 3. Diagnostic categories 
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DU=duodenal ulcer, GU=gastric ulcer, Bar-Barrett's oesophagus, HH=hiatus hernia, 
Dysp=dyspepsia, GORD=gastro-oesophageal reflux disease, GP=gastro-protection 
The chart above (Fig 3) shows the overall picture of the diagnoses as 
ascertained from the GP records. Nearly two thirds of patients (64%) had the 
diagnosis of dyspepsia or GORD. Gastro-protection was the predominant 
indication for long-term PPI use in 15% of users. 
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Figure 4. Diagnostic subcategories 
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RO 
28% 
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14% 
NUD 
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7% 
Uninv Dysp=uninvestigated dyspepsia, NUD=non-ulcer dyspepsia, ENRD=Endoscopy 
negative reflux disease, RO=reflux oesophagitis, GORD (univ) =gastro-oesophageal reflux 
disease (uninvestigated), GP (ASP) =gastro-protection (aspirin), GP (NSAID) =gastro-
protection (non-steroidal anti-inflammatory drugs). 
Figure 4 further classifies the dominant diagnostic categories into subgroups. 
Over a fifth of patients (21 %) on long-term PPis had a diagnosis of non-ulcer 
dyspepsia (14%) or ENRD (7%). No differences were noted in the use of 
long-term PPis for gastro-protection between aspirin and other NSAIDs. 
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7. 2. 1. 2 Use of long-term PP/s (investigation vs. non-investigation) 
Figure 5 shows the proportional percentage of patients in each diagnostic 
category in whom the diagnosis had been ascertained through upper Gl 
endoscopy or by clinical means alone (uninvestigated). In 51% of dyspepsia, 
6% of GORD, 64% of gastro-protection and 19% of those with hiatus hernia, 
the diagnostic terms were used in patients in who no upper Gl investigations 
had taken place. Overall, 28% patients of patients on long-term PPis were 
uninvestigated. 
Figure 5. Diagnosis by upper Gl Endoscopy or Uninvestigated 
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7.2.1.3 Diagnostic category by practice 
Table 3 shows the diagnostic categories identified in individual practices. 
There was a two-fold variation in the category of "dyspepsia" (19 to 38%), 
and for gastro-oesophageal reflux disease (25 to 52%). Use of long-term 
therapy for predominantly gastro- protection agent aspirin and non-steroidal 
anti-inflammatory drugs varied three-fold (8-24%), for duodenal and gastric 
ulcers six-fold (2 to 11% and 0 to 6%), for Barrett's nine-fold (0-9%) and for 
oesophageal stricture six-fold (1 to 6%) between practices. 
Table 3 Individual General Practice Diagnosis 
Practice Dysp% GORD% GP% DU% GU% BAR% HH% Stricture% 
A 23 52 8 3 3 3 3 1* 
8 27 25 18 8 2 6 7 6 
c 16 41 17 11 6 2 0 6 
D 38 38 11 8 0 0 0 5 
E 38 28 18 6 1 1 6 2 
F 19 38 21 2 2 9 5 5 
G 19 33 24 5 0 7 9 2 
H 33 37 10 6 3 4 5 1 
(Numbers within cells represent% of practice patients on long-term proton pump inhibitors) 
7.2.2 Consultation patterns 
Both generic and disease-specific consultation rates that took place in the 
two years preceding data collection were analysed. Generic consultations 
was defined as consultations that took place in general practice or at 
patient's house for any reason; disease-specific upper gastrointestinai(GI) 
consultations were defined as consultations that took place in general 
practice or at patient's house for predominantly an upper Gl reason. The 
consultations 
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The mean upper Gl consultation rate was 1.05 consultations per patient per 
year (range, 0.2 to 1.8, median 0.5, sd 1.3). For females, the mean was 1.03 
(median 0.5, sd 1.3) and for males 1.06 (median 0.5, sd 1.4). The mean 
generic consultation rate (all consultations) was 4.4 consultations per patient 
per year (range 2.4 to 7.2, median 4, sd 3.3); females 4.8 (median 4.5, sd 
2.9), males 3.8 (median 3.5, sd 2.67). Comparison between practices of their 
consultation rates is shown in figure 6. 
Figure 6. Upper Gl and generic consultation rates by practice 
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7.2.3 Consultation rates and PPI prescribing rates 
Figures 7 and 8 are scatter plots describing the correlation between 
consultation rates and rates of PPI prescribing in the eight general practices. 
Figure 7. Correlation graph PPI prescribing rates vs. upper Gl 
consultation rates 
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Figure 8. Correlation graph PPI prescribing rates vs. generic 
consultation rates 
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7.2.4 Uptake of repeat PPI prescriptions 
Over a 12-month period, an average of 11.3 repeat prescriptions (range 7.6 
to 15, median 11.5, sd 2. 7) per patient was issued; females 11.6 (median 12, 
sd 12.6) and males 11.1 (median 11, sd 2.8). One prescription was 
equivalent to 28 days supply of medications. Figure 9 compares the mean 
annual number of repeat scripts issued per patient between practices. The 
arrow that runs across the figure at the level of thirteen repeat prescriptions 
represents the expected level of repeat script collections per patient per year. 
Figure 9. Mean annual repeat prescription rates 
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7.2.5 Cost implications 
The total cost of 12 months maintenance treatment with PPis in the eight 
practices with a total of 24 GPs and covering a population of 46,933 was 
£25,3591 (mean £31 ,698, range £11,228 to £77,015, Table 4). The mean 
annual expenditure on long-term PPis per GP was £10,566 (range £3,742 to 
£17,114, Table 5). Based on average monthly PPI costs (Figure 10), the 
mean annual expenditure on long-term PPis per practice patient was £5.4 
(range £1.75 to £12, Figure 11). 
Figure 1 0 shows the cost of various PPis at different doses for 28 days 
treatment 305 
Figure 10. Base line costs of 28 days treatment with PPis 
0 
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Table 4. Practices and their maintenance PPI prescribing costs 
Practice 
8 
c 
D 
E 
F 
G 
H 
Total 
No of full-time Practice 
GPs population 
.. '' 
3.5 7,021 
4.5 8,250 
3 6,400 
2.5 5,800 
1 3,832 
1 2,400 
4.5 6,330 
24 46,933 
Maintenance 
PPI costs (£) 
• 
25,774 
29,330 
11,228 
23,606 
12,766 
12,447 
77,015 
253,591 
Table 5. Mean maintenance PPI expenditure per GP per practice 
8 
c 1,833 8,380 
D 2,133 3,742 
E 2,320 9,442 
F 3,832 12,766 
G 2,400 12,447 
H 1,406 17,114 
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Figure 11. Mean maintenance PPI expenditure per patient per practice 
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Comparison with PCT and national expenditure 
The total annual prescribing PPI costs (acute and maintenance) for each 
practice was obtained from the Primary Care Trust. It was therefore possible 
to determine the ratio of maintenance to acute PPI prescribing (figure 12). 
The mean ratio of long-term PPI to acute PPI prescribing was 69%: 31%. 
Figure 12. Maintenance vs. Acute PPI prescribing 
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The overall PPI prescribing expenditure (acute and maintenance) in the 12 
months of the study period for West Hull PCT (75 GPs, 34 practices, 
population 140,000) was £998,156. The extrapolated long-term PPI costs 
were determined to be £638,319 (64%of total PPI prescribing). In terms of 
the national average, this translates to £257 million for long-term PPI 
prescribing based on total PPI expenditure of £402 million in 2002 for 
England and Wales. 
The mean annual total expenditure on PPis (long-term and acute) per patient 
in this study was £7.7 (long-term £5.7, acute £2.0); this is in comparison to 
the local PCT expenditure £7.0 (long-term £4.48, acute 2.52) and national 
figure of £7.6 (long-term £4.84, acute £2. 76). 
7.3 Discussion 
General Practitioners prescribed significantly more omeprazole at treatment 
dose for maintenance in comparison to lansoprazole. As has been postulated 
this may have reflected their understanding and interpretation of evidence 
and guidelines, patient feedback, specialists influence, marketing by 
pharmaceutical companies, PCT influence and other personal preferences49. 
Compared to placebo, both omeprazole and lansoprazole in maintenance 
and treatment doses have been shown to be significantly more effective in 
maintaining remission of healed oesophagitis as well as endoscopy negative 
reflux disease30s-309. For non-ulcer dyspepsia, there is lack of long-term 
follow-up studies in patients on maintenance PPI therapy. A Cochrane 
systematic review ascertained that PPis were superior to placebo for non-
ulcer dyspepsia, with a relative risk reduction of 12%310. A further recent 
meta-analysis confirmed the effectiveness of PPis at reducing symptoms of 
non-ulcer dyspepsia, with a relative risk reduction of 14%. There was no 
evidence to suggest that the healing dose was more effective than the 
maintenance dose: the relative risk was 0.98 (95% Cl 0.92 to 1.05)p=0.59; 
nor was there heterogeneity in the findings 17. Concerning uninvestigated or 
undiagnosed dyspepsia, a Health Technology Assessment found that PPis 
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were superior to other acid suppression drugs in relieving symptoms of 
dyspepsia311 . Only one study has directly compared low dose omeprazole 
1 Omgm with low dose lansoprazole 15mg in primary care patients with 
undiagnosed dyspepsia. The authors of this study found that the relief of 
symptoms with lansoprazole 15mg was significantly better compared to 
omeprazole 1 Omg312 . 
A significant proportion of the patients in our study (64%) were diagnosed to 
have GORD, non-ulcer dyspepsia or uninvestigated dyspepsia. Based on 
current evidence, the majority of these patients could potentially be 
maintained long-term on low-dose PPis. This could translate into enormous 
cost benefits for the practices, PCTs and the NHS; at a national level it is 
estimated that prescribing savings could be in the region of £125m annually. 
The chief diagnostic indications for long-term PPI prescribing described in 
this study have similarities but also differences with other 
studies35;42;4s;s1;53;301 ;313. Dyspepsia and GORD were the main diagnoses 
recorded in the studies by Hungin, Ryder, Roberts and Boutet; this was also 
the case in our study. The differences in the frequency of diagnoses of 
dyspepsia and GORD between the various studies might have been the 
result of several factors: variations in GP recording, researcher variation in 
interpretation of diagnosis, or variation in the availability or use of open 
access endoscopy services. 
More than one in four patients in this study (28%) who were on long-term 
PPis had undergone no upper Gl investigations. Similar results have been 
obtained by other authors46;53;300;313. Up to recently it was considered 
inappropriate to prescribe long-term PPis to uninvestigated patients. 
However, the most recent guidelines from NICE support the use of PPis in 
primary care without the need for upper Gl endoscopy in most cases 17. 
Similar views are expressed in the Scottish Inter-Collegiate Network 
Guidelines (SIGN) on dyspepsia23 
One consistent observation in our study that appeared to be different from 
those in other studies was the frequent use of long-term PPis predominantly 
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for gastro-protection (15%) with no other recorded upper Gl diagnosis. This 
may reflect the increasing awareness of GPs of co-prescribing PPis with 
NSAIDs or aspirin, particularly in the elderly with multiple medical 
problems314. However, it is also likely that many such patients had their PPis 
imitated in hospital and have been continued on this by their GP315. 
No statistically significant correlation was demonstrated between consultation 
and PPI prescribing rates. However, the sample size of practices in this study 
was insufficiently powered to show such a correlation and a larger sample 
size would be required to confirm or refute the findings. Disease-specific 
consultations are more reliably collected in a hospital setting; in general 
practice, patients often consult with multiple problems316. It is therefore 
difficult to reliably ascertain disease-specific consultation rates. Inevitably, the 
rates may be skewed not only because of the variability in the accuracy of 
data recorded by the practitioner but also the interpretation of such data by 
the researcher. 
From this study, it was shown that many patients on long-term PPis did not 
regularly request their monthly repeat scripts. About a fifth (21%) of all 
patients had requested less than six and a quarter (24%) between six and 
nine prescriptions over 12 months. A previous study had concluded that such 
compliance was determined by the level of patient symptoms41 . Recent 
studies have supported the use of on-demand PPI therapy317-320 and the 
recent NICE guidelines 17 have also advocated this. 
The mean annual cost of PPI expenditure per GP from this study was nearly 
three times that of the only other study that has researched this area42. The 
difference is probably explained by the escalation of the use of long-term 
PPis over the last five years as mirrored in PCT and national expenditures on 
long-term PPis. The mean annual cost per patient for long-term PPI therapy 
may be a more reliable and important measure of inter-practice variation in 
prescribing. In this study such variation was seven-fold and correlated closely 
with PPI prescribing rates. 
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7.4 Conclusion 
Omeprazole in the treatment dose and lansoprazole in the maintenance dose 
formed the bulk of long-term PPI prescribing. GORD, dyspepsia and gastro-
protection were the main indications; more than one in four patients had no 
upper Gl investigations. Upper Gl disease-specific consultation rates varied 
nine-fold between practices but did not bear any correlation with PPI 
prescribing rates. The mean annual long-term PPI cost per patient was £5.7, 
more than two-thirds (69%) of all PPI prescribing was long-term. 
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Chapter 8 
Patients on long term PPis 
Prevalence of H. pylori infection 
Symptom frequency and severity 
Quality of life 
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8.1 Background 
From chapter six it was ascertained that more than two thirds of proton pump 
inhibitor prescribing in primary care was long-term prescribing and that 
GORD, dyspepsia and gastro-protection were the predominant indications. 
Despite the widespread use of long-term PPis and the consequential 
significant impact on UK National Health Service resources, there is limited 
information concerning on-going symptoms and quality of life in these 
patients. Furthermore, there are few studies ascertaining H. pylori infection 
and its influence on symptoms and quality of life. 
8.2 Description and rationale of questionnaires used in this study 
Leeds Dyspepsia Questionnaire 
This is a validated questionnaire (Appendix 1 0) currently available that 
reliably assesses both the presence and severity of dyspepsia321 . It is a 
robust instrument that has been tested for its validity in both general practice 
and hospital patients. In the general practice population, the sensitivity of the 
LDQ was 80% (95% Cl: 65-91%) and specificity 79% (95% Cl: 66-89%). The 
weighted kappa statistic for the agreement between the LDQ and the 
clinician for the severity of dyspepsia was 0.58 in the primary care population 
and 0.49 in hospital patients. The kappa statistic for test-retest reliability was 
0.83 and for inter-rater reliability 0.90. The LDQ was also significantly and 
reliably responsive to changes in symptoms as a result of therapy; the 
median LDQ score fell from 22.5 (range 9-36) to 4.5 (range 0-27) in 12 
patients one month after receiving appropriate therapy (Wilcoxon signed rank 
test, P < 0.0001 ). The LDQ is quick and simple to use and can be researcher 
or self administered. 
Other questionnaires have been developed to evaluate dyspepsia but either 
lack validity in primary care patients or only assess the severity of dyspepsia 
or sub-types of dyspepsia. The "Glasgow Dyspepsia Severity Score- a tool 
for the global measurement of dyspepsia"322 is a comprehensive and 
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validated questionnaire that provides a global dyspepsia score based on 
severity and some disease specific quality of life measures. The Nepean 
Dyspepsia Index is a disease-specific, health-related quality of life instrument 
for non-ulcer dyspepsia323. Other instruments in use324"327 similarly lack 
application in a primary care setting. 
Carlsson- Dent GORD questionnaire 
This is a formal, structured self administered questionnaire92 (Appendix 11) 
for identifying symptom patterns that are classical for reflux disease. It has 
seven items that focus on the nature of the symptoms and the precipitating, 
exacerbating, and relieving factors. The diagnostic validity of the 
questionnaire has been tested against endoscopy and 24-h pH monitoring. A 
further evaluation has been undertaken in patients with symptoms suggestive 
of GORD and in patients with non-ulcer dyspepsia to identify factors who 
might predict symptom relief during treatment with omeprazole. When 
endoscopic oesophageal mucosa breaks and 24-h pH data were used as 
criteria for the diagnosis of GORD, the questionnaire had a sensitivity of 92% 
but a very low specificity of 19%. Symptom relief during treatment with 
omeprazole was predicted by the presence of heartburn, described as 'a 
burning feeling rising from the stomach or lower chest up towards the neck' 
(P = 0.004), and 'relief from antacids' (P = 0.02). In non-ulcer dyspepsia a 
positive response to omeprazole was confined to the subgroup of patients 
who identified their main discomfort as heartburn as described above. This 
questionnaire, using descriptive language, usefully identified heartburn in 
patients presenting with upper abdominal symptoms, and this predicted 
symptom resolution during treatment with omeprazole. 
Thus, the Carlsson - Dent questionnaire is essentially a diagnostic instrument 
with some added benefit in evaluating responsiveness of heartburn to 
appropriate therapy. 
There are several questionnaires described in the literature concerning 
GORD symptom scales328• They include symptom scales as well as quality of 
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life (QoL) instruments. The symptom measurement tools have been designed 
to be discriminative, predictive or evaluative. In a recent systematic review328, 
the authors identified four GORO specific evaluative scales329-332 that met 
some of the criteria stipulated for adequacy. 
Other instruments that are not GORO specific have also been widely used in 
studies relating to GOR0333;334. In retrospect, a evaluative scale such as 
GERD score329, Gastrointestinal Rating Scale [GSRS]333 or GERD Activity 
Index [GRACI]332 would have been valuable in this study. 
EuroQoL (EQ-50) questionnaire 
This is a widely used, thoroughly validated quality of life instrument that has 
been applied in different areas of health335. The EQ-50 self-classifier 
describes health status according to 5 dimensions. Each dimension is divided 
into 3 levels. By combining different levels from each dimension, EQ-50 
defines a total of 243 health states. These may be converted to a score using 
"sets of values" derived from general population samples. 
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EQ-50 dimensions 
MOBILITY 
• I have no problems in walking about 
• I have some problems in walking about 
• I am confined to bed 
SELF-CARE 
• I have no problems with self-care 
• I have some problems washing or dressing myself 
• I am unable to wash or dress myself 
USUAL ACTIVITIES (e.g. work, study, housework family or leisure 
activities) 
• I have no problems with performing my usual activities 
• I have some problems with performing my usual activities 
• I am unable to perform my usual activities 
PAIN/DISCOMFORT 
• I have no pain or discomfort 
• I have moderate pain or discomfort 
• I have extreme pain or discomfort 
ANXIETY/DEPRESSION 
• I am not anxious or depressed 
• I am moderately anxious or depressed 
• I am extremely anxious or depressed 
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EuroQol Visual Analogue Scale (EQ VAS) 
The EQ VAS is a vertical 20 em visual analogue scale (similar to a 
thermometer), with endpoints of 100 (best imaginable health state) at the top 
and 0 (worst imaginable health state) at the bottom (figure 1). The EQ VAS 
offers a simple method for obtaining a self-rating of current health-related 
quality of life by generating a score. 
Figure 1 (EQ VAS) 
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More than 5% of all current gastrointestinal research involves the use or 
application of EQ-50 which provides an indication not only of its recognition 
as a valid, reliable and reproducible tool but also the ease and quickness of 
its administration. Other comparable instruments include the quality of well 
being scale, Health Utilities Index and Medical Outcomes Study Short-Form 
36336. However, they are more complex to administer. Also, in various studies 
the EQ-50 has compared favourably with other health related QOL scales337-
340 
8.3 H. pylori assessment 
The 13C Urea Breath Test (UBT) was used to determine the H. pylori status. 
The UBT has now been established to be the "gold standard" non-invasive 
and well accepted testing method for ascertaining the presence or absence 
of H. pylori198;341 . In various studies the sensitivities and specificities of both 
the unmodified and modified breath tests were similar and ranged between 
95 to 1 00% 342;343. 
The INFAI [Institute For Biomedical Analyticals and NMR imaging]344 and the 
Pylobactell345 13C-UBT were used to assess the H. pylori status of patients 
on long-term PPis in the current study. Both had sensitivity and specificity of 
greater than 98% and had previously been successfully used in primary care 
patients31 ;346 
8. 3. 1 Breath test procedure 
Patient Invitation 
Patients were invited to attend for a breath test to establish the presence of 
H. pylori after completed consent forms had been returned (appendix). 
Invitations for the breath test were sent to the patients' home giving full pre 
test instructions (appendix). 
The 13C urea breath test was performed using the following procedure. Each 
test lasted 40 minutes. 
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Patients were asked to drink a sachet of citric acid (4g) mixed with 200ml of 
water, followed by a 5 minute rest period. After 5 minutes a plastic drinking 
straw was inserted all the way to the bottom of a test tube, holding it at an 
angle, with the opening pointing upwards. The patients were instructed to 
exhale and the tube was pulled away from the straw whilst the patient 
continued to breathe out. As soon as the straw was withdrawn from the tube 
a cap was placed to seal in the breath sample. The procedure was then 
repeated with the same straw into a second test tube. The used straw was 
discarded. Patients were then asked to drink 50ml of water containing one 
soluble tablet of 100mg of 13C-Urea. The entire contents were consumed 
immediately followed by a 30 minute rest period. After 30 minutes the 
patients were instructed to give a further two breath samples in two more test 
tubes using the same procedure as for the first two test tubes. 
The test was then complete and all four test tubes were put into a box 
(provided) along with a patient detail sheet, before being sealed in a pre-paid 
envelope and sent by first class post to the reference laboratory for analysis. 
The laboratory that dealt with the breath test kit for analysis was: Espire 
Healthcare Ltd, Cranford House, Longley Road, Rainham, Kent, ME8 7RU. 
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8.4 Results 
Figure 1. H. pylori status in patients on long-term PPis 
Research Process 
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About a third of patients (35%) on long-term PPis were not deemed suitable 
to be invited for 13C-UBT because of the following reasons; 
• Lack of consent for researcher to collect information from GP records 
(58%) 
• Cognition factors (32%) 
• Concurrent serious illnesses excluding malignancy (7%) 
• Current malignant condition (3%) 
8.4. 1 Non participants 
Did not take part in research, 334 (63%) 
a) Did not return consent form, 202 (38%) 
b) Returned consent but refused, no reasons 
98, (18%) 
c) Reasons given for not taking part, 23 (4%) 
d) Agreed to take part, but did not attend, 10 
(2%) 
Reasons given for not taking part included: 
old age (8) 
other commitments (14) 
taking part in other research already (1) 
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Table 1. Baseline characteristics of H. pylori positive and negative 
patients 
Age (mean, sd, range) 67 .4, 12.5,34-90 65,12.8,34-89 
Sex (m,f),% 20(33%), 40(66%) 61(45%), 75(55%) 
Current smokers,% 10(17%) 22(16%) 
Current alcohol use,% 38(63%) 79(58%) 
BMI (mean, sd) 26.7, 5.8 28.2, 6.1 
No obvious differences were noted between the H. pylori positive and 
negative patients. 
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Figure 2. H. pylori status and diagnostic categories 
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Diagnosis 
P=H. pylori positive, N=H. pylori negative, GORD=gastro-oesophageal reflux disease 
UID=uninvestigated dyspepsia, NUD=non-ulcer dyspepsia, PUD=peptic ulcer disease, 
GP=gastro-protection 
Twenty patients (10%) had previous eradication therapy prior to taking part in 
this study. Of these, 18 had peptic ulcer of which 16 had been successfully 
eradicated as determined by their breath test results and in two patients the 
H. pylori status was still positive. One patient with uninvestigated dyspepsia 
and one with non-ulcer dyspepsia had also been successfully eradicated. 
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Table 2. Diagnoses and H pylori status 
Asymp. Exact 
Observed Test Slg. (2- Sig. (2-
Category N Prop. Prop. tailed) tailed) 
GORD Group1 H. pylori+ 20 .25 .50 .OOO(a) 
Group2 H. pylori- 59 .75 
Total 79 1.00 
UID Group1 H. pylori+ 19 .50 .50 1.000(a) 
Group2 H. pylori- 19 .50 
Total 38 1.00 
NUD Group1 H. pylori+ 11 .29 .50 .014(a) 
Group2 H. pylori- 27 .71 
Total 38 1.00 
PUD Group1 H. pylori+ 4 .19 .50 .007 
Group2 H. pylori- 17 .81 
Total 21 1.00 
GP Group1 H. pylori+ 5 .36 .50 .424 
Group2 H. pylori- 9 .64 
Total 14 1.00 
a= Based on Z Approximation. Prop=proportion. Asymp.Sign=Asymptomatic Significance. 
Exact. Sign=Exact Significance. Binomial test (table 2) determined through SPSS revealed 
highly significant differences between H. pylori positive and negative rates in patients 
diagnosed with GORD (p<0.0001) but not in other diagnoses. 
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8.4.2 H. pylori status and on-going upper gastro-intestinal symptoms 
Presence or absence of dyspepsia 
All patients (n, 196) [100%] reported some degree of dyspepsia symptoms in 
the preceding four weeks on the LDQ. 
Severity of dyspepsia (LDQ, Figs 3 & 4) 
The overall mean dyspepsia score on the LDQ was 15.1, sd 6.0, range (5-
30). In H. pylori positive patients, the mean score was 14.3, sd 6.9, range (5-
28); H. pylori negative16.2, sd 5.6, range (7-30), P = 0.23. 
Figure 3. Leeds Dyspepsia Severity Score and H. pylori status 
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The LDQ scores range between 0-40, higher scores indicating worse 
symptoms. 
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Figure 4. Classification of dyspepsia severity and H. pylori status (LDQ) 
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Definitions of dyspepsia severity (LDQ) 
• HP +ve 
• Hp -ve 
Severe 
Mild Does not interfere with activities of daily living and symptoms once per week or more 
(score 1 to 8), Moderate Interferes with activities of daily living less than once per week 
(score 9 to 15), Severe Interferes with activities of daily living more than once per week 
(score greater than 15) 
Activities of Daily Living: Sleeping, eating, working, leisure activities 
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Reflux symptoms assessment (Carlsson - Dent questionnaire) 
Scores on the CD ranged between -7 to +20; the higher the score, the 
greater was the probability of persistent GORD symptoms (Fig 6). The overall 
mean reflux score was 6.0, sd 3.8, range (0-15). In H. pylori positive patients, 
the mean score was 5.3, sd 3.2, range (0-11); H. pylori negative, 8.7, sd 
4.14, range (3-15), p = 0.001 (Fig 5). 
Figure 5. H. pylori status and reflux scores (Carlsson - Dent) 
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Figure 6. Reflux score severity and H. pylori status (Carlsson - Dent) 
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30/136 (22%) patients in the H. pylori negative group had a score of more 
than eleven compared to 3/60 (4%) in the positive group. 
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Table 3 The Leeds Dyspepsia and the CarlssonDent questionnaire 
results: Statistical considerations 
LDQ Carlsson - Dent 
Mann-Whitney U 707.000 448.000 
Wilcoxon W 917.000 658.000 
z -1.246 -3.377 
Asymp. Sig. (2-tai/ed) .213 .001 
Significance was calculated by using non-parametric test for two independent samples; 
group 1, H. pylori positive and group 2, H. pylori negative. The dependent variable was the 
questionnaire. Mann-Whitney U was the chosen test. 
Figure 7. Patterns of PPI strength and symptom severity by LDQ 
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Figure 8. Patterns of PPI use and symptoms score by the Carlsson -
Dent reflux questionnaire 
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Figures 7 and 8 represent the proportion of patients in each symptom 
category who are on either low or standard healing doses of maintenance 
PPI therapy. 
Self 
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8.4.3 H. pylori status and EQ-50 Visual Analogue Scale (VAS) 
Score ranges from 0-100, higher scores indicate better health. The overall 
mean score of patients' self-assessment of their health state on the visual 
analogue scale of the EQ-50 was 58, sd 9.2, range (35-89), for H. pylori 
positive 72.4, sd 9.1, range (55-89) and for H. pylori negative 44.8, sd 9.6, 
range (35-76), p < 0.001 (Fig 8). 
Figure 8. VAS score and H. pylori status 
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Table 4 : Statistical considerations for VAS 
VAS 
Mann-Whitney U 66.500 
Wilcoxon W 3807.500 
z -6.413 
Asymp. Sig. (2-
<.0001 
tailed) 
Grouping Variable: H. pylori. The Mann-Whitney U non parametric test for two independent 
samples revealed a statistically significant difference between H. pylori positive and negative 
groups. 
8.5 Discussion 
The number of non-respondents in this study was high (64%). This is despite 
two reminders to the non responders, following the initial invitation to take 
part. This highlights current trends in recruiting people in primary care 
research. There may be several reasons for this: it may be due to researcher 
and research or participant directed factors. Previous studies in the literature 
have identified the difficulty of recruiting patients in primary care, particularly 
for trials. Time constraints, forgetfulness, professional responsibilities and the 
inability to maintain motivation from researchers have been quoted as 
important factors for the failure to recruit347-349. Location and type of practice 
(academic or non-academic) may also influence recruitmene50. There may 
be factors unique to community research as opposed to hospital based 
research; including perceptions of research by participants in the community, 
healthcare issues, and ethical, moral and legal concerns351 . 
Participants can sometimes be overwhelmed with information and this may 
result in refusal to take part. Designing studies in a way that patients can 
identify with may help improve recruitmene52-354 . 
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With hindsight, recruitment in the current study could have been improved by 
consideration to some of the aforementioned factors; design of a simpler, 
clearer, shorter patient information sheet, help with increased practice 
involvement, campaigning through poster displays. 
Despite the relatively low uptake (36%), the overall numbers of participants 
who consented and attended for 13C-UBT was good (n=196); thus 
meaningful analysis of data and interpretation of results was possible. Indeed 
this is one of the largest series of any study in this field. 
The H. pylori positivity rate amongst patients on long-term PPis was 31%, 
somewhat less than anticipated. The rates determined probably reflect the 
true prevalence of H. pylori in patients on long-term PPis in primary care. In 
the general population the H. pylori infection rates vary and depend upon 
several factors; location (rural, urban, inner-city), age, sex, country, socio-
economic conditions, lifestyle factors and ethnicity355;356. In UK, the H. pylori 
population prevalence rates vary between regions; inner-cities are likely to 
have the highest rates357. It is well recognized that the infection is acquired in 
early childhood and the prevalence has an age-cohort effect with the highest 
prevalence being in the fourth, fifth and sixth decades of life358. Varying rates 
of prevalence between 27 to 62% in the adult general population have been 
quoted in the literature 355-359 reflecting the diversity of populations studied. 
Of those that were H. pylori positive, a third (33%) had the diagnosis of 
GORD, another third (32%) uninvestigated dyspepsia, 18% non-ulcer 
dyspepsia, 8% were receiving PPis for gastro-protection and 8% had peptic 
ulcer disease. In theory thus two-thirds of all positive cases on long-term 
PPis (i.e. excluding GORD) may benefit from eradication treatment with the 
possibility of stopping or reducing the frequency and dosage of long-term 
PPis. This clearly would have patient benefits as well as positive resource 
implications. Concerning GORD, current guidelines recommend that patients 
on long-term PPis should have their H. pylori status checked and, if positive, 
eradication to prevent potential complications such as gastric atrophy and 
cancer198. At the same time in this study, the diagnosis of GORD was 
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significantly lower in the H. pylori positive group. This adds further evidence 
to the prevailing view H. pylori may be protective against GORD197;360. 
Non-ulcer dyspepsia was also diagnosed less commonly in the H. pylori 
positive group. However the small sample sizes and retrospective nature of 
the study make drawing definitive conclusions difficult. Previous studies 
attempting to determine the prevalence of H. pylori in non-ulcer dyspepsia361 -
363 has been fraught with difficulties in defining dyspepsia364. Nevertheless, 
the benefits, albeit small, of H. pylori eradication has been shown in a 
systematic review248. 
Of those with uninvestigated dyspepsia on long-term PPis, half were positive 
for H. pylori. The recent draft NICE dyspepsia guidelines recommend 
eradication as first line treatment strategy in this group prior to endoscopy 
17;23, although they also suggest PPis as an initial approach. 
Amongst the peptic ulcer group of patients on long-term PPis, about a fifth 
(19%) tested positive and had not previously received eradication therapy. 
The benefits of eradication in this group have long been established365-367 
Just over a third (35%) of patients in whom long-term PPis were used 
primarily for gastro-protection tested positive for H. pylori. There is current 
evidence of significant patient and cost benefits of eradication in this group of 
patients368"370. 
Despite being on long-term PPis, all patients reported symptoms of 
dyspepsia on the LDQ; more than two-thirds had either moderate or severe 
symptoms. There were no statistically significant differences between the H. 
pylori positive and negative patients. Assessment of reflux score by CD 
questionnaire showed that nearly half of all patients had scores of greater 
than five indicating a good probability of the presence of persistent GORD. 
-
Also, the scores were significantly higher in the H. pylori negative patients 
possibly indicating that the severity of the primary GORD symptoms, namely 
heartburn and acid regurgitation, are worse in the absence of H. pylori. 
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It is generally assumed that quality of life in terms of upper gastrointestinal 
symptoms is vastly superior in patients on PPis, particularly those on long-
term therapy in primary care. However, this was not hitherto tested in clinical 
studies. A recent randomized trial from the Netherlands371 ascertained high 
dyspepsia severity in patients on long-term acid suppression; nearly 50% 
were taking PPis but this severity did not alter following reduction or 
stoppage of therapy through a patient-directed strategy. The authors 
concluded that the volume of long-term PPI prescriptions could be reduced 
without worsening of symptoms. As a corollary, the authors drew the 
inference that a significant amount of long-term PPI prescribing by GPs might 
not be consistent with clinical guidelines or indications. There may be other 
reasons for persisting upper gastrointestinal symptoms; inadequate dosages 
of PPI and poor compliance. 
When evaluating patterns of PPI use in terms of dosage (low or treatment 
dose maintenance) no obvious differences were noted between the different 
grades of dyspepsia and reflux severity. 
Concerning generic Qol, H. pylori negative patients rated their health 
significantly worse on the EQ-50 Visual Analogue Scale compared to the 
infected patients. However this result has to be viewed with caution. This is 
because of uneven sample sizes, the retrospective nature of the study and 
possible confounding that may have been introduced because of the 
influence of other unknown variables (e.g. co-morbidity, medications etc). A 
recent community study ascertained that H. pylori eradication did not improve 
Qol 161 while another study determined the opposite, but did not use a 
validated QOL questionnaire (Verma, 2002 426 /id). A large, prospective, 
RCT in primary care is needed to answer this important question. The author 
of this thesis is currently undertaking such a trial. 
8.6 Conclusion 
Patients on long-term PPis in primary care continue to experience significant 
dyspepsia symptoms, but H. pylori status does not appear to influence them. 
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Reflux symptoms and overall health seem significantly worse in the H. pylori 
negative patients. This study raises concerns about the appropriateness or 
dose adequacy of the use of long-term PPis in some patients. 
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Chapter 9 
Discussion and conclusions 
230 
9.1 Background 
The purpose of this thesis was to explore the relationship between H. pylori 
and gastro-oesophageal reflux disease (GORD) in the primary care setting. 
This is an important topic because GORD forms a large component of upper 
gastrointestinal workload in primary care, constituting some 5% of all 
consultations. Despite the apparently benign nature of GORD, the extent of 
prescribing for this condition is high with substantial cost implications. 
The role of H. pylori in the field of dyspepsia related to peptic ulcer disease, 
non-ulcer dyspepsia and chronic gastritis has been much better understood 
following research during the last decade. However, much less has been 
known with certainty of the link between H. pylori and reflux disease- this 
area has been relatively poorly explored. 
In order to understand and summarise known facts about the association 
between H. pylori and GORD, we gathered as much information as possible 
by undertaking two systematic reviews. These were conducted in accordance 
with Cochrane methodology. These studies shed light on associations 
between H. pylori and reflux and the influence of H. pylori eradication on 
GORD. This was followed through by a qualitative study aimed at 
ascertaining how much knowledge general practitioners had about such 
potential associations or indeed if they regarded this as an important topic in 
the practical clinical setting. Finally, fieldwork undertaken in primary care 
ascertained the extent of prescribing of long term proton pump inhibitors, 
confirming that GORD was the single largest diagnostic category for such 
prescribing. As well as determining H. pylori positivity rates in these patients, 
a comparison was made between those testing negative and positive in 
terms of demography, clinical characteristics and quality of life measures. 
The thesis used three methodologies; (a) systematic reviews (b) qualitative 
approaches (c) a cross-sectional survey with H. pylori testing of a selected 
population. 
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9.2 Summary of the studies 
Study 1 
The first study (Chapter 2) was a systematic review and a meta-analysis of 
studies to ascertain the prevalence of H. pylori in GORD. This review was 
undertaken because previous studies had given conflicting results and as 
such it was unclear if there was any association, positive or negative, 
between H. pylori and GORD. The results were that there was a significant 
negative association between H. pylori and proven GORD. This was 
particularly so in the East Asian studies, despite the overall higher H. pylori 
prevalence in these countries. Thus we ascertained that geographic location 
was an important determinant of whether or not GORD was associated with 
H. pylori infection. A potential inference might have been that H. pylori may 
be protective against GORD and its complications. However, association is 
not the same as causation and to determine cause and effect relationships, 
specific randomised controlled trials are required. 
A potential problem with this study was that the results could have been 
affected by significant heterogeneity between the studies included. The 
varying definitions of the comparator groups used in the different studies 
within the review may also have influenced results. The majority of patients in 
the control arms had endoscopy for clinical reasons and were thus not 
population-based groups per se. In an ideal situation, all patients in the 
comparator group for each study should have been asymptomatic volunteers 
from the community with a normal endoscopy result. In practice this is usually 
impossible to achieve, although some studies in our review had managed 
this. The ascertaining of prevalence of H. pylori in GORD is therefore 
necessarily dependent on those who might have had endoscopies for clinical 
reasons. Despite this, it was felt that the overall results were not seriously 
compromised because our selection criteria excluded patients with symptoms 
of GORD who had negative endos-copy or had normal pR tests. 
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As well as the country of origin, we could have explored findings by metre-
regression of other factors such as use of pH metering, the inclusion of 
patients without reflux symptoms, year of study and the choice of H. pylori 
test. This might have reduced bias and the effect of heterogeneity. Of these 
factors the most useful variable appeared to be the country of origin. This 
was on the basis that patterns of H. pylori infection in the Far East varied 
from that in Europe. Although the other items could have been subjected to 
metre-regression, they would not have detracted from the overall findings 
and would have added little because of the small number of studies available 
in each category. 
Study 2 
The second study (Chapter 3) was another systematic review in sequence 
from the previous one. Having determined that the patients with proven 
GORD had lower H. pylori prevalence rates compared to those without, it 
was important to ascertain the clinical implication of this finding. The results 
of the second review indicated that H. pylori eradication in patients with 
duodenal ulcers neither provoked reflux oesophagitis nor worsened 
heartburn. 
In the group of patients with proven oesophagitis without ulcer disease, 
despite the lack of any obvious differences in findings between H. pylori 
positive and negative cases, it was not possible to draw any firm conclusions. 
The review could be criticised for combining data from studies with different 
study designs and for not conducting a meta-analysis. It is acknowledged 
that the reviewed data has some weaknesses. There was very significant 
heterogeneity between the studies as well as between the randomised 
control trials. It was felt inappropriate and even misleading, given the 
weakness of data available to statistically pool results as a meta-analysis. 
Although combining trial and observational study designs may be open to 
bias, making interpretation difficult, the error was minimised by the statistical 
approach taken in this review. Despite the necessary use of jargon in 
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explaining the results, the conclusions themselves were straightforward. The 
review could also be criticised for attempting to draw inferences relating to 
more than one or two primary end-points. However, this was unavoidable; 
many of the available studies relating to the impact of H. pylori in 
oesophagitis patients had different primary outcomes. 
Hitherto, the majority of industry sponsored research had probably not 
concentrated on reflux disease and H. pylori because this link was not seen 
as worth pursuing in terms of therapeutic opportunities. Rather, researchers 
have followed peptic ulcer disease and H. pylori. The two systematic reviews 
within this thesis have indicated that there is a real gap in our knowledge of 
the relationship between gastro-oesophageal reflux disease and H. pylori. 
Study3 
The third study (Chapter 4) study was a qualitative study using focus groups 
with general practitioners to explore their views about proton pump inhibitors. 
The study concluded that despite adequate factual knowledge there was 
confusion amongst GPs about the link between GORD and H. pylori. Overall, 
GPs had not thought of testing and/or eradication of H. pylori in patients on 
long-term PPis. Despite this, many GPs had strong views about how GORD 
should be managed and seemed mostly content with the idea and safety of 
long-term acid suppression. This study highlighted that whilst guidelines 
such as the Maastricht 2000 are widely quoted in gastrointestinal circles, the 
message from this and other similar guidelines seem far away from practising 
GPs. 
As this was a qualitative study, it is accepted that the findings and 
interpretations were mainly contextual with limited implications for 
generalisablity. However, views of nearly 50 GPs of varying cross-section 
and background were obtained and it is likely that many of the conclusions 
drawn reflect those of practising GPs- at large. The study methodology could 
potentially have used one to one semi-structured interviews or followed 
through with other methods such as an open questionnaire. However, there 
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would have been no particular advantage to this as the aim was to get a 
spectrum of views rather than quantifying the extent to which people felt 
proportionately about one factor or another. The spread of participants within 
focus groups in our study varied from five to fifteen. It is acknowledged that 
focus groups function best when the numbers of participants are less than 
ten, and ideally between five and eight. The response rate to our invitations 
to attend the focus groups was also disproportionate and dependent on 
respondent personal circumstances. Despite two of the focus groups having 
ten or more participants it was evident from the respondent validation of the 
results that the views of all participants were well represented. 
Study4 
The fourth study (Chapter 6) was a cross-sectional survey of eight general 
practices to ascertain the rates of long-term PPI use. The study concluded 
that 1.7% of the population were on repeat PPI prescriptions. The study also 
found that repeat prescribing rates varied substantially between practices. 
The results of this study are topical and relevant because there is concern 
about the escalating costs of repeat PPI prescribing and the necessity for 
such prescribing. It is tempting to assume from the results of this study that 
"good" and "bad" prescribing behaviour is linked with low and high repeat PPI 
prescribing rates but this would be erroneous. Interestingly, this study found 
a weak negative association between repeat prescribing rates and 
endoscopy referral rates, so that the overall costs to the NHS, though not 
determined here, may not be very dissimilar between practices. 
It is acknowledged that the study had weaknesses; retrospective data 
collection, paucity and lack of reliable data in some patient records and the 
extrapolation of results to generality. Despite a seemingly adequate 
population sample studied, it was not possible to determine the influence of 
practice and demographic characteristics on the overall results, indicating 
that a much larger sample -size is required before undertaking reiTable 
regression analysis. Whilst the results provide information on existing 
practice variations of prescribing, the study did not examine intra-practice 
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features (individual doctor prescribing rates, appointment systems are 
examples) which may have skewed the results. Finally, there was the 
difficulty of defining what a long-term prescription constitutes; this may be 
open to different interpretations. We used a definition standardised in 
previous research in North-East England, i.e. patients had to be on the 
practice repeat prescribing system for at least six months. The overall results 
are necessarily dependent on the particular definition used. 
Study5 
The fifth study (Chapter 7) was an extension of the previous one and 
ascertained more closely the patterns and indications for repeat PPI 
prescribing, including any links to consultation rates by GPs. As would be 
expected, the study found that omeprazole and lansoprazole constituted the 
bulk of PPis used. The three major indications were GORD, dyspepsia and 
gastro-protection. Despite the fact that consultation rates varied substantially 
between practices, this appeared to have no obvious bearing on repeat 
prescribing rates. The cost per patient per practice of long-term prescribing 
was also estimated and compared with local area and national average, 
indicating that the study figures were in line with national figures but 
somewhat higher than the local average. 
Like the previous study some of the results, particularly those pertaining to 
consultation rates, have to be treated with caution. The records of the 
consultations, their accuracy, reliability and interpretation are prone to error. 
Despite all practices having being computerised the recording of 
consultations was not uniform or consistent between practices or even within 
practices. This created heterogeneity of data. However, such weaknesses 
were minimised by collecting information for two years preceding the study 
period and were re-checked by a second researcher in 25% of cases, the 
error between the two data collectors being 3%. It might have been that 
practices who reviewed patients regularly would have lower repeat 
prescribing rates and vice versa but a larger prospective study is required to 
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answer this and to ascertain this and to if regular review affect PPI 
prescribing. 
Study6 
The sixth and last study (Chapter 8) was an interventional study. The aim 
was to ascertain the H. pylori status of patients on long-term PPis and to 
record their reflux and dyspepsia symptoms and quality of life. This study 
concluded that the nearly a third of such patients were H. pylori positive. 
Many of these could potentially benefit from eradication therapy. A further 
conclusion was that most patients, despite taking long-term PPis, had 
ongoing and significant reflux and dyspepsia symptoms. 
A strength of this study was that both patients and the researcher were blind 
to the results of H. pylori test result, minimising bias. However, the study 
could be criticised for drawing conclusions based on heterogeneous 
diagnostic categories. Criticism can also be levelled at the type of 
questionnaires used. In retrospect, instead of the CarlssonDent 
questionnaire, other GORD specific evaluative questionnaires might have 
been preferable. The reduced sample size reflected the poor acceptance rate 
by patients for H. pylori breath tests, highlighting the difficulty of recruiting 
patients into such studies. It is also possible that the differences in symptoms 
and quality of life noted between positive and negative patients may be a 
reflection of uneven sample sizes, and heterogeneity between patients in 
terms of clinical factors. Despite these weaknesses, this was the first study 
undertaken in the pragmatic world of primary care and results are likely to be 
generalisable. 
9.3 Conclusions 
The following conclusions can be drawn from the six studies in this thesis. 
1. From a systematic review, there was a significantly lower prevalence 
of H. pylori infection in patients with gastro-oesophageal reflux disease 
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than in patients who did not have GORD (OR, 95% Cl 0.45, 0.78), and 
geographical location was the most important determinant of the 
association 
2. In a systematic review study variations rather than therapy influenced 
the results in relation to the presence or absence of oesophagitis in 
patients with duodenal ulcer who underwent H. pylori eradication at 6-
48 months follow-up. 
3. H. pylori positive and negative cases of oesophagitis did not differ in 
regards to their heartburn scores, pH values, healing and relapse 
rates. 
4. GPs' knowledge and awareness concerning the use of PPis was high 
and their prescribing decisions were mostly based on the dynamics of 
the individual consultation. No common factors that might have 
accounted for variations in prescribing between general practitioners 
were identified. 
5. Any possible links or associations between H. pylori, proton pump 
inhibitors and GORD were not appreciated by GPs. 
6. In a population sample of nearly 50,000 patients from eight general 
practices the overall rate of long-term PPI prescribing was 1. 73% 
(0.6% - 3.6%). The utilisation of upper Gl endoscopy in patients on 
long-term PPis varied from 33% to 82% between practices and 
appeared to be negatively correlated with repeat PPI prescribing rates. 
7. Omeprazole predominantly in the treatment dose and lansoprazole, 
predominantly in the low maintenance dose, accounted for 89% of the 
total repeat prescribing. GORD (36%), dyspepsia (28%) and gastro-
pr6tection (15%) were the three main prescribing indications. 
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8. Disease specific upper Gl consultation rates varied nine-fold between 
practices (0.2 to 1.8 per patient per year, mean 1.05}, generic 
consultation rates varied three fold (2.4 to 7.2 per patient per year, 
mean 4.4). There was no correlation between these and the 
prescribing rates. 
9. Of the 196 patients evaluated from a sample of 530 patients on long-
term PPis, dyspepsia symptoms of some degree were present in all 
and reflux symptoms in about half of them. Just under a third (31%) 
tested positive for H. pylori on the 13C-UBT. 
10. The proportion of patients with a diagnosis of GORD were 
significantly more in those who were H. pylori negative (p<0.001 ). 
11. Reflux symptoms and quality of life were both significantly worse in 
the H. pylori negative group of patients (p=0.001, p<0.001 ). 
9.4 Implications of this research 
The findings of this thesis have raised some important and practical patient 
management issues for the clinical setting of primary care. The area of 
topical relevance concerns the question of testing and eradication of H. pylori 
in patients on long-term PPis. Understandably such patients form a 
heterogeneous group in terms of their diagnosis. The results of this thesis 
ascertained that nearly a third tested positive for H. pylori and nearly 60% 
were determined to have diagnoses other than GORD. These included non-
ulcer dyspepsia, uninvestigated dyspepsia, peptic ulcer disease and gastro-
protection. Potentially, patients in these categories could all benefit from 
eradication therapy and this has indeed been advocated by the recent NICE 
2004 guidelines. In addition, patients with peptic ulcer have a real chance of 
being cured and this may also be true in some non-ulcer and uninvestigated 
-- -
dyspeptics. It may be expected that many patients following such eradication 
therapy will not require long-term PPis, with consequent economic benefits. 
Against this backdrop there are obvious resource implications for primary 
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care such as GP and nurse consultations, 13C-UBT testing, prescribing costs 
for eradication therapy and referrals to secondary care. 
The role of H. pylori eradication in patients with GORD is more controversial; 
despite the negative epidemiological association shown in this thesis and 
some evidence of worse reflux symptoms in H. pylori negative patients, the 
link between the two remains unclear. Overall the conclusions from the 
systematic reviews suggested no influence of H. pylori, positive or negative, 
on GORD. However, given that H. pylori has been accepted as Class 1 
carcinogen for gastric cancer by the WHO, the risks of which may be 
increased in the presence of long-term PPis, it seems prudent to eradicate H. 
pylori in patients with GORD, if only for potential long-term health benefits. 
This is also in keeping with the Maastricht-2000 guidelines. If applied in 
practice, this has further resource implications for primary care. 
9.5 Future research 
The biggest and perhaps the most striking aspect of GORD in addition to its 
rising prevalence is the increase in gastro-oesophageal cancer. Although it is 
established that Barrett's oesophagus is potentially pre-cancerous, it is 
unclear if Barrett's necessarily results from chronic inflammation of the lower 
oesophago-gastric junction or is a separate entity in itself. Despite the rapid 
increase in oesophageal adenocarcinoma over the last few decades, the 
diagnosis of this condition is often delayed. This area requires further 
research and ongoing studies of patients on long-term GORD treatment offer 
this possibility. 
The confirmation of a definitive link between H. pylori and GORD continues 
to be elusive. Following on from the work undertaken here, further research 
will be done in this field by the author. The subject of Cag A status and its 
association with GORD is also of continuing relevance and requires further 
investigation. One clinically important research question from a GP 
perspective that needs answering concerns the value and effectiveness of H. 
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pylori eradication in patients on long-term PPis. This requires a randomised 
trial; author of this thesis along with other researchers has embarked on this. 
The introduction of the new 2004 NICE dyspepsia guidelines which espouses 
the use of empirical PPis for dyspepsia (most of which will be for GORD) 
opens a potentially new chapter in the use of these drugs long term. The 
question of whether or not prior testing and treating for H. pylori is important 
remains open. 
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Appendix 1. Information letter to doctors concerning focus group 
research 
Anan S Raghunath 
General practitioner and NHSE Research Practitioner 
Marmaduke Health Centre, Hessle Road 
Hull HU3 3BH 
Tel: 01482-327708/222741 
Mob: 0802/940271 
e-mail: Raghu@Nath.Freeserve.co.uk 
«T~e»«Fo~names»«Sumame» 
«Surgery» 
«Street» 
«Area» 
«City» 
«Postcode» 
Invitation and a request to take part in a Focus Group discussion on Proton 
Pump Inhibitors: 
Dear «Title» «Surname» 
I would feel privileged if you were able to take part in a focus group 
discussion on PPis. This is one aspect of my PhD related research study, 
entitled "Use of PPis in General Practice". My supervisor is Prof. APS 
Hungin, Professor in Primary Care at Durham University. 
In this aspect of the study, I would like to use focus groups (a method of 
qualitative research) to explore the use of PPis by GP colleagues and our 
understanding of this, through participatory discussion. 
There is no preparation required, and the discussion is meant to be informal, 
enjoyable and informative. 
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All focus group material will be tape recorded (confidentiality will be 
maintained), transcribed and analysed in order to produce themes and 
categories of responses, to better understand our use of PPis.The 
information obtained may also help in producing a questionnaire relating to 
the use of PPis in General Practice that can be used to a larger audience of 
GPs. 
What is in it for you? 
A chance to take part in a small group (6-8 GPs) discussion in a relaxed 
atmosphere with colleagues, in which your views will be of great value and 
appreciated. Sharing of ideas may assist you in some of your own decision 
making. This is also an opportunity to take part in research. 
As a fellow GP, I am very much aware of the inroads into your time, but I do 
hope you will find taking part in this forum rewarding. 
Sandwiches and coffee/tea will be available and I am asking for about an 
hour of your time. 
As a token of appreciation of your effort to help with this study, I am able to 
offer you £50 from my research grant. 
I look forward to hearing from you. 
Yours Sincerely 
I am willing/not willing to take part in the focus group 
The focus groups are planned to take place over lunchtime (1-2PM). Please 
tick/circle your preferences below for the day/s that may be convenient for 
you. 
Tue/Wed/Thurs/Fri -
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Time. 1-2pm 
Venue. College House, East Riding Campus, Univ.of.Hull, Willerby 
If evenings are preferred, please mention. 
If the venue is too far for you to attend, please mention so that an effort could 
be made to arrange at a local venue. 
Please return your reply in the SAE 
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Appendix 2. Doctors taking part in the focus groups 
GP registrars 
Richard C, E 0 Jessa, Craig Dobson, Sarah Coupland, Linda Courtney, 
Richard, Rukhsana Jamali, Stewart Burdett, Martin Krusche, Cheryl, Russell 
Martin, Caroline Tinston, Katherine Glover, Thaseen Yousuff, Laurent Bare 
GPs 
Adhami Yassin Male The Surgery Hull 
The Health 
Alton Elisabeth Female Centre Beverley 
Wheelerstreet 
Ayyub Muhammad Male Healthcare Hull 
Sawn Bridget Lesley Female The Surgery Beverley 
Best Johnny George Male 7Weeton Way Hull 
Morrill Street 
Bolton Trevor Male Health Centre Hull 
129 Newland 
Chia Peng Sang Male Avenue Hull 
The Bridge Street 
Dale Susan Patricia Female Practice Driffield 
Kapur Sanjeev Male 83-85 Hall Road Hull 
Princes Avenue 
Musil Jan Male Medical Centre Hull 
129 Newland 
Percival Richard Male Avenue Hull 
Princes Avenue 
Queenan Paul John Male Medical Centre Hull 
Stryjakiewicz Eugene Glenn Male 2 Lomond Road Hull 
Petrus Newland Health 
Van Maarseveen Leonard us Male Centre Hull 
Brough & South 
Walters Joanne Female Cave Practice Brough 
Cottingham 
--~-··";;,_..:_ 
Willson John Christopher Male Medical Centre Hull 
129 Newland 
Westrop Richard John Male Avenue Hull 
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St Nicholas 
Fouracre Robert Male Surgery Withernsea 
The Bridge Street 
Wigglesworth David Fearnley Male Practice Driffield 
Ashworth lan Andrew Male Burnbrae Surgery Hull 
Orchard 2000 
A wan Ramzan Khan Male Medical Centre Hull 
117/119 
Beynon Beryl Female Walkergate Beverley 
Ghanshyam Clifton House 
Chauhan Singh Male Medical Centre Hull 
Highlands Health 
Raut Rajeev Male Centre Hull 
Holmquist Jennifer Caroline Female 2 Church Street Hull 
Dawber Emma Elizabeth Female 37 Eastgate Horn sea 
Wright Patrick Male Belmont surgery Durham 
Wylie Graham Male 48, Rosemount Durham 
28, Stanhope 
Jeavons David Male Road Darlington 
Grosvenor 
Srirangalingham Siva Female Terrace Durham 
Collingwood Newcastle-
Lipman Toby Male Terrace upon-Tyne 
Bransholme 
South Health 
Ghosh Pradeep Chandra Male Centre Hull 
Bransholme 
South Health 
Ghosh Krishna Female Centre Hull 
Maung Maung Male The Surgery Hull 
Marfleet Group 
Spokes Jonathan Mark Male Practice Hull 
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Appendix 3. QUORUM statement flow diagram (chapter 2) 
Potentially relevant studies 
identified and screened (n= 654) 
Studies excluded with 
reasons (n= 609) 
Studies retrieved for more Studies excluded 
detailed evaluation (n= 45) with reasons (n= 1 0) 
Potentially appropriate studies 
Studies to be included in the systematic 
review (n= 35) excluded with 
reasons (n=15) 
Studies included in systematic 
review (n= 20) 
Studies with usable information, Studies 
by outcome (n= 20) withdrawn, by 
outcome (n= 0) 
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Appendix 4. QUORUM statement flow diagram (chapter 3) 
--
Potentially relevant studies 
identified and screened (n= 654) 
Studies excluded with 
reasons (n= 602) 
Studies retrieved for more 
detailed evaluation (n= 52) 
Studies excluded with 
reasons (n= 19) 
Potentially appropriate studies 
Studies excluded to be included in the systematic r 
review (n= 35) with reasons (n=7) 
, 
Studies with usable information, 
by outcome (n= 28) 
StMgi~s in_9_I_!J,Qe(j in systf:)rTH~tic Studies 
revlew(n= ~r8) -- -- --- -- ---- withdrawn ,-by 
outcome (n= 0) 
- -
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Appendix 5. Information to GP practices 
Anan S Raghunath 
General practitioner and NHSE Research Practice 
N& Y Regional Research Fellow 
Honorary Research Fellow, Faculty of Heath, School of Medicine, 
Univ.Of.Hull 
Marmaduke Health Centre 
Hessle Road 
Hull 
Tel: 01482-327708/222741 
Mob: 07790850941 
E-mail : Raghu@Nath.Freeserve.co.uk 
Subject: A higher degree research project on "use of Proton Pump Inhibitors 
in General Practice". 
Dear Dr ..... 
This is a request and an invitation for your practice to take part in the 
following research study supported by the N& Y region, and supervised 
by Professor P Hungin, Professor in Primary Care, Durham University. 
The study is also supported by Prof. P Campion, University of Hull and 
by the WoReN. 
As a part of my PhD research project, I am interested in determining the 
effect of H. pylori eradication on symptoms and use of acid suppression 
in patients on long-term PPis. 
Long-term PPis appear to be mainly used for reflux disease, although in 
some prescribing might have been for other reasons, e.g. peptic ulcer 
diseases, NSAID protection etc. 
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You may be well aware of the confusion and controversy that exists in this 
area; there have been conflicting studies, none primary care based, that have 
alluded to the benefits versus risks of H. pylori eradication in patients that are 
on long-term PPis. 
The first part of this study is a cross-sectional survey in several practices to 
determine the extent of long-term PPI prescribing, reasons for long-term 
prescribing, and inter-practice variability. Secondly, the H. pylori status of all 
patients on long-term PPis will be ascertained through the C 13 Urea breath 
test and if patient agrees by serology (to determine Cag A status). The third 
and final part of this study is a double blind, placebo controlled, Randomised 
Controlled Trial of H. pylori eradication in patients that are H. pylori positive 
(Flow chart of study enclosed). 
There will be no intentional alteration to the therapy used by patients 
throughout the course of the study. 
Disturbance for your practice will be minimal, as a designated research data 
collection clerk will undertake all data collection and administrative work. The 
research team on behalf of the practice will again undertake all necessary 
contact with patients. 
I will be happy to come discuss with yourself and your partners further details 
of the study if you wish. 
I do hope that your practice will agree to take part in this study, I will provide 
an intermediate report relating to your practice patients on long-term PPis, as 
well as final report at the end of the study indicating the outcome of RCT in 
your practice patients. 
This study being an "action type research", should benefit the practice and 
patients alike. For instance, the extent and reasons for long-term PPI 
prescribing data provided by this study should help in practice audit. The 
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determining of H. pylori status and Cag A serology and the opportunity for H. 
pylori eradication allows patients to understand their problems and make 
informed choice about their management. 
The local medical research ethical committee has approved this study. 
As a token of appreciation and any effort that may be involved for your 
reception/computer staff to help the research clerk to collect data from your 
manual and computer records, my research fund allows me to pay your 
practice £250. 
Yours Sincerely 
Raghu 
Drs .... 
PRACTICE CONSENT TO TAKE PART IN THE STUDY ON "H. PYLORI 
AND PPis. 
AGREE/DO NOT AGREE TO TAKE PART 
*would like to have a meeting with Raghunath for further explanation yes/No 
Please return in the SAE 
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Appendix 6. A Study about acid indigestion problems in the stomach 
and gullet 
Subject: Research on drugs used for indigestion, ulcers, acid problems and 
a germ called Helicobacter Pylori (Hp). 
As a research and teaching practice, we conduct research that is directly 
relevant to the care of our patients. One such study that we are currently 
doing concerns indigestion, heartburn, acid problems in the stomach and a 
germ called Helicobacter Pylori. 
What is Helicobacter Pylori? 
It is a germ present in the stomach of nearly half the adult population of our 
country in most of whom it appears to cause no real problems. 
Does treating Helicobacter pylori cure ulcers in the stomach and duodenum? 
This is true in most cases. A course of treatment for 1-2 weeks to get rid of 
this germ can permanently cure ulcers in most people so that no further 
treatment may be required. 
What is Gastro-oesophageal reflux disease? 
This is a very common condition in which people suffer from heartburn and 
acid taste in the mouth. As doctors, we are not clear about the role of Hp in 
this condition. 
What do we want to find? 
Our study is about trying to find out a) your present level of indigestion 
symptoms b) whether you have this germ called Hp in your body and c) if 
getting rid of this germ, will over a period of time, make any difference to your 
symptoms, and amount of medications that you may require. 
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How can you help? 
We are aware that you are being prescribed indigestion treatment 
losec/zoton/protium/gaviscon/other) by your doctor to help with your 
symptoms or to protect against another drug. 
We are interested to know if you do or do not have H. pylori in your 
stomach. This can be found out by means of a simple test (breathing out 
your air into small tubes). Even if you have had this test previously, we would 
still/ike you to have this test again. A special blood test can also be arranged 
to find out if you carry a specific type of this germ in your system. However, 
this is not compulsory, and you can still take part in the study even you 
decided not to have the blood test. 
The tests will take place at the GP surgery and lasts for about 30 minutes. 
The date and time along with some instructions for the test will be notified to 
you shortly once you have agreed to take part in this study. 
Next ... 
Your results will be informed to you. 
If your test shows that you have no H. pylori, no further action is required. 
Simply continue to take your medications in the usual way. If your test shows 
that you have H. pylori, then you will have the opportunity to be included in 
the randomised control trial part of the study (explained in another 
enclosed leaflet). 
If you do not give your consent, your care with our Practice will not be 
affected in any way. 
How this study may help you? 
If your test shows that you have H. pylori present, then this can be got rid of 
with likely benefit in the long-term. This result of this study is likely to increase 
knowledge-in this-area- that hopefUlly wilroenefit people like-you-with-thTs 
condition. Taking part in research like this may help you to find out more 
about your condition and thus help in deciding regards to your future 
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treatment. If you wish, we would be happy to send you our results at the end 
of the study. 
In doing this project, we are supported by the health and research 
department of the University of Hull, the local research network and the 
gastroenterolgy (stomach and bowel) department at Castle Hill Hospital. 
Ethics 
The Hull and East Yorkshire ethical research committee as well as the 
Hospital trust ethical committee have given this study ethical approval. 
Your consent 
We do sincerely hope, you are able to take part in this research study and 
look forward to receiving the enclosed consent form signed by yourself. Many 
thanks for your time spent in reading this information. 
Dr A S Raghunath 
298 
Appendix 7. Invitation to attend for 13C breath test 
Gastro Intestinal Physiology Department 
WARREN JACKSON BSc (HONS) RCCP CLINICAL PHYSIOLOGIST 
PLEASE READ CAREFULLY 
Tel: 01482 622155 (Direct line) 
Date as postmark 
Dear 
You may remember that some time ago you consented to take part in a 
study for Dr Raghunath (Marmaduke Street Health Centre), an 
appointment has been made for you to attend for a 13C breath test on: 
DATE .............................................................................. . 
TIME .................... . 
The test will be carried out at your GPs surgery: 
The test is carried out to determine the presence of bacteria within your 
stomach, which may be responsible for your current symptoms. The test is 
very easily performed. It requires you to drink 200ml of water containing a 
sachet of citric acid; you will then have a 5-minute rest. You will then 
breathe down a straw into two tubes, then you will drink 50ml of water 
containing Urea (this is a tasteless test solution), you will then have a 30 
minute wait, while you are waiting I will also take a blood sample (if you 
agree) and ask you to fill in some questionnaires relating to your 
symptoms, after which you will breathe down a straw into two more tubes. 
The test is then complete. 
In order to obtain useful results, it is necessary for you to carry out the 
following instructions; 
Please have nothing to eat or drink for 6 hours prior to the test. 
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If you are on any medication for your heart, breathing problems or 
hormone replacement therapy, please continue to take them as usual. 
However, it is important that you stop taking any of the following: 
28 days before your appointment: Please ensure that you do not 
take any antibiotics. 
14 days before your appointment: Omeprazole (Losee), 
Lansoprazole (Zoton), Rabeprazole (Pariet), Esomeprazole (Nexium) 
or Pantoprazole (Protium). 
3 days before your appointment: Ranitidine (Zantac), Cimetidine 
(Tagamet), Nizatidine (Axid), Famotidine (Pepcid), Prepulsid 
(Cisapride), Domperidone (Motilium) or Metoclopramide (Maxolon). 
24 hours before your appointment: Gaviscon, Rennies, Maolox, 
Algicon or settlers. 
The test will take 40-45 minutes to complete. I do not use any sedation 
for the study so you will be able to travel or drive as normal. 
If this appointment is unsuitable for you for any reason, please feel free 
to contact me on the above number and I will arrange another 
appointment for you. If it is your intention not to have these studies 
carried out please let me know as I can give your appointment to 
someone else. 
If you have any questions/concerns lease give me a call on the above 
number (at Castle Hill Hospital), and not the GP surgery. 
Yours sincerely, 
W Jackson 
Mr Warren Jackson 
Clinical Physiologist 
(GI Physiology, Castle Hill Hospital) 
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Appendix 8. Letter to patients following positive Urea Breath test 
Dear 
Subject :A Study about acid indigestion problems in the stomach and 
gullet 
Many thanks for recently attending your surgery in order to do the breath and 
blood tests with Warren Jackson. Thank you also for filling in the 
questionnaires. 
Your breath test has shown that you are positive for H. pylori. This means 
that you have the germ Hp present and you are therefore suitable to be 
entered into the next part of the project that involves treatment. 
Please do not worry because you have tested positive for this germ. As 
explained before in the information sheet, this germ is normally present in 
most of us without causing any problems. Your doctor has been informed of 
the results. 
As you have agreed to take part further in my research, I will be contacting 
you shortly and making an appointment to see you in your doctor's surgery. 
You should hear from within four weeks but in the meantime if you have any 
concerns or queries please do not hesitate to contact me. 
However if you decide not to take any further part in the research please 
contact your GP for a short course of treatment to eliminate this germ from 
your body. 
Best Wishes 
Yours sincerely, 
Anan S Raghunath 
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Appendix 9. Letter to patients following negative Urea Breath test 
Dear 
Subject : A Study about acid indigestion problems in the stomach and 
gullet 
Many thanks for recently attending your surgery with Warren Jackson for the 
breath and blood tests concerning my research study, as well as filling in the 
questionnaires. 
I am pleased to inform you that you have tested negative for the germ 
Helicobacter Pylori. This means that no further action is required in your 
case. Please continue to take your usual treatment unless advised differently 
by your doctor. 
I like to take this opportunity to personally thank you for your contribution to 
the project. 
Best Wishes. 
Yours sincerely, 
Anan S Raghunath 
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Appendix 1 O.Leeds Dyspepsia Questionnaire 
Patient name: 
Patient identity: 
PLEASE ANSWER QUESTIONS BY INSERTING A TICK IN THE BOX 
1. Over the last FOUR WEEKS have you had any indigestion (a pain 
in the upper abdomen) (see picture)? 
If the answer is no please go to question 2 
YES [ 1 
NO [ 1 
a) How often have you had indigestion over the last FOUR WEEKS? 
Less than once a month [ ] 
Between once a month and once a week [ ] 
More than once a week 
At least once a day 
[ ] 
[ ] 
b) How severe has your indigestion been over the last FOUR WEEKS? 
Very mild 
Mild 
Moderate 
Severe 
[ ] 
[ ] 
[ ] 
[ ] 
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Very severe [ ] 
2. Over the past FOUR WEEKS have you ever experienced 
heartburn (a burning feeling behind the breast bone) (see 
picture)? 
If the answer is no please go to question 3. 
YES [ ] 
NO [] 
a) How often have you had heartburn over the last FOUR WEEKS? 
Less than once a month [ ] 
Between once a month and once a week [ ] 
More than once a week 
At least once a day 
[ ] 
[ ] 
b) How severe has your heartburn been over the last FOUR WEEKS? 
Very mild [ I 
Mild [ ] 
Moderate [ ] 
Severe [ ] 
Very severe [ ] 
3. Over the past FOUR WEEKS has food or drink ever stuck behind 
your breast bone as it went down? 
YES [ 1 
NO [1 
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If the answer is no please go to question 4. 
a) What sticks behind your breast bone as it goes down? 
Food [ ) 
Drink [ ] 
Both food and drink [ 1 
b) How often does it stick behind your breast bone? 
Less than once a month [ 1 
Between once a month and once a week [ 1 
More than once a week 
At least once a day 
c) How long does food or drink stick here? 
[ ] 
[ ] 
A few seconds [ 1 
More than one minute [ ] 
4. Over the last FOUR WEEKS have you experienced any 
regurgitation (an acid taste coming up into your mouth from your 
stomach)? 
If the answer is no please go to question 5. 
YES [ ] 
NO [ ] 
a) How often have you had regurgitation over the last FOUR WEEKS? 
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Less than once a month [ ] 
Between once a month and once a week [ ] 
More than once a week 
At least once a day 
[ ] 
[ ] 
b) How severe has your regurgitation been over the last FOUR WEEKS? 
Very mild [ ] 
Mild [ ] 
Moderate [ ] 
Severe [ ] 
Very severe [ ] 
5. Over the last FOUR WEEKS have you noticed excessive burping 
or belching? 
YES [ ] 
NO [] 
If the answer is no please go to question 6. 
a) How often have you experienced belching over the last FOUR 
WEEKS? 
Between once a month and once a week [ ] 
More than once a week 
At least once a day 
[ ] 
[ ] 
b) How severe has your belching been over the last FOUR WEEKS? 
Very mild [ ] 
Mild [ ] 
Moderate [ ] 
Severe [ ] 
Very severe [ ] 
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6. Over the last FOUR WEEKS have you experienced any nausea (a 
feeling of sickness without actually being sick? 
If the answer is no please go to question 7. 
YES [ ] 
NO (] 
a) How often have you experienced nausea over the last FOUR 
WEEKS? 
Less than once a month [ ] 
Between once a month and once a week [ ) 
More than once a week 
At least once a day 
[ ] 
[ ] 
b) How severe has your nausea been over the last FOUR WEEKS? 
Very mild [ ] 
Mild [ ] 
Moderate [ ] 
Severe [ ] 
Very severe [ ] 
7. Over the last FOUR WEEKS have you experienced any vomiting? 
If the answer is no please got to question 8. 
YES [ ] 
NO [] 
a) How often have you vomited in the last FOUR WEEKS? 
Less than once a month [ ] 
Between once a month and once a week [ ] 
More than once a week [ ) 
At least once a day [ ) 
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b) How severe has your vomiting been over the last FOUR WEEKS? 
Very mild [ ] 
Mild [ ] 
Moderate [ ] 
Severe [ ] 
Very severe [ ] 
8. Over the last FOUR WEEKS have you noticed an excessive 
feeling of fullness after eating? 
If the answer is no please go to question 9. 
YES [ ] 
NO [ ] 
a) How often have you experienced fullness over the last FOUR 
WEEKS? 
Less than once a month [ ] 
Between once a month and once a week [ ] 
More than once a week [ ] 
At least once a day [ ] 
b) How severe has your fullness been over the last FOUR WEEKS? 
Very mild [ ] 
Mild [ ] 
Moderate [ ] 
Severe [ ] 
Very severe [ ] 
9. Which, if any, of these symptoms has been the most troublesome 
to you in the last FOUR WEEKS? TICK ONE BOX ONLY 
a) Heartburn [ ] 
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b) Regurgitation [ ] 
c) Indigestion [ ] 
d) Belching [ 1 
e) Nausea [ ] 
f) Vomiting [ ] 
g) Excessive fullness [ ] 
h) None of these have troubled me [ ] 
10. Does your indigestion come and go? YES [ ] or NO [ ] 
11. Is your indigestion there all the time? YES [ ] or NO [ ] 
12. Is your indigestion relieved by antacids? YES [ ] or NO [ ] 
13. Is your indigestion relieved by food? YES [ ] or NO [ ] 
14. Does your indigestion wake you up at night? YES [ ] or NO [ ] 
15. Have you lost weight? 
YOUR TEL NO FOR CONTACT: 
THANK YOU FOR YOUR TIME AND HELP 
DR RAGHU NATH 
YES [ ] or NO [ ] 
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Appendix 11. Carlsson Dent Reflux Questionnaire 
Patient Name: 
Patient identity: 
PLEASE ANSWER ALL QUESTIONS BY INSERTING A TICK. 
Please answer the following questions 
by ticking one box only except for 
question 3 where you must tick one box 
for each statement. 
4. Which one of the following BEST 
DESCRIBES the effect of Indigestion 
medicines on your main discomfort? 
o No benefit 
o Definite relief within 15 minutes 
o Definite relief after 15 minutes 
o Not applicable (I don't take indigestion 
medicines) 
1. Which one of these four 5. 
statements BEST DESCRIBES the 
main discomfort you get in your 
stomach or chest? 
Which of the following BEST 
DESCRIBES the effect of lying fiat, 
stooping or bending on your main 
discomfort? 
o A burning feeling rising from your 
stomach or lower chest up 
towards your neck 
o Feelings of sickness or nausea 
o Pain in the middle of your chest 
when you swallow 
o None of the above, please describe 
below: 
o No effect 
o Brings it on or makes it worse 
o Gives relief 
o Don't know 
2. Having chosen one of the above, 6. 
please now chose which one of 
Which of the following BEST 
DESCRIBES the effect of lifting or 
straining (or any other activity that 
makes you breath heavily) on your main 
discomfort? 
the next three statements BEST 
DESCRIBES the timing of your 
main discomfort? 
o Any time, not made better or worse 
by taking food 
o Most often within 2 hours of taking 
food 
o Always at a particular time of day or 
night without any relationship to 
food 
3. How do the following affect your 
main discomfort? 
Worsens Improves 
effect/Unsure 
Larger than usual meals 
Food rich in fat 
Strongly flavoured or 
spicy food 
0 0 0 
0 0 0 
0 0 0 
No 
o No effect 
o Brings it on or makes it worse 
o Gives relief 
o Don't know or this does not apply to me 
7. If food or acid tasting liquid returns to 
your throat or mouth what effect does it 
have on your main discomfort? 
o No effect 
o Brings it on or makes it worse 
o Gives relief 
o Don't know ot this does not apply to me 
